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In 2016, over 1.68 million people in the United States are expected to be 
diagnosed with cancer, with approximately 35% of these cases resulting in death making 
cancer the second most common cause of death in the US [1]. Specifically, the American 
Cancer Society predicts that approximately 250,000 new breast cancer cases will be 
diagnosed in 2016, with approximately 16% of these cases resulting in death [1]. While 
significant progress has been made in the field of cancer treatment, many therapy regimes 
still rely heavily on the systemic administration of toxic chemotherapeutic agents. Most 
clinically used chemotherapeutic drugs are non-specific and as a result are highly toxic to 
both cancerous and non-cancerous tissues, leading to dangerous side effects and overall 
low treatment efficacy.  
 Ultrasound contrast agents (UCA) have emerged as a drug delivery vehicle to 
overcome these challenges, consisting of a small (<6µm) gas bubble stabilized within a 
lipid, protein, or polymer microcapsule shell that can be injected intravenously and pass 
freely through the capillaries. Upon entering the focused ultrasound beam, the UCA gas 
core rapidly expands and contracts, a phenomenon known as cavitation, and ultimately 
ruptures producing drug-loaded particles (up to 400nm) that can exit the vasculature, 
embed in the target tissue, and provide localized drug release. Our lab has previously 
developed hollow polymeric microspheres that encapsulated doxorubicin (Dox) within 
the polylactic acid (PLA) shell [2, 3]. These Dox-loaded UCA have been shown to 
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exhibit high echogenicity, and also shatter into nanoshards (n-Sh) of less than 400nm, 
when exposed to ultrasound [4]. When evaluated in an in vivo rat hepatocellular 
carcinoma model, we found these n-Sh were able to effectively exit the vasculature and 
deliver Dox to tumor tissue [5]. However, elevated Dox levels were also observed in the 
healthy liver and spleen tissues, suggesting immune recognition and uptake of circulating 
agents and n-Sh.  
 Here we describe the development of non-immunogenic, functionalized PLA 
UCA for use in targeted breast cancer therapy. We believe that the use of a targeting 
ligand in conjunction with polyethylene glycol (PEG) will help to shield the UCA from 
immune recognition and improve the treatment efficacy at the target site. For ultrasound 
(US) imaging with polymeric contrast agents, it is necessary to modify the shell to create 
“stealth” microbubbles but without these modifications sacrificing the agent’s ability to 
interact with the focused US beam. We hypothesize that addition of the classic immune 
shielding molecule PEG to a polylactide (PLA) microbubble shell will affect the acoustic 
and physical properties of the resulting agents.  
In an effort to determine the best formulation to achieve a balance between stealth 
and acoustic activity, we compared two PEGylation techniques; addition of increasing 
amounts of PEG-PLA copolymer and employing incorporation of a PEG lipid 
(LipidPEG) into the shell. Loss of acoustic enhancement occurred in a dose-dependent 
manner for both types of PEGylated agents (loss of signal occurred at >5 wt% PEG-PLA 
and >1 wt% LipidPEG), while immune activation was also reduced in a dose-dependent 
manner for the PEG-PLA agents. This study shows that the balance between acoustic 
behavior and improved immune avoidance was scalable and successful to different 
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degrees with both PEGylation methods, and was best achieved using for PEG-PLA at 5 
wt% and for LipidPEG at 1 wt%. 
The added advantage to the use of the targeting ligand, specifically tumor necrosis 
factor-related apoptosis inducing ligand (TRAIL), is that it also induces tumor cell death 
upon binding to the cell surface receptors DR4 and DR5 and initiating a transmembrane 
apoptosis signal. Healthy cells possess decoy receptors (DcR1 and DcR2) that cannot 
process the apoptotic signal, therefore being protected from non-specific binding. 
Additionally, the UCA were designed to co-encapsulate the chemotherapeutic drug 
doxorubicin (Dox) that can be released from the polymer shell in response to US focused 
at the tumor site, shielding healthy tissues from the toxic substance while also increasing 
the potency and efficiency of treatment to the tumor tissue. The ability of the ligand to 
cause cell death was tested against ligand-sensitive MDA-MB-231 human breast 
adenocarcinoma cells and ligand-resistant MCF7 human breast adenocarcinoma cells, 
comparing the efficacy of the microbubble formulations. It is believed that co-
administration of Dox to cancer cells that are normally resistant to TRAIL increases the 
expression of death receptors on the cell surface, sensitizing the cell to TRAIL and 
improving its efficacy. For the MDA-MB-231 cells, cell viability was reduced by 
approximately 25-50% (52.84±11.65% to 76.34±3.25% live cells) upon incubation with 
the TRAIL-ligated US-generated nanoshards, and was further reduced to approximately 
40-80% (20.32±6.91% to 64.19±2.68% live cells) with the addition of doxorubicin 
compared to TRAIL alone. TRAIL-resistant MCF7 cells showed little apoptotic response 
to TRAIL-ligated nanoshards (93.44±2.88% to 98.18±1.04% live cells); however, co-
administration of doxorubicin increased apoptosis and reduced cell viability 
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(37.37±5.39% to 67.78±3.98% live cells), supporting the sensitization effect of the drug. 
Healthy MCF-12A human breast epithelial cells were also tested, to confirm the selective 
targeting and apoptotic activity of TRAIL to cancer cells and not healthy cells. These 
cells exhibited from 90.64±2.54% to 97.46±0.62% cell viability when incubated with 
TRAIL-ligated nanoshards, confirming their insensitivity to TRAIL-induced death. 
However, cell viability was greatly decreased (44.73±15.26% to 68.79±6.89% live cells) 
when also exposed to doxorubicin, demonstrating the toxic effects of the 
chemotherapeutic agent on surrounding healthy cells during systemic treatment.  
Overall, this work has resulted in the production of effective ultrasound-triggered, 
non-immunogenic, targeted drug delivery agents for potential use in cancer therapy. This 
platform has many advantages over the systemic administration of chemotherapeutic 
drugs, and represents a promising treatment to better serve the population with breast 
cancer, and solid cancerous tumors as a whole.  
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1. INTRODUCTION 
1.1 Problem Statement 
 In 2016, over 1.68 million people in the United States are expected to be 
diagnosed with cancer, with approximately 35% of these cases resulting in death making 
cancer the second most common cause of death in the US [1]. Specifically, the American 
Cancer Society predicts that approximately 250,000 new breast cancer cases will be 
diagnosed in 2016, with approximately 16% of these cases resulting in death [1]. While 
significant progress has been made in the field of cancer treatment, many therapy regimes 
still rely heavily on the systemic administration of toxic chemotherapeutic agents. Most 
clinically used chemotherapeutic drugs are non-specific and as a result are highly toxic to 
both cancerous and non-cancerous tissues, leading to dangerous side effects and overall 
low treatment efficacy. Additionally, there are many challenges associated with treatment 
of solid cancerous tumors that further reduce the efficacy of systemic chemotherapy 
including high interstitial pressures, high cell density, unusual tumor tissue and 
extracellular matrix composition, an absence of supporting lymphatic drainage structures, 
and reliance on passive targeting through the Enhanced Permeability and Retention 
(EPR) effect [6-9]. However, reliance on EPR is limited by slow accumulation (up to 6 
hours), inconsistent degrees of tumor vessel permeability, and is precluded entirely in 
some tumors [10, 11].  
 Ultrasound contrast agents (UCA) have emerged as a drug delivery vehicle to 
overcome these challenges, consisting of a small (<6µm) gas bubble stabilized within a 
lipid, protein, or polymer microcapsule shell that can be injected intravenously and pass 
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freely through the capillaries. Much research has been focused on the development of 
drug-loaded UCA, which can interact with an ultrasound beam focused at a point of 
interest to trigger localized drug delivery. Upon entering the focused ultrasound beam, 
the UCA gas core rapidly expands and contracts, a phenomenon known as cavitation, and 
ultimately ruptures producing drug-loaded particles (up to 400nm) that can exit the 
vasculature, embed in the target tissue, and provide localized drug release. Our lab has 
previously developed hollow polymeric microspheres that encapsulated doxorubicin 
(Dox) within the polylactic acid (PLA) shell [2, 3]. These Dox-loaded UCA have been 
shown to exhibit high echogenicity, and also shatter into nanoshards (n-Sh) of less than 
400nm, when exposed to ultrasound [4]. When evaluated in an in vivo rat hepatocellular 
carcinoma model, we found these n-Sh were able to effectively exit the vasculature and 
deliver Dox to tumor tissue [5]. However, elevated Dox levels were also observed in the 
healthy liver and spleen tissues, suggesting immune recognition and uptake of circulating 
agents and n-Sh.  
 Here we describe the development of non-immunogenic, functionalized PLA 
UCA for use in targeted breast cancer therapy. We believe that the use of a targeting 
ligand in conjunction with polyethylene glycol (PEG) will help to shield the UCA from 
immune recognition and improve the treatment efficacy at the target site. The added 
advantage to the use of the targeting ligand, specifically tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL), is that it also induces tumor cell death upon binding 
to the cell surface receptor and initiating a transmembrane apoptosis signal. Healthy cells 
possess decoy receptors that cannot process the apoptotic signal, therefore being 
protected from non-specific binding. As such, this platform has many advantages over the 
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systemic administration of chemotherapeutic drugs, and represents a promising treatment 
to better serve the population with breast cancer.  
1.2 Thesis Objectives 
 The overall goal of this research is the development of a multi-functional 
PEGylated UCA that is loaded with TRAIL for targeting cancer cells and inducing 
apoptosis as well as Dox chemotherapeutic to allow for local, sustained treatment within 
the tumor interstitial. A strategy comprised of the following three specific aims was used 
to reach these goals.  
  
Specific Aim 1: Develop and characterize polymeric UCA functionalized with 
TRAIL, without compromising the ability to produce n-Sh upon interaction with 
diagnostic ultrasound. This study served as a “proof of concept” to establish the 
feasibility of decorating the UCA surface with TRAIL molecules to produce functional 
agents that exhibit apoptotic activity against susceptible cells while retaining the ability to 
interact with diagnostic ultrasound. This was achieved by pursuing maleimide TRAIL-
ligation to the UCA surface and evaluating the resulting agent for its acoustic and 
apoptotic behavior against MDA-MB-231 breast cancer cells. Our hypothesis is that 
TRAIL ligation does not inhibit UCA inertial cavitation and shattering into n-Sh when 
the agents are exposed to a focused ultrasound beam. We also hypothesize that the 
TRAIL molecule will remain attached to the polymeric surface upon cavitation and 
shattering into n-Sh, and that it will retain its apoptotic activity toward susceptible cells 
after ligation.  
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Specific Aim 2: Develop and characterize non-immunogenic PEGylated polymeric 
UCA, without compromising the acoustic properties and cavitation ability of the 
UCA. We have previously found that native PLA UCA collected in the healthy liver and 
spleen in an in vivo rat hepatocellular carcinoma model, suggesting that these agents were 
being sequestered from circulation by the immune system without reaching the intended 
target [5]. Therefore, our objective is to modify the native UCA to include PEG along the 
polymeric shell surface, in an effort to circumvent opsonization and immune response to 
the circulating agent. Two methods of PEGylation are investigated in this thesis; one 
method evaluating the use of a co-polymer as the shell material, and the other method 
evaluating the use of lipid-anchored PEG molecules extending from the UCA surface. 
We hypothesize that PEGylation will not significantly affect the UCA shell properties, 
thus allowing for acoustically-triggered n-Sh production in an in vitro ultrasound 
environment. We also hypothesize that PEGylation will reduce the agent 
immunogenicity, as measured against C3 complement protein activation. At the 
conclusion of this aim, we determined that 5 wt% PEG-PLA co-polymer and 1 wt% 
LipidPEG represented the most viable PEGylated agents for continued investigation into 
targeting, drug loading, and drug delivery capabilities.  
 
Specific Aim 3: Functionalize PEGylated UCA for targeted cancer therapy with 
TRAIL ligation to the UCA surface and encapsulate Dox within the UCA shell to 
increase target sensitivity against breast cancer models. The work in this aim focused 
on the attachment of TRAIL to the UCA surface to target and induce apoptosis in 
susceptible cancer cells, as well as the co-encapsulation of Dox within the polymeric 
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shell to further sensitize TRAIL-resistant cells and synergistically act with TRAIL to 
induce tumor cell death. It is hypothesized that the TRAIL molecule retains its apoptotic 
activity when attached to the UCA surface and PEG molecules, and that this attachment 
is not detrimental to the acoustic behavior of the functionalized agents. We also 
hypothesize that the co-encapsulation of Dox will provide a sustained, local release of the 
chemotherapeutic to improve the treatment efficacy and further sensitize cells to the 
apoptotic action of TRAIL. These functionalized agents were evaluated against TRAIL-
sensitive MDA-MB-231 breast adenocarcinoma cells, TRAIL-resistant MCF-7 breast 
adenocarcinoma cells, and TRAIL-negative MCF-12A healthy breast epithelial cells. 
Additionally, the agents were evaluated for Dox release during cavitation into n-Sh to 
determine any burst release effects as well as from the resulting n-Sh to determine the 
long-term release profile.  
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2. BACKGROUND AND LITERATURE REVIEW 
2.1 Cancer and Cancer Therapies 
Cancer is a broad term that is used to describe a group of diseases characterized 
by uncontrolled cell division that can invade other tissues. Cancer results from a change 
in cell differentiation, accumulating mutations in the genes involved in regulating cell 
division. Genetic mutations can occur from DNA damage due to radiation, microbes and 
viruses, toxins, inherited mutations, certain lifestyle concerns (obesity, poor diet, lack of 
exercise), immune conditions, or chronic inflammation. Left unchecked, cancerous cells 
can multiply, spread through the blood and lymphatic systems causing metastases, and 
eventually lead to death if not controlled. Cancer is the second leading cause of death in 
the United States, exceeded only by heart disease. According to the American Cancer 
Society, almost 1.7 million people in the United States are expected to be diagnosed with 
new cancer cases in 2016, with over 590,000 deaths expected from cancer [1].  
2.1.1 Breast Cancer 
While the platforms designed and discussed in this thesis are expected to be 
useful in the treatment of a variety of cancers, a breast cancer model is used for proof of 
principle. In 2016, breast cancer is projected to be the most common type of cancer 
diagnosed in women in the United States, with over 246,000 new cases expected to be 
diagnosed [1]. For women diagnosed with localized breast cancer that has not spread to 
lymph nodes or other tissues outside the breast, the five-year survival rate can be as high 
as 99%; however, 5-year survival rates drop to 85% when cancer spreads to regional, or 
nearby, lymph nodes, and further drops to 26% if cancer spreads to distant lymph nodes 
or tissues. The overall survival rates 5, 10, and 15 years following diagnosis are 89%, 
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83%, and 78% respectively. Despite relatively high survival rates, breast cancer is still 
projected to be the second leading cause of cancer deaths in women in the United States 
after lung cancer, with over 40,000 deaths expected in 2016 [1]. Common 
chemotherapeutic drugs for the treatment of breast cancer include anthracyclines such as 
doxorubicin (Dox) [12, 13], making these drugs excellent candidates for encapsulation 
into microbubbles for ultrasound-triggered drug delivery.  
2.1.2 Solid Tumor Biology, Architecture, and Treatment 
Solid tumors develop in a large percentage of cancers (approximately 85% of all 
cases), with close to 50% of these cases leading to metastases and death [14]. 
Tumorigenesis, the transformation of normal cells into cancer cells, is initiated by a 
combination of mutational activation of oncogenes together with mutational inactivation 
of tumor suppressor genes within a cell, leading to aberrant cell division [15]. Mutated 
cells continue to divide as a small avascular nodule (1-2mm) until reaching a steady state 
of balance between apoptosis and cell division [16]. Similar to healthy cells, cancerous 
cells require oxygen and nutrient supply to support metabolism making it necessary for 
tumor cells to access the vascular system through formation of a new blood supply 
through angiogenesis [17]. Angiogenesis in healthy tissues is a highly regulated process, 
but disproportionate production of angiogenic growth factors such as vascular endothelial 
growth factor as well as inhibitors such as thrombospondin-1 in the tumor environment 
lead to abnormal vascular development that varies from tumor to tumor [17-19]. Tumor 
angiogenic vessels can be comprised of cancer cells and abnormal endothelial cells, 
contributing to their irregularity [20]. These vessels are also chaotic in nature, ranging in 
diameter from 10-200µm and lacking traditional features such as basement membrane, 
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functional pericytes for constriction, arterioles, capillaries, and venules [17, 20, 21]. 
These physiological differences together with rapid development result in highly 
permeable “leaky” vessels, with endothelial gaps ranging from 100-1000nm and 
averaging approximately 700nm [22]. Studies have shown that tumors possess a 
characteristic pore cutoff size ranging from 380-780nm, with the size of these pores 
increasing with stage and malignancy [6, 23-25].  
Increased vascular permeability causes an increase in the osmotic pressure of the 
tumor interstitium, due to outflow of proteins and other molecules from the vascular 
pores [26]. In normal tissues, this pressure would be dissipated by a system of lymphatic 
vessels collecting the outflow and transporting it back into the vascular system; however, 
many tumors lack lymphatic vessels causing accumulation within the tumor interstitium 
[9, 11, 26, 27]. While these high pressures (up to 18mmHg) reduce the transport of large 
molecules and drugs from the blood to the tumor, the lack of lymphatic drainage can 
allow small particles to accumulate in the interstitia in a phenomenon known as the 
Enhanced Permeability and Retention (EPR) effect [9, 26, 28]. Several studies have 
focused on exploiting the EPR effect for chemotherapeutic delivery, aiming to 
encapsulate drug within delivery vessels small enough to pass freely through the leaky 
tumor vasculature allowing for accumulation and delivery to the tumor tissue [6, 8, 10, 
29]. However, reliance on the EPR effect is limited by slow accumulation (up to 6 hours) 
and inconsistent degrees of tumor vessel permeability, and is precluded entirely in some 
tumors that do not exhibit an EPR effect [8-11]. 
There are a number of factors that inhibit direct drug delivery to solid tumors, 
including irregular vasculature, uneven blood flow, and high interstitial pressures [11, 23, 
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30]. As such, primary options for cancer treatment include chemotherapy, radiation and 
ablation treatment, and surgical removal.  
Chemotherapy is one of the most common methods of cancer treatment, 
applicable to a variety of cancer types. Chemotherapy treatment involves systemic 
injection and circulation of drugs, often toxic, that attack rapidly dividing cells such as 
cancer cells. However, most chemotherapy drugs are non-selective, and patients 
receiving treatment often experience strong negative side effects, such as lowered 
resistance to infection, anemia, increased bleeding, dehydration, alopecia/hair loss, 
nausea, fatigue, and pain. Another concern with traditional chemotherapy is systemic 
toxicity, causing complications such as collateral damage to heart, liver, and kidney 
tissues. Treatment efficacy is often limited due to the low doses administered to control 
these dangerous side effects, further reducing the potency and efficiency at the tumor site. 
Doxorubicin, the drug evaluated in this thesis, is a commonly used chemotherapy drug 
that will be discussed in more detail later in this chapter.  
Development of localized treatments, such as 3D confocal radiation therapy, have 
greatly improved cancer treatment with radiation. Recent developments have not yet been 
able to mitigate the side effects of these treatments, which include hair loss, damage to 
healthy tissue, nausea, and vomiting. Additionally, deep tumors are difficult to treat with 
radiation, as attenuation through tissue and positioning behind other organs or tissues 
limit the ability to reach the region of interest. In some cancers, radiation has been shown 
to only relieve symptoms with no improvement to survival rates [31]. Tumor ablation is 
also very limited in applications, only being considered viable for very small tumors (≤ 
1cc) that are accessible by the probe, and is limited by high recurrence rates [32, 33]. 
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One of the more invasive cancer treatments is surgical tumor removal, and is 
limited by ability to reach the tumor without significant damage to surrounding tissues 
and organs. Recurrence rates can be high for surgical resection, especially if cancer cells 
have metastasized and spread to other areas of the body. Many times, surgical removal is 
followed by radiation and/or chemotherapy to help reduce the chance of recurrence and 
improve survival rates.  
2.1.3 Current Treatment for Breast Cancer 
Breast cancer treatment often depends on the stage of the disease and tumor 
characteristics. Among the treatment options discussed in the preceding section, breast 
cancer treatment usually involves surgical intervention by way of removing the tumor 
and its surrounding tissue (lumpectomy) or removal of the entire breast (mastectomy). 
Surgical removal is often combined with radiation therapy, hormone therapy, or 
chemotherapy. Recurrence is decreased when lumpectomy is combined with radiation 
therapy, and 20-year survival rates are similar to those of patients who underwent 
mastectomy without additional radiation [34]. These findings represent a great advantage 
for breast cancer patients, allowing them to undergo a less invasive surgery and to retain 
their breast tissue and improve their self-image and emotional state during and following 
treatment.  
When radiation therapy is utilized, ionizing radiation is focused at the tumor site 
with an external beam of X-rays or gamma rays. The radiation creates free radicals that 
damage the cancer cell DNA in the hopes of inhibiting proliferation, leading to cell death 
through apoptosis or necrosis [35]. Even though state-of-the-art technology is used to 
create 3D maps of the tumor area for highly-controlled dose, radiation therapy still causes 
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DNA damage to healthy cells in the area surrounding the region of interest, especially the 
skin cells that the beam must pass through to reach the tumor.  
Chemotherapy is often co-administered with surgical removal, both before and 
after surgery to help kill any metastatic cells that have spread beyond the region of 
interest. Common drugs used to treat breast cancer include Dox, docetaxel, paclitaxel, 
and 5 fluorouracil (5FU), and these drugs are often administered in combination to help 
improve survival rates up to 38% for patients receiving combination therapy [12, 13].  
2.1.4 Doxorubicin and TRAIL 
While the platforms developed and discussed in this thesis are not drug specific, 
the main focus is on delivery of Dox as it is widely used as a cancer chemotherapeutic. 
As a member of the anthracycline class of drugs, Dox (brand names Adriamycin®, 
Rubex®, Doxil®) is a hydrophilic compound with a molecular weight of 543 Daltons 
and consists of an aglycone ring covalently bound to an amino sugar, as shown in Figure 
2.1 [36].  
 
 
 
 
Figure 2.1: Chemical structure of doxorubicin. 
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Dox is effective against cancer cells via two main mechanisms of action: 
intercalation of the aglycone ring between DNA base pairs and inhibition of 
topoisomerase II. As a result of intercalation, Dox blocks DNA synthesis and 
transcription, limiting cell replication. In normal cell division, topoisomerase II assists 
DNA transcription by creating transient breaks in the DNA strands that allow the double 
helix to untwist and then resealing the untwisted DNA strands without any sequence 
changes. When Dox inhibits this enzyme by forming a complex between the amino sugar, 
DNA, and topoisomerase II, DNA cannot be resealed thus stopping any replication [37, 
38].  
 As stated previously, Dox has been used to treat various cancer types, including 
liver, breast, ovarian, esophageal, endometrial, and lung tumors [39, 40]. However, 
systemic administration of Dox results in side effects including hair loss, nausea, 
leukopenia, myelosuppression, and neutropenia, most of which are temporary during the 
duration of treatment. One of the more serious risks associated with Dox treatment is 
cardiotoxicity, as the generation of free radicals from administration can cause dilative 
cardiomyopathy and congestive heart failure (CHF) [37, 40]. Congestive heart failure risk 
is dependent on cumulative Dox dose, with 4% of patients developing CHF when 
cumulative dose reaches 500mg/m2 and 36% of patients developing CHF when 
cumulative dose exceeds 600mg/m2 [40]. 
 Another treatment associated with cancer therapy is receptor-specific ligands to 
induce anti-cancer action, and this thesis specifically investigates tumor necrosis factor-
related apoptosis inducing ligand (TRAIL). TRAIL can act as both a targeting and 
therapeutic entity, selectively binding to specific cell surface receptors on cancer cells 
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that signal apoptosis upon this binding, but do not induce apoptosis in healthy cells. 
TRAIL induces apoptosis in tumor cells by binding to death receptors TRAIL-R1 (DR4) 
and TRAIL-R2 (DR5). Activation of DR4 and DR5 causes induction of an apoptotic 
signal from the membrane through the cytoplasm to the nucleus, resulting in cell death 
[41-44]. An advantage of TRAIL over other similar ligands, such as tumor necrosis factor 
(TNF) and Fas ligand (FasL), is that TRAIL is non-toxic to healthy cells, which do not 
express DR4 and DR5 receptors but instead express DcR1 and DcR2 decoy receptors that 
lack the transmembrane signaling component [42, 44, 45]. All four receptors have been 
shown to exhibit high affinity for TRAIL binding in several cancer types [46]. For 
example, evaluation of tumor tissue from colon cancer patients revealed that 92% of 
tumors expressed DR4 and 87% expressed DR5 [47]. In clinical trials, however, TRAIL 
has performed below expectations, with two mechanisms suggested to be the cause. First, 
bioavailability may be diminished due to non-productive binding to decoy receptors, 
limiting productive binding to DR4 and DR5 [48]. Secondly, some cancer cells are 
resistant to TRAIL-induced apoptosis, limiting efficacy. Several studies have investigated 
methods of overcoming this resistance, identifying compounds such as proteasome 
inhibitors and other drugs, including Dox, that can potentiate the apoptotic activity of 
TRAIL [49-54].  
 TRAIL acts by inducing apoptosis in cancer cells, which is a process of 
programmed cell death characterized by chromatin condensation, DNA fragmentation, 
membrane blebbing, and cell shrinkage, and plays critical roles in homeostatic 
maintenance [55]. Apoptosis occurs through extrinsic and intrinsic pathways, with a 
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caspase cascade that cleaves regulatory and structural molecules to cause cell death as the 
final step in each pathway (Figure 2.2).  
 
 
 
 
Figure 2.2: Apoptosis: the 'extrinsic' and 'intrinsic' pathways to caspase activation. 
Reprinted with permission from [56]. 
 
 
The extrinsic pathway, also known as the death receptor (DR) pathway, is induced 
by extracellular agents such as TRAIL, TNF, and FasL through activation of specific 
DRs expressed on the cell membrane. When their specific ligands bind and form 
dimer/trimer complexes, DRs recruit adaptor molecules such as caspase-8 and caspase-10 
to further transmit the death-induction signal [55, 56]. The intrinsic apoptotic mechanism 
acts by perturbing the mitochondrial membrane, relying on release of apoptogenic factors 
for activation [56]. Both the extrinsic and intrinsic pathways activate caspase cascades, 
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which are responsible for inducing the morphological and biochemical changes 
associated with apoptotic cellular phenotype [56]. 
2.1.5 Targeted Drug Delivery in Cancer 
Effectiveness of systemic cancer treatment is limited by lack of sensitivity and 
selectiveness of most anticancer drugs, resulting in undesirable side effects and 
significant toxicity to healthy tissues. Targeted drug delivery in cancer therapy refers to a 
system that delivers therapeutic concentrations of drug to the intended tumor cells (target) 
while reducing systemic exposure, limiting uptake by healthy cells, and improving the 
overall therapeutic index [57]. Drug carriers, such as liposomes, dendrimers, 
nanoparticles, microspheres, or polymer-drug conjugates are common targeted drug 
delivery systems used for cancer treatment [58]. These particles must either rely on 
passive targeting through the EPR effect, or be actively targeted to cells of interest 
through cell markers such as integrins and monoclonal antibodies. Carriers can also be 
designed to be environmentally responsive, triggered to release drugs at the region of 
interest in response to changes in pH or temperature, or through external stimuli such as 
heat, light, magnetic fields, or ultrasound waves [59-61]. A PEGylated liposomal Dox-
carrying agent, Doxil® (Johnson & Johnson, Langhorne, PA), is an FDA-approved drug 
carrier that has been demonstrated to reduce cardiotoxicity and systemic side effects 
while also improving survival rates [62]. Studies such as this provided preliminary 
evidence that drug encapsulation can help reduce systemic side effects while still 
providing effective drug delivery at the target site. As a result, many research efforts have 
focused on development of drug-loaded microspheres as more efficient drug delivery 
vehicles.  
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2.2 Ultrasound and Contrast Agents 
Ultrasound (US) has become one of the most widely used imaging modalities in 
diagnostic imaging. Some of the advantages of US are that it is non-invasive, non-
ionizing, less expensive than other imaging modalities, portable, and provides real-time 
imaging [63]. Imaging sensitivity can be improved with the use of ultrasound contrast 
agents (UCA), which are injectable bubbles that increase the impedance mismatch and 
enhance the US image.  
2.2.1 Ultrasound 
Ultrasound is characterized by the transmission of a short cyclic pressure (sound) 
wave from a transducer through the body. As these acoustic waves pass through the 
tissue, some of the energy is lost to attenuation caused by scattering and friction. 
Attenuation can be estimated by:  
  𝐴𝑡𝑡𝑒𝑛𝑢𝑎𝑡𝑖𝑜𝑛 = 	𝛼𝐿𝑓    (Eq. 1) 
where α is the attenuation coefficient (assumed to be 0.3dB/MHz cm-1 along the beam 
axis for most soft tissue), L is the transmission distance (cm), and f is the transmission 
frequency (MHz).  
 When transmitted waves passing through the tissues reach a boundary with an 
impedance mismatch, some of the energy is reflected back to the transducer while the 
remaining energy continues to pass through the tissue until it encounters another 
boundary or is absorbed by the body. Reflected waves are used to generate images. The 
acoustic impedance (Z) of a material is defined as:  
  𝑍 = 	𝜌𝑐     (Eq. 2) 
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where ρ is the density of the material (kg/m3) and c is the speed of sound in that material 
(m/s). The reflection coefficient (R) describes the degree of reflection exhibited by an US 
wave when passing from one medium to a second medium. The reflection coefficient of 
an acoustic wave passing through two media is defined as:  
  𝑅 = 	 234	25236	25 7     (Eq. 3) 
where z is the acoustic impedance (kg/m2s). An R value of 1 signifies 100% wave 
reflection, while an R value of 0 signifies 100% transmission of the wave. 
 Some characteristics used to describe an acoustic signal, which can be selected by 
the sonographer, include its center frequency in MHz, pressure amplitude or peak 
negative (rarefactional) pressure (PNP) in Pa, pulse length in seconds, pulse repetition 
frequency in Hz, duty cycle, and intensity in W/cm2. The intensity (I) of a continuous 
wave is defined as:  
  𝐼 = 9:937; = 	 9<=>3;    (Eq. 4) 
where PRMS (Pa) is the root mean square of the pressure wave. For pulsed US, wave 
intensity can also be described as the spatial peak temporal average intensity ISPTA 
(W/cm2) and the spatial peak pulse average intensity ISPPA (W/cm2), which are defined as:  
  𝐼?9@A = 𝐼	×	𝐷𝐶    (Eq. 5) 
  𝐼?99A = 	𝐼     (Eq. 6) 
where DC is the duty cycle of the acoustic wave [64]. The current FDA recommendations 
for diagnostic ultrasound suggest a derated maximum ISTPA of 0.72 W/cm2 and an ISPPA of 
190 W/cm2 [64]. 
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 Clinical US, administered to patients, is also described by a safety index, 
mechanical index (MI), that relates to the risk of non-thermal damage to the tissue. MI is 
an empirical factor that is standardized across all medical transducers and US systems, 
and is defined by:  
  𝑀𝐼 = 9:9FG	     (Eq. 7) 
where PNP is the peak negative pressure (MPa) of the US wave, and FC is the center 
frequency (MHz) of the US wave [65, 66]. The maximum allowable MI for clinical use 
on humans is 1.9 by current FDA standards.  
2.2.2 Ultrasound Contrast Agents 
The numerous advantages of US imaging have led to various research efforts 
focused on developing technology to expand the range of imaging applications while also 
improving the overall imaging quality. For example, cardiac imaging has been improved 
by introducing small stabilized gas bubbles, known as contrast agents, into the blood 
stream to enhance tissue delineation [67]. Broadly, ultrasound contrast agents (UCA) are 
gas-filled microbubbles that can be injected intravenously to provide an impedance 
mismatch (increasing contrast by at least 20dB) [68, 69]. These microbubbles reflect US 
due to the acoustic impedance mismatch between air and water, or in the body the blood 
to gas interface (Eq. 3). Air is considered a “perfect” reflector of US waves in blood and 
tissue, as the reflection coefficient for a boundary between air (Zair = 415 Pa*s/m) and 
water (Zwater = 1.49 x 106 Pa*s/m) is nearly 1 at 20°C, 1 atm, and 20dB, indicating that 
almost all energy is reflected back to the transducer [70]. The strong signal generated by 
microbubbles results from the difference in compressibility between a gas bubble and the 
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surrounding tissue (~20,000x greater than tissue), allowing the microbubbles to resonate 
and reflect an US signal roughly 1,000 times greater than a gas microbubble of the same 
diameter in a rigid shell [71]. 
 Understanding how UCA will behave in circulation and under insonation are 
important considerations to determine the type and dosage of UCA to use, as well as the 
appropriate US imaging parameters for optimal visualization. Various in vitro models 
have been used to predict how UCA will function in vivo. Here we will briefly discuss 
three main UCA characterization categories: UCA stability, backscattering radius, and 
resonant frequency.  
 The encapsulated gas bubble within the UCA must be stabilized to prevent 
diffusion of the gas into the solution when suspended in solution. UCA stability can be 
determined by exposing suspended agents to intermittent US scanning over a set period 
of time, either in vitro or in vivo, and comparing normalized enhancement values. Many 
research efforts have focused on modeling gas diffusion through the stabilized UCA, 
resulting in the Epstein-Plesset model with modifications to account for shell resistance:  
 
HIHJ = 	 4KLM 6N>OPQQ 5R3STULVG5RWSXTUL    (Eq. 8) 
where t is time, r is UCA radius, L is Ostwald’s coefficient, D is the diffusion coefficient 
of the gas in liquid, RShell is the resistance of the shell to gas permeation, and C is the ratio 
of concentration of dissolved gas to its saturated concentration, γ is bubble surface 
tension, and PF is hydrostatic fluid pressure [72, 73]. Based on this model, the presence 
of a stabilizing shell reduces the rate of bubble shrinkage over time, due to the reduction 
of surface tension and gas diffusion that comes with shell encapsulation.  
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 UCA expand and contract as the acoustic wave passes through it, in a 
phenomenon known as cavitation. The degree to which the agent expands and contracts is 
proportional to the pressure rarefaction and compression of the sound wave, respectively. 
Microbubble backscattering radius, or scattering cross-section, can be modeled 
empirically with the following equation, under the assumption that the product of US 
wavenumber and radius scatterer value is much less than one:  
 𝜎 = 	 Z>	×	[\	×	]3Z^      (Eq. 9) 
where σ represents the scattering cross-section, I0 represents the applied wave intensity, 
IS is the scattering intensity, and d represents the distance between the UCA and the 
transducer. Backscattering area describes how well a contrast agent reflects US waves, 
and provides an indication of how effectively a UCA will provide acoustic enhancement. 
It is important to note that the UCA scattering cross-section can be orders of magnitude 
larger than the physical area of the UCA itself [74]. A more precise calculation of 
scattering cross-section taking into account the adiabatic compressibility and density of 
the UCA and surrounding fluid can be performed with the following equation:  𝜎 = 	 [\I_`Xa bc4bdbd 7 + fg hc4hd7hc6hd 7   (Eq. 10) 
where K represents the wavenumber, κs is the scatterer compressibility, κf is the fluid 
compressibility, ρs represents the scatterer density, ρf represents the fluid density, and r is 
the UCA radius. Scattering cross-section is sensitive to insonation parameters, increasing 
with frequency (wavenumber) to the fourth power, and UCA characteristics, increasing 
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with radius to the sixth power, both having great importance to the overall effectiveness 
of the UCA to provide acoustic enhancement.  
 UCA backscatter and scattering cross-section are maximized when UCA can 
oscillate at harmonics, or its resonant frequency. The resonant frequency of a free bubble 
is modeled with the following equation:  
   𝑓i = 	 jkii7I     (Eq. 11) 
where f0 is the frequency (kHz) and r is the radius of the free bubble (µm) [75]. Models 
have also been developed to estimate the natural frequency of encapsulated gas bubbles, 
taking into account elastic compression modulus (χ) and harmonics, such as this equation 
by Marmottant:  
 𝑓i ≈ 	 f7\N^ fh 3𝑘𝑝i − 7q N^N^ (3𝑘 − 1) + [uN^  (Eq. 12) 
where R0 is the microbubble radius, γ is microbubble surface tension, ρ is the liquid 
density, p0 is pressure, and k is the polytropic gas exponent [76, 77]. This model 
demonstrates that resonant frequency increases as Young’s Modulus of the UCA 
increases. Resonance also affects scattering cross-section, increasing backscattering area 
up to three orders of magnitude over the actual cross section of a free bubble, as shown in 
the following model by Anderson and Hamilton:  
 𝜎 = 	 [\I3dd^ 34f 36	 dd^ XH3   (Eq. 13) 
where δ represents the bubble shell damping coefficient [74, 78, 79]. UCA performance 
can be optimized with a solid understanding of the stability, backscattering radius, and 
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resonant frequency of the agents for proper use. Empirical calculations can be used to 
estimate these properties during agent design, but they can also be determined 
experimentally for thorough agent evaluation and characterization.  
2.2.3 Existing Ultrasound Contrast Agents 
UCA have been developed using a variety of materials and gases. An ideal UCA 
would provide a high degree of acoustic enhancement, be non-toxic, be injected 
intravenously, have a diameter of 6µm or less to pass freely through the capillary bed, 
and have appropriate stability to withstand the duration of an US examination [79]. Initial 
attempts involved agitation of a saline or sugar solution, but these free air bubbles were 
highly unstable and often filtered by the lungs upon administration [80]. This instability 
is due to the pressure difference (ΔP) across the gas to blood interface, which can be 
determined using the LaPlace equation:  
   ∆𝑃 = 𝑃x − 𝑃F = 7qI             (Eq. 14) 
where PG is the gas pressure within the microbubble (N/m2), PF is the hydrostatic fluid 
pressure (N/m2), γ is the bubble surface tension (N/m), and r is the radius of the 
microbubble (m). For a free air bubble of radius 2µm, ΔP is approximately 1bar making it 
highly unstable in solution [80]. Based on these calculations, the majority of research to 
develop UCA has focused on creation of gas bubbles encapsulated within an outer shell 
for added stability.  
 Over the last few decades, many iterations of UCA have been developed with 
various combinations of gases (i.e. air, sulfur hexafluoride (SF6), and oxygen) and shell 
materials (i.e. synthetic polymers, proteins, phospholipids, and surfactants) with mixed 
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success [69, 81, 82]. Currently, only three UCA (Optison, Definity, and Lumason) are 
FDA-approved for use in the United States. Optison contrast agents (GE Healthcare, 
approved 1997) are human albumin-stabilized perfluorocarbon (C3F8) gas bubbles, while 
Definity (Lantheus Medical Imaging, approved 2001) is a phospholipid-stabilized, 
PEGylated C3F8 microbubble. Lumason contrast agents, formerly known as SonoVue, 
(Bracco Diagnostics, approved 2014 (heart) and 2016 (liver)) are lipid microspheres 
filled with sulfur hexafluoride (SF6), and are approved for use in echocardiograms and 
liver imaging. SonoVue contrast agents (Bracco Diagnostics) have been approved for use 
in Europe, South America, and China, and are comprised of an SF6 core encapsulated 
within a phospholipid shell containing PEG4000, non-PEGylated lipids, and palmitic 
acid. 
2.2.4 Polymer Ultrasound Contrast Agents 
Polymer-shelled UCA have also been developed and investigated, however no 
polymeric UCA have been approved for clinical use in humans in the United States as of 
2015. Initial efforts involved the use of natural polymers, such as alginate and collagen, 
but have since largely transitioned to synthetic polymers such as poly(lactic-co-glycolic) 
acid (PLGA) and poly(lactic acid) (PLA). Synthetic polymer UCA fabrication generally 
involves emulsification of an ammonium acetate or ammonium bicarbonate solution 
(aqueous phase) with the polymeric solution (organic phase) followed by spray drying or 
lyophilization [83-86].  
The polymeric UCA that have been developed in the Wheatley Lab are fabricated 
using a water in oil in water (w/o/w) double emulsion process to create an air-filled 
microbubble stabilized by a PLA shell with residual poly(vinyl alcohol) (PVA) [3, 87-
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90]. The resulting UCA have an average diameter of 1-2µm, with a shell thickness of 
100-200nm (10% of diameter), have been shown to provide an acoustic enhancement of 
over 20dB at 5MHz in vitro and in vivo, and are stable enough to withstand the duration 
of a typical US examination (15-20 minutes) [87-89, 91]. 
PLA (Figure 2.3) is a logical choice for our UCA shell material, since it is 
biodegradable, its breakdown product (lactic acid) is a natural body metabolite, and it is 
FDA approved for clinical use in injectable devices. Important material properties of 
PLA that enhance its candidacy as UCA shell material and a drug delivery vehicle are its 
Young’s Modulus (350-2800MPa), glass transition temperature (45-65°C), and density 
(1210-1430kg/m3) [92].  
 
 
 
 
Figure 2.3: Chemical structure of poly(lactic acid) repeating unit. 
 
 
 
Polymeric UCA have been shown to withstand higher US pressures than lipid-
based UCA, with studies showing tolerance of over 0.54MPa higher PNP levels than 
phospholipid agents [93]. Polymeric agents also have increased shell volume compared to 
lipid-based agents, suggesting that polymeric agents can encapsulate higher drug 
payloads within the shell for therapeutic applications.  
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2.2.5 Ultrasound-induced Contrast Agent Action 
Aside from US image enhancement, UCA can be used to cause physiological 
effects for therapeutic applications as a result of their unique interaction with and 
response to acoustic waves. As discussed previously, the highly compressible gas core of 
UCA cavitates when exposed to the rarefaction and compression of a pulsed acoustic 
pressure wave [94]. At moderate US intensities (lower MI, 0.1-0.3), UCA undergo stable 
cavitation, where the encapsulated gas bubble will oscillate around the resonant diameter, 
vibrating millions of times per second with a velocity up to 700m/s [95, 96]. At higher 
US intensities (higher MI, 0.3-0.5), UCA undergo inertial cavitation characterized by 
rapid expansion in the rarefaction phase followed by rapid collapse due to inertia of the 
surrounding fluid during the compression phase [96]. This violent bubble collapse can 
create local physiological effects such as microstreaming, mechanical shock waves, 
microjets, free radical generation, and temperatures as high as 5000K [97]. As the bubble 
collapses against a boundary, fluid away from the boundary will be focused and 
accelerated through the bubble, forming a liquid jet in the direction of the boundary that 
can travel over 20µm with an average velocity of roughly 80m/s and pressures up to 
60MPa [94, 98]. These microjets have been shown to be capable of penetrating the cell 
membrane, in a phenomenon known as sonoporation [99]. Research efforts are being 
pursued to exploit this cell permeabilization ability for drug delivery and gene therapy.  
2.2.6 Blood Vessel Permeability and Radiation Force 
Sonoporation is not only limited to cell membranes, but has also been used to 
increase vascular permeability. US triggering of UCA has been shown to create gaps in 
artificial endothelia and cell monolayers under in vitro conditions [100]. Further studies 
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have demonstrated formation of discrete extravasation points in skeletal muscle in 
response to insonation (1MHz, 0.75MPa, pulse length 100µs) of Optison UCA flowing 
through capillaries, and that nanoparticles 100nm in diameter can escape through these 
pores [101]. Additionally, capillary rupture and cell death can be correlated with the MI 
used while imaging in these studies [102]. In this second study and another similar study, 
research shows that red blood cells, polymer microspheres up to 500nm in diameter, and 
Opticell fragments exhibited extravasation from the US-cavitation induced capillary 
rupture [102, 103]. However, other groups have demonstrated that US-induced increased 
in capillary permeability is transient, with permeability returning to near normal levels 
approximately 60 minutes after completion of insonation until healed through platelet 
activation [104, 105].  
Since sonoporation is most effective when the UCA is against the boundary of the 
vessel wall, harnessing the radiation forces on the cavitating UCA help maximize the 
capillary rupture and extravasation potential. When placed in an acoustic field, UCA 
experience directional radiation force in response to the pressure gradient generated by 
acoustic waves passing through a medium. The primary radiation force UCA experience 
is directed away from the transducer, and is defined as:  
  𝐹I = 	 7\9z3I{|H}^ ~@     (Eq. 14) 
where Pa represent the peak applied acoustic pressure, r is the UCA radius, δ is the 
damping coefficient, ϱ is the medium density, w0 is the angular resonance frequency of 
the UCA, and [D/T] is the US duty cycle [106]. Dayton et al. also developed an equation 
to describe the primary radiation force averaged over an acoustic cycle:  
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 𝐹 = 	~(93N^)h| dLddLd 34f 36	 dLd 3  (Eq. 15) 
where δ is the total damping coefficient, fr is the UCA resonance frequency, f is the 
driving US wave frequency, and R0 is the initial UCA radius [107]. When the resonance 
frequency of the UCA and US frequency used for insonation are the same, the force 
equation can be simplified to:  
  𝐹 = 	~(93N^)h|H     (Eq. 16) 
This group went to use high-speed photography to show that radiation forces can move 
microbubbles up to 5µm during a single 20 cycle pulse (2.25MHz, 380kPa) at an average 
velocity of 500mm/s [108]. This same group went on to demonstrate deposition of 
fluorescent nanoparticles attached to phospholipid UCA onto a biotin-coated cellulose 
tube surface using radiation forces [109].  
 Radiation force is not only dependent on the intensity of the applied US wave, but 
also on the size of the particle with forces exerted decreasing as particle size decreases. 
Smaller particles are also characterized by higher resonance frequencies, causing lower 
radiation forces to be exhibited by these particles. Additionally, the US-reflective UCA 
core plays a critical role in driving particles with radiation forces. Studies have shown 
that radiation forces on solid particles in the micron-nanometer range were significantly 
lower than those observed on gas-filled particles [110]. UCA in solution under insonation 
are also susceptible to secondary Bjerknes forces as a results of the US-induced 
oscillations causing attraction between particles. However, these forces are generally very 
small (0.5pN at a separation distance of 200µm, 2MHz insonation at 122kPa and PRF 
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10Hz) compared to radiation forces (0.9nM at the same parameters) [106]. These forces 
can be harnessed and exploited to improve delivery efficacy of drug-loaded, polymer-
shelled, micron-sized UCA.  
2.2.7 Ultrasound-triggered Targeted Drug Delivery 
The physiological effects induced by US insonation have been used in a variety of 
ways for targeted drug delivery, both with and without the use of contrast agents. Studies 
have demonstrated increased cytotoxicity and drug retention at the tumor site when 
exposed to therapeutic US (up to a 3-fold increase for Dox) compared to cells that were 
not insonated [111, 112]. Increased cytotoxicity is likely due to increased cell uptake of 
drug in response to US-induced increases in cell membrane permeability [112].  
These therapeutic benefits of combining chemotherapy with US insonation 
become even more clear and significant when UCA are also utilized in drug delivery. 
Several groups have demonstrated enhanced drug uptake, cytotoxicity, and tumor 
suppression when UCA are co-administered with chemotherapy drugs such as Dox and 
bleomycin in the presence of US, compared to groups receiving drug and US without 
UCA and groups receiving drug only [113, 114]. Other studies have shown that small 
molecules, such as genes and peptides, can be effectively delivered to the intracellular 
space when administered with UCA and focused insonation causing cavitation-induced 
permeability [115-117]. 
Drugs have also been loaded into UCA for drug delivery without systemic 
administration of free drug, aiming to increase bioavailability at the tumor site while 
sparing healthy tissues from collateral damage from exposure to the toxic drug. This 
treatment modality uses US pressures to induce inertial cavitation and UCA destruction, 
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resulting in drug release localized to the region of interest. Several studies have 
investigated the development of lipid-based, drug-loaded UCA, demonstrating successful 
drug release in response to exposure to US. For example, Lentacker et al. loaded Dox-
filled, nano-sized liposomes to the surface of a phospholipid-shelled UCA (total loading 
roughly 3.25 x 10-8 µgDox/bubble) and showed significantly more cytotoxicity when 
UCA were triggered with US in vitro (1MHz, I= 2W/cm2) [118]. Similarly, Huang et al. 
demonstrated that calcein was successfully released from phospholipid liposomes when 
exposed to a 1MHz transducer [119]. As an alternative to thin-walled lipid-based UCA, a 
good deal of research is being directed toward the development of polymer-shelled UCA 
where the thicker shell (100-400nm) can increase drug loading and ultimately improve 
targeted, US-driven drug delivery. As an example, the gas core can be partially replaced 
with hexadecane oil loaded with lipophilic drugs that can release from the UCA when the 
polymeric shell is cracked by cavitational destruction in response to US exposure [120]. 
Additionally, drugs encapsulated within the UCA shell can undergo sustained release as 
the surrounding polymer hydrolyzes, providing prolonged treatment times. However, 
lipid-based UCA for drug delivery currently dominate the literature, due to their ease of 
fabrication, immediate release profile, and commercial availability. Nonetheless, the 
increased shell stability, potential for increased drug loading, and sustained release of 
encapsulated drug from polymer-shelled UCA warrants further investigation for targeted 
drug delivery applications.   
Specifically to the polymeric UCA created in the Wheatley lab, we have reported 
on encapsulation of Dox within the air-filled PLA shell, the presence of which has been 
visualized using confocal microscopy [2, 3]. The double emulsion (w/o/w) preparation 
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method used to fabricate our PLA-shelled UCA is versatile for encapsulation of drugs or 
other species for US-guided delivery, since species can be incorporated into either the 
organic or aqueous phase [2, 4, 121, 122]. Dox-loaded PLA UCA have shown significant 
greater cytotoxic effects on cancer cells in vitro when triggered with US, compared to 
non-insonated controls [121]. In a separate study, insonation of these resulted in 
significant particle size reduction (below 400nm), likely due to shell fragmentation into 
nanoshards (n-Sh) induced by inertial cavitation [4]. Promising in vivo studies in a rat 
hepatocellular carcinoma model demonstrated extravasation potential of these US-
generated n-Sh in addition to effective delivery of Dox to tumor tissue, resulting in 
measureable tumor stasis [5]. However, elevated Dox levels were also observed in the 
spleen and healthy liver, indicating mononuclear phagocyte system (MPS) involvement 
[123-127]. Based on these results, we hypothesize that intact MB and/or n-Sh that were 
not taken up into the tumor were recognized by the immune system while circulating 
through the blood stream and thus accumulated in the spleen and healthy liver. Therefore, 
the major focus of this thesis is to develop drug-loaded UCA that can avoid recognition 
and removal by the immune system, improving delivery to the target site while protecting 
susceptible organs and tissues.  
2.3 Immune Considerations with Drug Delivery in Cancer 
Many of the side effects associated with chemotherapy drug administration 
involve an immune component, especially inflammation and damage to the liver, spleen, 
and kidneys. Systemically-injected drug, whether freely administered or encapsulated 
within a drug carrier, can be recognized as a foreign body in the blood stream and 
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removed from circulation by the components of the immune system. The most relevant 
immune components to the platform investigated in this thesis are discussed below.  
2.3.1 Mononuclear Phagocyte System 
 A major factor that has limited efficacy and success of most injectable drug 
delivery vehicles has been immune recognition through the mononuclear phagocyte 
system (MPS) and its rapid detection and removal of injected particles from the blood 
stream. The MPS is comprised of a group of highly phagocytic mononuclear cells, such 
as macrophages in tissues and monocytes in blood [128]. Macrophages are responsible 
for clearing the blood, lymph, and tissues of particles, microorganisms, and dead cells, 
essentially acting as the cleaning system. The MPS acts by recognizing foreign objects 
circulating in the blood stream and removing these objects within minutes through the 
spleen and liver, through processes known as opsonization and phagocytosis respectively 
[125, 129-131]. In terms of response to injected drug delivery agents, removal by the 
MPS reduces the amount of drug available for delivery to the region of interest, while 
also causing a buildup of the toxic drug in the liver and spleen. When these particles are 
exposed to blood flow, opsonization is activated as proteins such as immunoglobulins 
and complement proteins adsorb to the particle surface and subsequently bind to 
macrophages of the MPS eventually leading to phagocytosis of the injected particle 
before ever reaching the target site [132, 133]. 
2.3.2 Complement System 
The complement system is a group of blood proteins responsible for facilitating 
opsonization and phagocytosis of foreign bodies to maintain host defense and 
inflammation [129, 134, 135]. Complement activation leads to a cascade of enzymatic 
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reactions ultimately resulting in formation of anaphylatoxins that can induce 
chemoattraction and cell death [135]. There are three different complement activation 
pathways, classical, alternate, and lectin, which all converge at complement protein C3 
activation and eventually lead to the formation of the membrane attack complex. The 
classical complement pathway is activated when immunoglobulins IgG and IgM bind to 
pathogens or other foreign bodies in the blood. Recognition of carbohydrates, lipids, and 
proteins found on foreign bodies by C3b protein triggers activation of the alternate 
complement pathway, while the lectin pathway is activated when mannose binding lectin 
binds to surfaces on yeast, bacteria, parasites, or viruses [135]. When C3, the most 
abundant complement protein in the blood, is activated in forms cleavage products C3a 
and C3b which are two of the main regulators of the complement system. While C3a is 
mainly associated with facilitating the inflammatory response, C3b identifies foreign 
bodies, adsorbs to their surface, and signals their opsonization [136]. Immunogenicity 
evaluations in this work will focus on activation of the C3 complement protein as an 
indicator of immune activation.  
2.3.3 Polyethylene Glycol 
Many strategies for avoiding immune activation and uptake have been 
investigated, including particle size, chemical makeup, and surface coating. Particle 
surface characteristics play a large role in determining which proteins will adsorb to the 
surface and how quickly they will adsorb. When designing “stealth” particles that can 
evade the immune system, hydrophobic and ionic interactions that can drive protein 
adsorption are major factors to consider; for example, highly charged particles have been 
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shown to activate more complement proteins and more rapidly bind opsonins than neutral 
particles [133, 137]. 
 In an effort to prevent opsonization and complement activation, particles can be 
modified to become “invisible” to monocytes and macrophages. One of the most 
common methods of circumventing MPS and complement recognition is surface 
modification with polyethylene glycol (PEG) [132, 137-144]. PEG is more effective at 
immune shielding than other polymers because it is highly hydrophilic, neutral in charge, 
flexible, and usually non-immunogenic [133, 145, 146]. Additionally, PEG is FDA-
approved, inexpensive, and easily modified, making it an excellent candidate for 
conjugation to various lipids and polymers for immune shielding. Surface coating with 
PEG has been shown to extend particle circulation times by reducing protein adsorption; 
however, PEG chain length and density must be optimized to the particular agent in order 
to create a “brush” that prevents protein adsorption through steric hindrance without 
creating entanglement within the chains [130, 137, 140, 145, 147]. 
 In addition to shielding particles from immune recognition, several studies 
describe PEGylation of TRAIL for increased circulation time [141, 148]. One study in 
particular investigated the sustained release of PEGylated and non-PEGylated TRAIL 
following encapsulation within PLGA microspheres [149]. PEGylated TRAIL exhibited 
sustained release from the microspheres over a period of 15 days, while non-PEGylated 
TRAIL exhibited a burst release from the microspheres and was completely cleared from 
the plasma within 3 days[149]. Studies such as this form a good basis for the PEG-
TRAIL complexes investigated in this thesis.  
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 UCA Fabrication Materials 
 Polylactic acid (PLA) 100 DL 7E, MW 118kDa, Lot# LX00414-119 was 
purchased from Evonik Lakeshore Biomaterials (Birmingham, AL). Polyethylene glycol-
polylactic acid (PEG-PLA) co-polymer 100 DL mPEG 5000 6CE, 67 mol% PLA, 33 
mol% PEG, MW 69kDa, was purchased from Evonik (Essen, Germany). 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (LipidPEG), 
MW 2.8kDa, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxyfluorescein(polyethylene glycol)-2000] were purchased from Avanti Polar 
Lipids (Alabaster, AL). Ammonium carbamate and camphor were purchased from 
Sigma-Aldrich (St. Louis, MO). Poly(vinyl alcohol) (PVA), MW 25kDa, 88 mol% 
hydrolyzed, was purchased from Polysciences (Warrington, PA). Methylene chloride 
(MeCl), isopropyl alcohol (IPA), and hexanes were purchased from Fisher Scientific 
(Pittsburgh, PA).  
3.1.2 Cells and Cell Culture Materials 
 Human breast adenocarcinoma cell lines MDA-MB-231 and MCF7, human breast 
epithelial cell line MCF-12A, human epidermal growth factor, cholera toxin, Tryspin-
EDTA 1x, USDA-tested fetal bovine serum (FBS), Eagle’s Minimum Essential Medium 
(EMEM), Ham’s F12 medium, horse serum, and bovine insulin were purchased from 
American Type Culture Collection (ATCC) (Manassas, VA). Dulbecco’s Modified 
Eagle’s Medium (DMEM) with L-glutamine, sodium pyruvate, and 4.5g/L glucose, an 
antibiotic solution (10,000 units penicillin and 10mg streptomycin per mL) and 
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hydrocortisone were purchased from Sigma-Aldrich (St. Louis, MO). Phosphate buffered 
saline (PBS) was purchased from Fisher Scientific (Pittsburgh, PA). Accutase cell 
detachment solution, FITC Annexin V Apoptosis Detection Kit II, FITC Annexin V, and 
propidium iodide (PI) were purchased from BD Biosciences (Franklin Lakes, NJ). 
Live/dead cytotoxicity assay was purchased from Invitrogen (Waltham, MA).  
3.1.3 Other Materials 
 Doxorubicin HCl (Dox) was purchased from Tecoland (Irvine, CA). Dimethyl 
sulfoxide (DMSO), acetone, glacial acetic acid, phosphate buffered saline (PBS), N-beta-
maleimidopropionic acid hydrazide (BMPH), 2-(N-morpholino)ethanesulfonic acid 
(MES), thioglycolic acid and lab consumables were purchased from Fisher Scientific 
(Pittsburgh, PA). Tumor necrosis factor-related apoptosis inducing ligand (TRAIL), 
expressed in E. coli, MW 19.6kDa, n-hydrosulfosuccinimide (NHS), and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) were purchased from 
Sigma-Aldrich (St. Louis, MO). Ethanol (200 proof) was purchased from Decon 
Laboratories (King of Prussia, PA). Human complement-preserved serum was purchased 
from Valley Biomedical (Winchester, VA). Human C3 ELISA Kit (catalog #550499) was 
purchased from BD Biosciences (Franklin Lakes, NJ). Pierce LAL Chromogenic 
Endotoxin Quantitation Kit (catalog #88282) was purchased from Life Technologies 
(Carlsbad, CA).  
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3.2 Methods 
3.2.1 Contrast Agent Fabrication 
 UCA were prepared using the water/oil/water (w/o/w) emulsion process that has 
been well-established in our lab previously [88]. Briefly, 10mL of methylene chloride, 
0.05g camphor, and 0.5g PLA were added to a 50mL beaker, and stirred for 15 minutes 
to ensure that all of the polymer had dissolved. Then, 1mL of 0.4M ammonium 
carbamate solution was added to the organic phase and sonicated with 110W applied 
power (Misonix XL2020 CL4 tapped horn probe with 0.5” tip, Farmingdale, NY) on ice 
for 30 seconds, with 1 second pauses between 3 second pulses. The first w/o emulsion 
was then added to 50mL of 5% w/v PVA solution kept at 4°C, and homogenized 
(Brinkman PT 3100 homogenizer with a Polytron PT-3020/2 saw tooth probe, Westbury, 
NY) at 9500rpm for 5 minutes to create the second emulsion. After homogenizing, 
100mL of 2% v/v isopropanol (IPA) was added, and the solution stirred at 375rpm for 90 
minutes at room temperature to evaporate off the organic material. The remaining UCA 
solution was centrifuged at 5000rpm (~2600g) for 5 minutes, and the pellet was collected 
and washed three times with hexane to remove any remaining organic material. After 
allowing the residual hexane to evaporate in the fume hood for 20 minutes, the UCA 
were washed with deionized (DI) water. The particles were then flash frozen in liquid 
nitrogen and lyophilized for 48 hours using a Virtis Benchtop freeze drier (Gardiner, NY) 
with the chambers exposed to room temperature and a pressure of 10-30µbar. The 
aqueous core material and camphor from the polymer shell were sublimated during 
lyophilization to create a porous polymer shell encapsulating a void, resulting in the 
formation of air-filled hollow microcapsules when exposed to the atmosphere. 
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3.2.2 Fabrication Modifications for UCA Functionalization 
3.2.2.1 TRAIL Ligation via Maleimide Chemistry 
Once the UCA were formed, TRAIL was ligated to the UCA surface using a 
maleimide reaction [150, 151] with a BMPH spacer arm of 0.81nm in length, using EDC 
and NHS to activate and catalyze the reactions (Figure 3.1).  
 
 
 
 
Figure 3.1: Maleimide reaction to bind TRAIL to the UCA surface. 
 
 
 
Briefly, 60mg of UCA were suspended in 4mL of 0.1M MES buffer (pH 5.2), while the 
solutions for crosslinking were prepared (14.86mg BMPH in 1mL DI water, 19.17mg 
EDC in 1mL DI water, and 12mg NHS in 1mL DI water). These solutions were added to 
the UCA suspension, which was then shaken end over end at room temperature for 30 
minutes. Activated UCA were then centrifuged at 5000rpm (~2600g) for 5 minutes and 
washed with DI water to remove unreacted EDC. The UCA were then resuspended in a 
solution of 1.2µg TRAIL in 4mL phosphate buffered saline (PBS), and shaken end over 
end at room temperature for 90 minutes. The crosslinking was stopped by adding 50µL 
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thioglycolic acid to the solution and shaking end over end for 10 minutes. TRAIL-ligated 
UCA (TRAIL-UCA) were then centrifuged (5000rpm for 5 minutes), washed 3 times 
with DI water, flash frozen in liquid nitrogen, and lyophilized for 48 hours. In 
preliminary studies, a control group was created following the ligation procedure, but 
without the use of BMPH, EDC, and NHS (non-linker control), to account for the 
possibility that observed effects were from TRAIL that was only adsorbed to the surface 
rather than covalently linked. Such adsorbed TRAIL would be easily eluted when 
contacted with cell cultures, releasing free TRAIL. 
 
3.2.2.2 PEGylation via PEG-PLA Co-polymer 
 For PEGylated MB using the co-polymer method, an aliquot of 500mg polymer 
was proportionally comprised of PEG-PLA and PLA by weight, at concentrations of 1, 2, 
5, 10, and 15 wt% (mg PEG-PLA/mg PLA). These polymers were mixed while 
dissolving in MeCl before the first emulsion, and the standard UCA fabrication procedure 
was followed to produce PEGylated agents.  
 
3.2.2.3 PEGylation via Lipid Anchoring 
 For PEGylated MB using the LipidPEG method, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-n-[carboxy(polyethylene glycol)2000] (LipidPEG), in powder 
form, was added to the PLA solution at concentrations of 0.2, 1, and 2 wt% (mg 
LipidPEG/mg PLA) prior to the first emulsion. Agents were then produced following the 
standard UCA fabrication procedure. 
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3.2.2.4 Doxorubicin Encapsulation 
 UCA loaded with Dox were generated by modifying the standard UCA 
fabrication procedure to dissolve 15mg (3% w/w) of the chemotherapeutic agent in the 
polymer solution before the primary emulsion, then proceeding with the standard 
procedure. This Dox loading procedure was followed for all agents that encapsulated the 
chemotherapeutic, regardless of PEGylation method.   
 
3.2.2.5 TRAIL Ligation to LipidPEG Molecules 
 TRAIL was attached to LipidPEG by modifying the maleimide chemistry 
technique used to ligate TRAIL to the UCA surface. Five milligrams of LipidPEG was 
suspended in 5mL MES buffer while crosslinking solutions were prepared (95.85mg 
EDC in 5mL DI water and 60mg NHS in 5mL DI water). These 5mL crosslinking 
solutions were added LipidPEG suspension, and the resulting solutions were shaken end 
over end for 30 minutes at room temperature to prepare the carboxy end group on the 
LipidPEG for crosslinking with TRAIL. After 30 minutes, 6 µg of TRAIL was added to 
the solution, which was then shaken end-over-end for 90 minutes at room temperature. 
The crosslinking reaction was stopped by adding 250 µL thioglycolic acid to the solution 
at the end of the 90 minutes. After 10 minutes, the solution was poured into Spectra/Por 7 
dialysis tubing (1kDa MW cutoff, 24.4mm diameter, Cole Parmer #132104, Vernon 
Hills, IL) and stirred in 3L DI water for 6 hours, changing the DI water every 2 hours, to 
remove the salts. The dialyzed LipidPEG-TRAIL solution was then flash frozen with 
liquid nitrogen, frozen at -20°C overnight, and lyophilized for 48 hours. 
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3.2.3 Characterization of UCA 
3.2.3.1 Acoustic Testing in vitro 
Acoustic Tank Testing of Dose and Time Response 
 Acoustic testing was performed in vitro to determine the ability of the UCA to 
interact with a focused ultrasound beam to provide enhancement as well as to measure 
the stability of the agent during insonation. The custom-built in vitro acoustic setup used 
for this testing is shown in Figure 3.2.  
 
 
 
 
Figure 3.2: Custom built acoustic setup for in vitro testing. Rendering courtesy of Nutte 
Tarn Teraphongphom. 
 
 
 
Dose and time response tests were performed using a 5 MHz, 12.7mm diameter, single 
element ultrasound transducer (Panametrics, Waltham, MA) spherically focused at a 
length of 50.8mm, 6dB bandwidth of 91%, submerged in a 37°C water bath and focused 
through the acoustically transparent window of an acrylic sample holder holding 50mL of 
1x PBS at 37°C (pH 7.4) continuously stirred on a magnetic stir plate. The cover of the 
water bath was fitted with an x-y-z positioning system (Edmund Scientific, Barrington, 
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NJ) to hold and position the ultrasonic transducer. The transducer was connected to a 
Panametrics 5072 pulser/receiver (Waltham, MA) to generate an acoustic pulse with a 
pulse repetition frequency (PRF) of 100Hz and pulse length of 1µs (duty cycle 0.01). The 
reflected signal from the UCA was detected with the transducer and amplified 40dB 
before being read by an oscilloscope (Lecroy 9350A Chestnut Ridge, NY). Data 
acquisition and processing was performed using LabView 7 Express (National 
Instruments, Austin, TX).  
 Acoustic backscattering enhancement was measured to determine the ability of 
the agent to respond to ultrasound for imaging sensitivity and drug delivery applications. 
A cumulative dose response of acoustic enhancement was performed by suspending 3mg 
of dry UCA in 800µL 1x PBS and briefly vortexing and then adding 20µL of the UCA 
suspension to the sample vessel every 30 seconds and measuring the acoustic backscatter 
signal at each time point. A PRF of 100Hz and peak negative pressure amplitude of 
0.45MPa (energy level 1) was used for these studies. The acoustic backscattering 
enhancement is defined as  𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 = 20 logfi I[A]I[]   (Eq. 17) 
where rms[UCA] represents the root mean square of the backscatter signal measured 
from the UCA and rms[Blank] represents the root mean square of the backscatter signal 
measured from the PBS solution alone prior to injection of UCA. All values were based 
on an average of three readings from five individual samples (15 readings, n=5).  
 Stability of the UCA in the presence of ultrasound was measured to determine the 
effect of these pressures on the shell stability and to determine whether the agents would 
last for the duration of a typical imaging session in a medical clinic (using 15 minutes as 
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a benchmark length of imaging time). A dosage on the linear rise portion of the dose 
response curve (generally 4µg/mL) of UCA was added to 50mL of 1x PBS at 37°C and 
continuously stirred and insonated at a peak negative pressure of 0.45MPa (energy level 
1) with a PRF of 100Hz. Enhancement was measured immediately following injection 
and every minute for a total of 15 minutes, and was then normalized with respect to the 
initial enhancement. Detailed protocols for these tests are included in Appendix A. 
Flow Phantom Imaging 
All UCA samples were evaluated with a clinical ultrasound scanner (used for 
imaging of patients in a hospital setting) and a tissue mimicking flow phantom at Thomas 
Jefferson University with the assistance of Dr. John Eisenbrey. Imaging was performed 
with an ACUSON S3000 Ultrasound System HELX™ Evolution equipped with a 9L4 
probe (Siemens, Erlangen, Germany) operated under nonlinear contrast imaging mode 
with dual contrast/grayscale imaging. A concentration of 1.0x107 UCA in 800mL 1x PBS 
was circulated through a tissue mimicking flow phantom (ATS Laboratories, model 524, 
Bridgeport, CT) with a 6mm diameter vessel embedded at a depth of 2cm in urethane 
rubber using a peristaltic pump at 350mL/minute. Dual non-linear contrast mode and 
fundamental B-mode images were captured pre-injection, at time of injection, and every 
5 minutes post injection for a total of 20 minutes.  
 
3.2.3.2 Characterization of Nanoshard (n-Sh) Behavior 
 All agents were evaluated for the potential to generate n-Sh by performing 
ultrasound triggering in the acoustic tank setup described previously (Figure 3.2). Ten 
milligrams of dry UCA was suspended in 50mL 1x PBS at 37°C and continuously stirred. 
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The sample was insonated at 5MHz with the transducer described previously, at a PRF of 
100Hz and a peak negative pressure of 0.94MPa (energy level 4). US-generated particles 
were collected after 15 minutes of insonation for size evaluation with dynamic light 
scattering in a Malvern Nano ZetaSizer (Worcestershire, United Kingdom), described in 
detail in the Size and Zeta Potential Measurements section. All experiments were 
completed in triplicate and are reported as average peak particle size by number.  
 UCA were also evaluated for the potential to extravasate as a result of cavitation 
with an in vitro model of the leaky tumor vasculature using Corning Transwell inserts 
with a 24mm diameter polyester membrane containing 400nm pores with a density of 
4x106 pores/cm2 (Lowell, MA). Inserts were modified by placing clear adhesive tape over 
the openings in the sides of the inserts to allow for higher fluid levels, which helped 
reduce the chances of creating a standing wave during insonation. An insert was placed 
into a 6 well plate containing a suspension of 3mg dry UCA in 3mL 1x PBS at 37°C. 
Three milliliters of 1x PBS was then added to the upper compartment of the insert, and 
the plate was suspended on the surface of the DI water in the acoustic tank. The 5MHz 
spherically focused transducer was oriented to insonate from below the plate at a length 
of 50.8mm from the membrane surface so that the beam would be focused at this point. A 
rubber stopper was placed above the insonated well to serve as an acoustic absorber to 
minimize reflected energy at the air-liquid interface. A schematic of this testing setup is 
shown in Figure 3.3.  
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Figure 3.3: Schematic of extravasation testing setup showing Transwell insert (light 
pink) and well plate (dark pink), with transducer and acoustic absorber. Schematic 
courtesy of Dr. John Eisenbrey [87]. 
 
 
 
The sample was insonated for 20 minutes with a peak negative pressure of 
0.94MPa (energy level 4) and a PRF of 5000Hz. At the end of the 20 minutes, a 1mL 
sample was taken from the top chamber, placed into a plastic cuvette and assessed for 
particle size using a ZetaSizer with dynamic light scattering. For Dox-loaded samples, 
200µL samples were taken from the top chamber at 0, 5, 10, 15, and 20 minutes and 
fluorescence was read in a Tecan fluorimeter (λex 495nm, λem 585nm). Dox concentration 
was then calculated based on a standard curve and expressed as the amount present above 
the membrane. All tests were performed in triplicate, and control tests were performed 
without ultrasound.  
 
3.2.3.3 Resonant Frequency Measurements 
Given the multiple modifications made to the UCA shell, it is important to 
understand the effect of these modification on the resonance and cavitation activity of the 
resulting UCA. It is important that the UCA are insonated at a frequency that matches 
their resonance to best harness their ability to serve as contrast agents and ultrasound-
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triggered drug delivery agents. To determine the resonant frequency, a pulse-echo setup 
was employed with a custom-built sample holder, equipped with an acoustically 
transparent window and an air-backed metallic reflector, holding 250mL of 1x PBS at 
37°C and stirred continuously. This sample holder was submerged in the DI water bath 
held at 37°C, and a single element, 12.7mm diameter, unfocused transducer (both 5MHz 
and 10 MHz were used) was positioned to transmit through the acoustically transparent 
window (Panametrics, Waltham, MA). The 5MHz transducer had a -6dB bandwidth of 
91% and a pulse length of 1.2mm, and the 10MHz transducer bandwidth was 65% with a 
pulse length of 0.75mm. A schematic of this setup is shown in Figure 3.4.  
 
 
 
 
Figure 3.4: Schematic of resonant frequency testing setup. Rendering courtesy of Nutte 
Tarn Teraphongphom. 
 
 
 
The Panametrics model 5072 pulser/receiver was used to pulse the transducers at 
a PRF of 100Hz, gain of 0dB, peak negative pressure of 0.45MPa (energy level 1), 
damping level of 3, and mode 1 for pulse-echo. The signals were received and visualized 
with an Agilent Technologies InfiniiVision MSO-X 2014A digital oscilloscope (Agilent, 
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Santa Clara, CA). The signals were converted to Fast Fourier Transforms (FFT) using the 
Math function of the oscilloscope. Data was acquired by collecting 250 samples of the 
baseline signal (1x PBS) and the signal after addition of 15mg UCA to a final 
concentration of 0.06mg/mL PBS. Resonant frequency was determined similarly to 
calculations by de Jong [152, 153] (Equation 18), where FFTbaseline represents the 
transform of the signal before agent was added, FFTattenuated represents the transform of 
the signal after the agent was added, and D represents the distance from the acoustic 
window (6cm).  𝐴𝑡𝑡𝑒𝑛𝑢𝑎𝑡𝑖𝑜𝑛 = 	 (FF@zcPQP4	FF@zPzP)~    (Eq. 18) 
Samples were tested in triplicate for both the 5MHz and 10MHz transducers. The 
attenuated signals were analyzed using OriginPro 8 software (OriginLab, Northampton, 
MA), using the smoothing filter with 20 points to smooth out noise signals. Final 
processed data from both the 5MHz and 10MHz transducers were plotted together with 
attenuation (dB/cm) against frequency (MHz) according to the appropriate bandwidth 
ranges for the transducers. Resonant frequency was determined as the frequency at which 
attenuation reaches a minimum point on the curve. A more detailed protocol for this 
testing is included in Appendix A. 
 
3.2.3.4 Size and Zeta Potential Measurements 
 Particle size distribution and zeta potential (ζ) measurements were performed 
using a Malvern Nano ZetaSizer (Worcestershire, United Kingdom) to assess the UCA 
population average diameter and surface charge of the agents. For particle sizing, 1mg of 
dry UCA was suspended in 1.5mL DI water by vortexing for 10 seconds, transferred to a 
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clear plastic cuvette, and measured in triplicate at room temperature. The peak particle 
size by number was recorded and reported as an average. The polydispersity index (PDI) 
was also recorded as an indication of size distribution for the population. Zeta potential 
was measured by suspending 1mg dry UCA in 1mL DI water, loading the suspension into 
a Malvern Zeta Capillary Cuvette, and reading in triplicate at room temperature. Detailed 
protocols for these tests are included in Appendix A.  
 
3.2.3.5 Scanning Electron Microscopy 
Scanning electron microscope (SEM) images were taken with a Philips FEI XL30 
Environmental SEM (Hillsboro, OR) to assess the MB surface morphology. One 
milligram of dried UCA was gently fixed onto an aluminum stub using conductive 
adhesive tape and sputter coated with platinum-palladium for 40 seconds using a Denton 
Desk-II sputtering system (Denton Vacuum, Moorestown, NJ). Imaging was performed 
under hi-vac conditions, at an average of 7x10-6 mbar vacuum pressure. Images were 
taken at varying magnifications at an accelerating voltage of 5.0kV, working distance of 
11mm, and spot size of 3. Three images are taken from a random location on each SEM 
stub holding the UCA sample. All SEM imaging and sample preparation was performed 
at the Drexel University Centralized Research Facility Materials Characterization Lab.  
 
3.2.3.6 Drug Encapsulation Measurements 
Amounts of encapsulated Dox were determined by dissolving 2mg of dry Dox-
loaded UCA in 2mL DMSO by vortexing for 30 seconds. Fluorescence of the solution 
was then read in triplicate using a Tecan fluorimeter (Männedorf, Switzerland) at an 
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excitation wavelength of 495nm and an emission wavelength of 585nm. Dox 
concentration was then calculated based on a standard curve of known amounts of Dox in 
DMSO and reported as an average. Encapsulation efficiency was determined using 
Equation 19:  𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛	𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 	 F	~	| JIJK]¡	~	| JIJ (Eq. 19) 
Encapsulation of Dox within the UCA shell was also visualized with confocal 
microscopy with assistance from Nutte Tarn Teraphongphom. Confocal microscopy was 
performed using an Olympus IX81 microscope equipped with Olympus Fluorview 1.7b 
software (Olympus, Tokyo, Japan). One milligram of dry UCA was suspended in 1mL 1x 
PBS by vortexing, and a droplet of the solution was placed onto a glass microscope slide. 
The UCA were observed at 100x magnification with the use of microscope oil 
immersion.  
 
3.2.3.7 Drug Release in vitro 
Initial drug release from Dox-loaded UCA, commonly known as burst release 
effect, was measured for each type of agent by suspending 10mg of dry UCA in 50mL of 
1x PBS at 37°C while stirring. This was performed both with and without the presence of 
a focused ultrasound beam to determine any difference in release behavior. One milliliter 
of the solution was removed immediately after suspension and every two minutes for 20 
minutes while stirring. Immediately after sampling, samples were centrifuged at 7500g 
for 2 minutes to pellet the polymer. A 200µL sample of the supernatant was read in 
triplicate using a Tecan fluorimeter at an excitation wavelength of 495nm and an 
emission wavelength of 585nm. Free Dox concentration was then calculated using a 
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calibration curve of known amounts of Dox in PBS, and expressed as a percent of total 
concentration encapsulated within the UCA.  
Long-term release profiles of Dox encapsulated within UCA were measured to 
determine the potential for sustained drug release over time, both with and without 
exposure to US. Samples were weighed to have a UCA concentration equivalent to that 
of 6mg unloaded native 100% PLA UCA and were suspended in 50mL of 1x PBS at 
37°C. The insonated group was then continuously stirred while insonated for 20 minutes 
in the same setup used for the dose and time response testing at 0.94 MPa peak negative 
pressure (Energy Level 4) and a PRF of 5000Hz. Following insonation samples were 
transferred to 50mL centrifuge tubes and rotated end-over-end in an incubator at 37°C. 
Non-insonated samples were suspended in PBS directly in the 50mL centrifuge tubes. 
For Dox measurement, samples were centrifuged at 48,000g for 20 minutes (SorvallWX 
Ultra80 Ultracentrifuge, AH-629 rotor, Thermo Electron Corp, Waltham, MA). The 
supernatant was collected for measurement, and the pellet was resuspended in 50mL 
fresh 1x PBS to maintain sink conditions. Resuspended samples were then returned to the 
rotator in the incubator until the next reading. Samples of 200µL from the collected 
supernatant were measured for Dox release by reading fluorescence using a Tecan 
Fluorimeter at an excitation wavelength of 495nm and an emission wavelength of 585nm. 
Measurements were taken at 1hr, 2hr, 4hr, 6hr, 8hr, 12hr, 24hr, 36hr, 48hr, 72hr, 96hr, 
120hr, 144hr, and 168hr after initial suspension. Concentrations of released Dox were 
determined in triplicate using a standard curve of known amounts of Dox in 1x PBS. 
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3.2.3.8 LipidPEG Quantification 
PEG loading via lipid anchoring into the MB polymeric shell was quantified using 
a PEG lipid conjugated with a carboxyfluorescein (CF) tag (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-n-[carboxyfluorescein(polyethylene glycol)2000] incorporated into 
the polymer solution prior to the first emulsion at a concentration of 1 wt%. A 1mg 
sample of the resulting UCA was dissolved in DMSO and read in triplicate with a Tecan 
Fluorimeter (λex 485nm, λem 523nm) and compared against a standard curve of CF-tagged 
LipidPEG. Anchoring of CF-tagged LipidPEG within the UCA shell was also visualized 
with confocal microscopy with assistance from Nutte Tarn Teraphongphom, as described 
previously.  
 
3.2.3.9 UCA Counting 
UCA counting was performed using a BD Accuri C6 flow cytometer (BD 
Biosciences, Franklin Lakes, NJ). Dried UCA were suspended in DI water at a 
concentration of 20µg UCA/mL DI water. An aliquot of 0.5mL of the diluted UCA 
solution was added to a round-bottomed 2mL Eppendorf tube, along with 10µL of UV 
CountBright absolute counting beads (Life Technologies, Carlsbad, CA). Counting beads 
and UCA were separated using Forward Scatter A and Phycoerythrun-A filters. A 
detailed protocol for this test is included in Appendix A. 
 
3.2.3.10 Immunogenicity Evaluations 
C3 complement activation was determined by modifying a procedure performed 
by Borden and colleagues to the properties of our microbubbles [140, 154]. All testing 
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was performed under sterile conditions with certified sterile endotoxin-free materials. 
One milligram UCA were exposed to UV light for 60 minutes for sterilization prior to 
testing. UV-irradiated UCA were suspended in a solution of 1.5mL PBS with 1mL 
human complement-preserved serum and shaken end over end at room temperature for 
30min. This suspension was then centrifuged at 300g for 3min to precipitate the MB, and 
the supernatant was collected for C3a activation analysis and diluted 1:5 with 20mM 
EDTA. The amount of activated C3a per MB species was assayed using a Human C3 
ELISA kit using the manufacturer’s instructions. Absorbance was read at 570nm with a 
Tecan Fluorimeter in triplicate and C3a activation reported as an average.  
Samples were evaluated for endotoxin contamination using a Pierce LAL 
Chromogenic Endotoxin Quantitation Kit. All testing was performed under sterile 
conditions with certified sterile endotoxin-free materials. One milligram UCA were 
exposed to UV light for 60 minutes to inhibit biological activity and for sterilization. UV-
irradiated UCA were suspended in 25mL endotoxin-free water for testing. The endotoxin 
quantitation assay was performed using the manufacturer’s instructions. Absorbance was 
read at 405nm with a Tecan Fluorimeter in triplicate and endotoxin concentration was 
reported as an average.  
3.2.4 In vitro Evaluation of UCA Against Breast Cancer Cells  
3.2.4.1 Cell Culture Techniques 
MDA-MB-231 human breast adenocarcinoma cells were grown in DMEM 
medium with L-glutamine, sodium pyruvate, and 4.5 g/L glucose supplemented with 10% 
(v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotic (Penicillin/Streptomycin). MCF7 
human breast adenocarcinoma cells were grown in EMEM medium supplemented with 
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10% (v/v) FBS and 0.01 mg/mL human recombinant insulin. MCF-12A human breast 
epithelial cells were grown in a 1:1 mixture of DMEM and Ham’s F12 media 
supplemented with 20 ng/mL human epidermal growth factor, 100 ng/mL cholera toxin, 
0.01 mg/mL bovine insulin, 500 ng/mL hydrocortisone, and 5% (v/v) horse serum. All 
three populations of cells were maintained in a humidified incubator at 37°C with a 5% 
CO2 atmosphere.  
 
3.2.4.2 Treatment and Evaluation Techniques 
 Cells were plated in 6-well plates at a concentration of 0.6x105 cells per well, and 
grown to 70-80% confluency for testing. Cells were treated with 1.5mg of UCA or n-Sh 
species suspended in 3mL of the appropriate medium, as explained in Table 3.1.  
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Table 3.1: Cell treatments arranges by type of UCA shell material and functionalization. 
No 
Treatment 
100% PLA 
UCA 
100% PLA 
n-Sh 
5% PEG-
PLA 
UCA 
5% PEG-
PLA 
n-Sh 
1% 
LipidPEG 
UCA 
1% 
LipidPEG 
n-Sh 
Free Dox 100% PLA UCA 
100% PLA 
n-Sh 
5% PEG-
PLA UCA 
5% PEG-
PLA n-Sh 
1% 
LipidPEG 
UCA 
1% 
LipidPEG 
n-Sh 
Free 
TRAIL 
100% PLA 
UCA + 
Free Dox 
100% PLA 
n-Sh + 
Free Dox 
5% PEG-
PLA UCA 
+ Free 
Dox 
5% PEG-
PLA n-Sh 
+ Free 
Dox 
1% 
LipidPEG 
UCA + 
Free Dox 
1% 
LipidPEG 
n-Sh + 
Free Dox 
Free Dox 
+ Free 
TRAIL 
100% PLA 
UCA + 
Free 
TRAIL 
100% PLA  
n-Sh + 
Free 
TRAIL 
5% PEG-
PLA UCA 
+ Free 
TRAIL 
5% PEG-
PLA n-Sh 
+ Free 
TRAIL 
1% 
LipidPEG 
UCA + 
Free 
TRAIL 
1% 
LipidPEG 
n-Sh + 
Free 
TRAIL 
 
100% PLA 
UCA + 
Free Dox 
+ Free 
TRAIL 
100% PLA  
n-Sh + 
Free Dox 
+ Free 
TRAIL 
5% PEG-
PLA UCA 
+ Free 
Dox + 
Free 
TRAIL 
5% PEG-
PLA n-Sh 
+ Free 
Dox + 
Free 
TRAIL 
1% 
LipidPEG 
UCA + 
Free Dox 
+ Free 
TRAIL 
1% 
LipidPEG 
n-Sh + 
Free Dox 
+ Free 
TRAIL 
 
Dox-
loaded 
100% PLA 
UCA 
Dox-
loaded 
100% PLA  
n-Sh 
Dox-
loaded 5% 
PEG-PLA 
UCA 
Dox-
loaded 5% 
PEG-PLA 
n-Sh 
Dox-
loaded 1% 
LipidPEG 
UCA 
Dox-
loaded 1% 
LipidPEG 
n-Sh 
 
TRAIL-
loaded 
100% PLA 
UCA 
TRAIL-
loaded 
100% PLA  
n-Sh 
TRAIL-
loaded 5% 
PEG-PLA 
UCA 
TRAIL-
loaded 5% 
PEG-PLA 
n-Sh 
TRAIL-
loaded 1% 
LipidPEG 
UCA 
TRAIL-
loaded 1% 
LipidPEG 
n-Sh 
 
TRAIL-
loaded 
100% PLA 
UCA + 
Free Dox 
TRAIL-
loaded 
100% PLA  
n-Sh + 
Free Dox 
TRAIL-
loaded 5% 
PEG-PLA 
UCA + 
Free Dox 
TRAIL-
loaded 5% 
PEG-PLA 
n-Sh + 
Free Dox 
TRAIL-
loaded 1% 
LipidPEG 
UCA + 
Free Dox 
TRAIL-
loaded 1% 
LipidPEG 
n-Sh + 
Free Dox 
 
Dox- and 
TRAIL-
loaded 
100% PLA 
UCA 
Dox- and 
TRAIL-
loaded 
100% PLA  
n-Sh 
Dox- and 
TRAIL-
loaded 5% 
PEG-PLA 
UCA 
Dox- and 
TRAIL-
loaded 5% 
PEG-PLA 
n-Sh 
Dox- and 
TRAIL-
loaded 1% 
LipidPEG 
UCA 
Dox- and 
TRAIL-
loaded 1% 
LipidPEG 
n-Sh 
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Free Dox was added at a concentration of 1µM per well, and free TRAIL was 
added at a concentration of 100ng/well. For treatment, n-Sh were prepared by insonating 
UCA as described previously for a period of 20 minutes at a peak negative pressure of 
0.94MPa (energy level 4) and a PRF of 100Hz. The resulting particles were then frozen 
at -20°C overnight and lyophilized for 48 hours to obtain the post-insonation n-Sh. Both 
the UCA and n-Sh were irradiated under UV light for 60 minutes for sterilization.  
Growth media was removed from the cells to be replaced by the treatment media. 
Treatments were applied to the cells, which were then incubated in a humidified 
incubator at 37°C with a 5% CO2 atmosphere for 24 hours. After 24 hours, the treatment 
media was removed from the wells and the cells were washed with 1mL of 1x PBS at 
room temperature. The treatment media and PBS wash solutions were discarded, as they 
contained mostly microbubbles and n-Sh that would obscure the flow cytometry readings. 
Once washed, the cells were incubated at 37°C with 1mL of Accutase cell detachment 
solution for 20 minutes. The detached cells were then collected, and the wells were 
washed with 1mL 1x PBS at room temperature. Both the Accutase solution and PBS 
wash were combined in a 2mL round-bottom Eppendorf tube, and the cells were 
centrifuged at 4000rpm at 4°C for 7 minutes to collect the cell pellet. The cells were 
washed in 1mL cold PBS and centrifuged at 4000rpm at 4°C for 7 minutes. After the 
final wash, the cell pellet was then suspended in 200µL of cold 1x annexin binding 
buffer, and 5µL FITC annexin V and 5µL propidium iodide were added to this solution. 
The cell suspension was incubated in the dark at room temperature for 15 minutes, when 
an additional 200µL of cold 1x annexin binding buffer was added to stop staining.  
 55 
Cell fates were quantified using a BD Accuri C6 flow cytometer calibrated for 
multi-color analysis of stained cells. Cells suspensions were evaluated by sampling for 2 
minutes at fast fluidics (66µL/min), followed by a 30 second wash of the sampling needle 
with DI water and plate agitation between each sample. Tests were performed in 
triplicate, and results were reported as an average of the cell population for each cell fate. 
An additional round of cell testing was performed to acquire fluorescent images of the 
cell fates. The treatment procedure was followed as explained previously, but cells were 
washed three times with 1x PBS in the wells, and then stained with Alexa Fluor 488 
annexin V for apoptotic cells, red-fluorescent propidium iodide for dead cells, and 
Hoescht blue for live cells. Early apoptotic cells are positive for annexin V (green) only, 
while late apoptotic and necrotic cells are positive for both annexin V and PI (red and 
green). Live cells are positive for Hoescht (blue) only. Apoptosis was qualitatively 
assessed visually with fluorescent microscopy using an EVOS FL Cell Imaging System 
(Thermo Fisher Scientific, Waltham, MA).  
 
3.2.5 Statistical Analysis 
All data are expressed as a mean value ± standard error of the mean calculated 
with Microsoft Excel (Microsoft Corporation, Redmond, WA). Statistically significant 
differences for multiple groups were determined using a one-way ANOVA with 
Bonferroni correction for multiple comparisons and Tukey’s multiple comparison post-
test when appropriate. These tests were used to determine significance for the acoustic 
evaluations, immunogenic assays, and cell viability results. Differences were evaluated 
across all groups, and also within each group for more robust analysis. Statistical 
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significance between individual groups for pre- and post-US size comparison was 
determined using a matched pairs Student’s t-test. All statistical testing was done using 
Prism 7 (GraphPad, San Diego, CA) using α=0.05 significance level. Error bars were 
displayed as standard error about the mean (SEAM).  
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4. RESULTS AND DISCUSSION 
4.1 Development and Characterization of a TRAIL-Ligated UCA 
 This study serves as a feasibility study for the functionalization of PLA 
microbubbles with tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and 
the ability of these agents to interact with US for targeting and therapeutic applications. 
Building upon previous studies with TRAIL and microbubbles, we were specifically 
interested in determining the effect of TRAIL ligation on the acoustic behavior of the 
UCA, as well as the effect of insonation and cavitation on the apoptotic activity of 
TRAIL.  
4.1.1 Effects of TRAIL Ligation on Acoustic Enhancement and Stability  
To assess whether the agents retained their function as contrast agents, acoustic 
enhancement and stability were assessed. The cumulative dose response results are 
shown in Figure 4.1A, where a 5-8 decibel (dB) reduction in maximum enhancement at a 
value of 12µg/mL is seen in the TRAIL-UCA groups when compared to blank PLA 
controls at the same dose, suggesting that UCA shell properties are altered during 
maleimide attachment of TRAIL.  
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Figure 4.1: Acoustic evaluation of UCA. a) Cumulative acoustic enhancement of each 
agent, 15µg/ml doses added and read every 30 seconds, with cumulative enhancement 
reported in dB. b) Acoustic stability of each agent, normalized to 1, with readings taken 
every minute, dotted lines indicate half-life of agent.  Blank PLA (n=3), n Non-linker 
TRAIL-UCA (n=1), ⏏ Ligated TRAIL-UCA (n=1). Error bars = SEAM.  
 
 
 
Despite this modification-induced reduction, both test groups were still able to 
reflect a clinically-relevant US signal as judged by our previous in vivo work [89], 
suggesting that TRAIL-UCA are still effective contrast agents. In fact, Figure 4.1B 
suggests that the process of TRAIL ligation may actually enhance acoustically-triggered 
n-Sh production, since the stability in the US beam is reduced for these groups compared 
to the blank PLA control. The acoustic half-life, or time until the enhancement signal is 
halved, is assumed to be due to UCA rupture. For comparison, this half-life was 
approximately 9 minutes for the ligated TRAIL-UCA and approximately 12 minutes for 
the surface adsorbed TRAIL-UCA, whereas the half-life of the control blank UCA is 
greater than 15 minutes. However, there is not a large enough difference between the 
ligated UCA and non-linker controls (p>0.05) to suggest that the ligation itself has a large 
effect on the UCA shell properties.  
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Overall, these results suggest that the aqueous environment to which the UCA are 
exposed during TRAIL attachment modifies the UCA structure, likely due to swelling 
and hydrolysis of the PLA. As shown by Proikakis and colleagues, the nature and pH of 
aqueous buffer has a significant effect on the swelling behavior of solid PLA tablets, 
which can be even more disruptive to the shell structure of hollow PLA microbubbles 
during TRAIL ligation and subsequent lyophilization [155]. The results also indicate that 
the agents are still capable of functioning as contrast agents that shatter when exposed to 
US. The larger dose that is required to reach maximum enhancement for TRAIL-UCA is 
probably due to the fact that a portion of the UCA are destroyed or rendered less 
echogenic during the ligation process, resulting in a lower concentration of intact UCA.  
4.1.2 Effects of TRAIL Ligation on Surface Morphology and UCA Size 
TRAIL-UCA and unmodified blank UCA were characterized by evaluating 
surface morphology and average diameter before and after modification. As shown in 
Figure 4.2, SEM images demonstrate that TRAIL attachment does not significantly affect 
surface morphology as pre- and post-ligation images show smooth, spherical UCA. 
 
 
 
 
 
a b c
Figure 4.2: SEM images of UCA. a) Pre-ligation blank UCA. b) Ligated 
TRAIL-UCA. c) Non-linker control TRAIL-UCA. Accelerating voltage 
5kV, spot size 3, magnification 2500x, scale bar 4µm. 
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Additionally, these SEM images were used to measure UCA diameter, and the results are 
shown in Figure 4.3. While the average diameter of blank UCA (1.055±0.060µm) and 
non-linker TRAIL-UCA (0.999±0.066µm) were nearly identical, the SEM images 
indicate a shift in the size distribution for the non-linker controls. The average diameter 
of TRAIL-ligated UCA (1.190±0.072µm) was significantly larger than the controls 
(p=0.0642).  
 
 
 
 
Figure 4.3: Average UCA diameter, as measured from SEM images. *p=0.0642. 
 
These changes in size can be expected, due to structural modifications, especially 
swelling and hydrolysis, being made to the UCA shell during the ligation process [155]. 
Nonetheless, all of these agents are within the desired 1-2µm range [88] for average 
diameter, and are therefore acceptable for these experiments. Characterization of these 
agents determined that they would be considered viable based on our design constraints, 
allowing progression into in vitro cell studies.  
 61 
4.1.3 In vitro Tumoricidal Activity of TRAIL-UCA 
To evaluate these agents for potential use in targeted cancer therapy, we used a 
human breast cancer cell line, MDA-MB-231, which is known to be apoptotically 
sensitive to TRAIL. As a control population, we also used 3T3 fibroblasts to represent 
TRAIL-insensitive non-cancerous cells. Cell fates were determined with a live/dead 
assay, fluorescent microscopy, and counted using customized macros in NIH Image J.  
Cells were treated with modified cell culture media consisting of the appropriate 
intact UCA or n-Sh population suspended in the medium (Table 4.1). The treatment 
groups were: intact non-linker TRAIL-UCA, non-linker n-Sh after 30 minutes of 
insonation, intact ligated TRAIL-UCA, and ligated n-Sh after 30 minutes of insonation. 
The control groups were: no treatment (negative control), intact blank PLA UCA (1mg, 
negative control), and free TRAIL (10ng, positive control representing the maximum 
TRAIL concentration used in the ligation step). 
 
 
 
Table 4.1 Treatment groups for in vitro cell studies, both TRAIL-sensitive and TRAIL-
resistant cell lines. 
Negative 
Controls 
Positive 
Controls Test Group 1 Test Group 2 
No Treatment Free TRAIL Intact Non-linker UCA 
Intact TRAIL-
ligated UCA 
Intact Blank 
UCA  
Non-linker n-Sh 
(30 mins 
insonation) 
TRAIL-ligated n-
Sh (30 mins 
insonation) 
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The live/dead assay results for the MDA-MB-231 breast cancer cells are shown in 
Figure 4.4. As expected, there is little cell death in both negative controls (Figure 4.4A – 
no treatment, 2.299±0.347% cell death, and Fig. Figure 4.4B – intact blank UCA, 
0.519±0.216% cell death), while a visibly large degree of cell death (32.820±0.796%) is 
evident in the free TRAIL positive control (Figure 4.4C). Cell death is characterized by 
both the red stained cells and the large black patches, which corresponds to areas where 
dead cells detached from the plate, with subsequent loss due to washing. For the ligated 
TRAIL groups, the live/dead assay indicates cell death for both intact UCA 
(8.296±0.169%, Figure 4.4D) and n-Sh (38.420±0.020%, Figure 4.4E). Figure 4.4 clearly 
shows that the ligated TRAIL n-Sh were much more effective in inducing cell death in 
these susceptible cells. In fact, TRAIL-ligated n-Sh induced significantly more cell death 
than the intact TRAIL-UCA (p<0.0001). Additionally, cell death induced by TRAIL-
ligated n-Sh is significantly greater than treatment with free TRAIL (p<0.0001). 
However, since the images show large areas where dead cells detached and were lost 
during washing and staining steps, this result could be even more significant. In 
agreement with our expectations, we saw little cell death in both control non-linker 
groups (Figure 4.4F – intact non-linker UCA, 2.397±0.299%, and Figure 4.4G – non-
linker n-Sh, 2.020±1.358%), which is not significantly different from the no treatment 
group (p=0.8502 and p=0.8608, respectively). The non-linker control group results 
indicate that the observed cell death effects are not incidental events due to release of 
physically adhered TRAIL, and that the active TRAIL molecules are those that are 
ligated to the UCA surface. 
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Figure 4.4: Fluorescent images of MDA-MB-231 human breast cancer cells under 
various treatments. Green indicates live cells, red indicates dead cells, scale bar 100µm. 
a) no treatment (negative control), b) intact blank PLA UCA (negative control), c) free 
TRAIL (positive control), d) intact ligated TRAIL-UCA, e) ligated n-Sh, g) intact non-
linker TRAIL-UCA, and g) non-linker n-Sh. 
 
 
On the other hand, very little cell death is observed in the TRAIL-insensitive 3T3 
fibroblasts, as expected (Figure 4.5). 3T3 fibroblast cell were grown to 30% confluence, 
and after treatment very few, if any, red-stained dead cells are visible in any of the test 
groups. For comparison, the free TRAIL group (C) also shows very few dead cells, 
indicating that TRAIL has no effect on non-sensitive healthy cells. All 3T3 fibroblast 
samples exhibited less than 3% cell death in images collected (Table 4.2). In all of these 
a b c 
d e 
f g 
 64 
samples, the dark patches represent areas that were never populated with cells, and did 
not change throughout the experiment. 
 
 
 
        
Figure 4.5: Fluorescent images of 3T3 fibroblasts under various treatments. Green 
indicates live cells, red indicates dead cells, scale bar 100µm. a) no treatment (negative 
control), b) intact blank PLA UCA (negative control), c) free TRAIL (positive control), 
d) intact ligated TRAIL-UCA, e) ligated n-Sh, f) intact non-linker TRAIL-UCA, and g) 
non-linker n-Sh. 
 
 
 
 
 
a b c 
d e 
f g 
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Table 4.2: Cell death percentages for 3T3 fibroblast cells. 
 Cell Death (%) 
No Treatment  
(Negative Control) 1.742±0.076% 
Intact Blank PLA UCA  
(Negative Control) 2.548±0.016% 
Free TRAIL  
(Positive Control) 1.669±0.056% 
Intact Ligated TRAIL-UCA 2.753±0.051% 
Ligated TRAIL n-Sh 0.799±0.041% 
Intact Non-linker TRAIL-UCA 1.106±0.031% 
Non-linker TRAIL n-Sh 0.659±0.267% 
 
 
For comparison, Figure 4.6 shows cytotoxicity of the TRAIL-ligated treatments and 
control groups against both cell types.  
 
 
 
 
Figure 4.6: Cytotoxicity of TRAIL-ligated treatments and controls against cells of 
interest. A) MDA-MB-231 breast cancer cell cytotoxicity results, B) 3T3 fibroblast 
cytotoxicity results. ***p<0.0001, error bars = SEAM, n=2. 
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There was no significant difference between any of the fibroblast groups, which 
all showed little to no cell death, as expected since these cells are known to be insensitive 
to the apoptotic activity of TRAIL [156]. We also saw significant cell death in the MDA-
MB-231 cells when they were exposed to TRAIL, a trend which has been observed in 
numerous studies [44, 150, 151, 157]. Interestingly, the TRAIL-ligated n-Sh showed 
significantly higher cell death than the intact TRAIL-ligated UCA (p<0.0001). This 
suggests that the full surface area of the UCA was utilized, as the n-Sh more effectively 
covered and treated the cells than only a portion of each UCA at its contact point with the 
cell surface. Overall, these studies demonstrated the selective efficacy of TRAIL against 
susceptible breast cancer cells, but not resistant or normal cells, that doxorubicin 
sensitized the resistant cells and that ligation to the UCA surface and subsequent UCA 
shattering did not negatively impact TRAIL apoptotic activity.  
4.1.4 TRAIL Ligation Conclusions 
In conclusion, ligation using maleimide chemistry was an effective method for 
attaching TRAIL directly to the surface of UCA, and these modified UCA maintained 
both acoustic properties and apoptotic activity towards susceptible cancer cells but not 
toward a healthy cell model. Additionally, MDA-MB-231 breast cancer cells treated with 
n-Sh generated by US treatment of ligated TRAIL-UCA showed the greatest extent of 
apoptosis/cell death among test groups (p<0.0001). Ultrasound-generated particles had a 
more extensive effect on the sensitive cells, suggesting that the treatment generated a 
greater number of particles that could interact with a larger number of cells. Ligation did 
not significantly affect UCA size or morphology, resulting in spherical agents that can 
easily pass through the vasculature to reach the target tumor tissue.  
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4.2 Development and Characterization of UCA with Reduced Immunogenicity 
 Two different techniques have been developed for incorporating PEG into our 
PLA UCA in an effort to inhibit opsonization and immunogenicity to the circulating 
agent and n-Sh while retaining the acoustic behavior of the UCA. Our initial loading 
technique consisted of incorporating small proportions of PEG-PLA copolymers 
combined with PLA during the double emulsion fabrication process, where the PEG 
molecule is a part of the UCA shell. The second incorporation method involved the use of 
small proportions of functionalized PEG phospholipids, where the phospholipid head 
embeds itself into the PLA shell and the PEG chains extend out from the surface to create 
a physical brush surrounding the UCA. Loading methods were optimized to provide 
UCA with strong acoustic enhancement, tight size distribution preferably in the 1-2µm 
range, smooth surface morphology, and reduced immunogenicity for future targeting and 
drug delivery applications. Formulation selection and optimization are discussed in terms 
of these properties over the remainder of the subsection.  
4.2.1 Loading Efficiency of LipidPEG Molecules 
A primary concern with the LipidPEG method of UCA PEGylation was the 
amount of surface coverage using PEG phospholipids, since previously this had only 
been attempted with lipid microcapsules where phospholipid incorporation is more 
straightforward [140, 147, 154]. PEG lipid fluorescently-tagged with carboxyfluorescein 
(CF) was loaded into the LipidPEG-type UCA during the organic phase at a 1 wt% ratio 
to the PLA, chosen based on the favorable characteristics for this formulation. Readings 
of the resulting microbubbles indicate 97.77% PEG lipid loading efficiency, with 13.97 
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µg PEG lipid per mg of UCA, based on the standard curve of known amounts of CF-
tagged LipidPEG in DMSO (Figure A.1). 
This high degree of loading is in line with loading efficiency observed with lipid-
based microbubbles [140, 147, 154], which is surprising given the lack of studies 
investigating this method with polymeric microbubbles. Loading was confirmed visually 
with confocal microscopy (Figure 4.7), where the CF tag on the LipidPEG molecule 
fluoresces green within the UCA shell.  
 
 
 
 
Figure 4.7: Confocal microscopy image of UCA loaded with CF-tagged LipidPEG 
molecules. Size bar = 5µm, , λex =495nm, , λem = 517nm. 
 
 
 
Understanding the level of PEG incorporation is important when assessing 
whether the agents elicit an immune response, as higher expression of PEG groups on the 
UCA surface should translate into higher degrees of immune shielding [137, 138, 140, 
147, 154]. The results indicate that the expected loading of LipidPEG in the resulting 
5µm 
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UCA is very close to the initial loading, suggesting an efficient PEGylation method for 
polymeric UCA.  
4.2.2 Effects of PEGylation on UCA Quantity 
Concentration of each UCA sample was determined by counting the number of 
microbubbles present in a known weight using a flow cytometer (Figure 4.8).  
 
 
 
 
Figure 4.8: Concentration of UCA by weight. A) PEG-PLA groups, B) LipidPEG 
groups. Error bars = SEAM, n=3, *p=0.0284, **p=0.0031 for 1 wt% PEG-PLA to 5 wt% 
PEG-PLA, **p=0.0095 for 1 wt% PEG-PLA to 10 wt% PEG-PLA, ***p<0.0001. 
 
 
 
There is a somewhat linear trend (R2=0.7023) between increasing proportions of 
PEG-PLA and reduction in concentration of UCA per milligram, and all PEG-PLA 
formulations resulted in less UCA/mg than 100% PLA UCA (p<0.0001, Figure 4.8A). 
There was no significant different between the concentration of 1 wt% and 2 wt% PEG-
PLA UCA, nor between 5 wt% and 10 wt% PEG-PLA UCA. Compared to 1 wt% PEG-
PLA, there are significantly less 5 wt% PEG-PLA UCA (p=0.0031), 10 wt% PEG-PLA 
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UCA (p=0.0095), and 15 wt% PEG-PLA UCA (p<0.0001). There was also a significant 
reduction in UCA concentration between 2 wt% and 15 wt% PEG-PLA groups 
(p<0.0001). The 15 wt% PEG-PLA group was also significantly less than the 10 wt% 
group (p=0.0284), with this group comprising approximately half an order of magnitude 
less microbubbles/mg than 100% PLA (p<0.0001). This trend could be due, in part, to the 
interaction of co-polymer end groups within the shell, making the UCA shells thicker and 
heavier as more PEG-PLA is added to the formulation [158, 159]. Additionally, 
formulations including 5 wt% PEG-PLA and higher exhibited a bimodal distribution of 
intact microspheres and non-spherical debris which could skew the measurement of 
spheres in this method. There were no significant differences in concentration of 
UCA/mg in the LipidPEG group, both when compared to 100% PLA UCA and among all 
three formulation proportions (Figure 4.8B). This suggests that the lipid anchoring does 
not influence the double emulsion process, and produces similar populations to the 100% 
PLA native group.  
We demonstrated a dose-dependent reduction in UCA quantity with increasing 
PEG-PLA proportions, suggesting structural changes within the polymeric shell in 
response to the additional co-block-polymer groups since this trend was not observed in 
the LipidPEG group. These results are important for proper preparation of future 
functionalized agents for treatment groups, to help standardize the number of 
microbubbles and subsequently co-encapsulated drug administered with each treatment. 
4.2.3 Effects of PEGylation on Acoustic Enhancement and Stability  
Microbubbles at resonance undergo inertial cavitation and shatter. Incorporation 
of PEGylated species will affect the material properties of the shell and hence behavior 
 71 
within an US beam. Therefore, the PEGylated UCA were tested acoustically to determine 
the degree to which they can still interact with the US beam.  
Previous studies were performed in our lab to evaluate a series of incorporations 
between 100 wt% PLA and 100 wt% PEG-PLA together with 25 and 50 wt% PEG-PLA 
to determine the relative proportions of PEGylated and non-PEGylated polymer upon 
which to focus [160]. Agents with 100 wt% PEG-PLA were not echogenic above 
background, and higher proportions of PLA resulted in increasingly improved acoustic 
performance. Figure 4.9 displays the linear trend between wt% PEG-PLA and reduction 
in echogenicity observed in these preliminary studies, which informed our decision to 
study the formulation range 1, 2, 5, 10, and 15 wt% PEG-PLA in detail. The linear 
regression line plotted from the preliminary study data (blue diamonds -®-) was used to 
predict the echogenicity values for our ratios of interest (orange squares -¡-). The actual 
echogenicity data collected in this study is plotted to show correlation with the trend 
(purple circles --).  
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Figure 4.9: Effect of PEG-PLA incorporation on echogenicity. -®- Average maximum 
echogenicity data from preliminary study performed previously. -¡- Predicted maximum 
echogenicity for PEG-PLA ratios of interest. -- Actual maximum echogenicity data 
from PEG-PLA ratios of interest in this study. Error bars represent SEAM, n=3. Linear 
trend with R2=0.98895. Dotted line represents 16dB cutoff for effective interaction with 
US [5, 150, 160]. 
 
As expected, shell modification had a demonstrated effect on acoustic response 
(proportions of interest shown in Figure 4.10 and summarized in Table 4.3). The dose 
needed to achieve maximum enhancement nearly doubled with the addition of 1 wt% 
PEG-PLA, requiring 13.5µg/mL UCA compared to 7.5µg/mL UCA for the unmodified 
100% PLA UCA, and above 5 wt% PEG-PLA at least 15µg/mL was needed. With 10 
wt% PEG-PLA, there was also a significant decrease in the maximum enhancement 
compared to the 100% PLA UCA (p=0.0214). Similar losses of echogenic response were 
observed with LipidPEG incorporation, with a higher dose needed for maximum 
enhancement (9µg/mL for 0.2 wt%, and 13.5µg/mL for both 1 and 2 wt%). Incorporation 
of 2 wt% LipidPEG significantly reduced echogenicity (p<0.0001), possibly by inhibiting 
cavitation among fewer intact UCA 
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Figure 4.10: Acoustic results plotted as dose response curves. A) PEG-PLA 
formulations, B) LipidPEG formulations. Error bars = SEAM, n=5, *p=0.0214, 
***p<0.0001. 
 
Table 4.3: Acoustic properties of PLA, PEG-PLA, and LipidPEG UCA groups. 
 
Initial dB 
Enhancement 
(Dose in 
µg/ml) 
Maximum dB 
Enhancement 
(Dose in 
µg/ml) 
US Half-
life at 
Lower 
MI (min) 
US Half-
life at 
Higher 
MI (min) 
100% PLA 
UCA 
16.45±0.63 
(1.5 µg/ml) 
18.30±0.25 
(7.5 µg/ml) >15 3 
1 wt% 
PEG-PLA 
UCA 
13.63±0.67 
(1.5 µg/ml) 
18.35±0.58 
(13.5 µg/ml) >15 4 
2 wt% 
PEG-PLA 
UCA 
12.67±1.00 
(1.5 µg/ml) 
18.09±0.56 
(13.5 µg/ml) >15 3 
5 wt% 
PEG-PLA 
UCA 
13.14±0.67 
(1.5 µg/ml) 
18.85±0.44 
(15 µg/ml) >15 4 
10 wt% 
PEG-PLA 
UCA 
11.15±1.36 
(1.5 µg/ml) 
15.46±1.15 
(15 µg/ml) 13 3 
15 wt% 
PEG-PLA 
UCA 
10.88±0.81 
(1.5 µg/ml) 
17.00±0.54 
(15 µg/ml) 7 3 
0.2 wt% 
LipidPEG 
UCA 
13.13±1.01 
(1.5 µg/ml) 
16.49±0.54 
(9 µg/ml) >15 3 
1 wt% 
LipidPEG 
UCA 
10.19±0.98 
(1.5 µg/ml) 
16.71±0.83 
(13.5 µg/ml) 4 2 
2 wt% 
LipidPEG 
UCA 
5.58±0.46 
(1.5 µg/ml) 
8.08±0.50 
(13.5 µg/ml) 1 1 
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In terms of instability within an US beam (loss of echogenicity with time, Figure 
4.11) at a lower mechanical index (MI) useful for imaging (0.152 at peak positive 
pressure (PPP) of 0.7 MPa), UCA with low proportions of PEG-PLA showed similar 
stability to unmodified 100% PLA UCA (acoustic half-life, t1/2, >15 min). At the higher 
PEG-PLA ratios (10 wt% and 15 wt% PEG-PLA), the agents lost echogenicity faster than 
the native PLA agent (10 wt% acoustic t1/2 = 13 min, p=0.0018; 15 wt% acoustic t1/2 = 7 
min, p<0.0001) indicating that the shells were more easily disrupted. Both 1 and 2 wt% 
LipidPEG lost echogenicity more rapidly at the lower MI than 100% PLA UCA (1 wt% 
acoustic t1/2 = 4 min, p<0.0001; 2 wt% acoustic t1/2 = 1 min, p<0.0001). The 0.2 wt% 
LipidPEG agents exhibited similar stability to the 100% PLA UCA, with an acoustic t1/2 
of greater than 15 minutes.  
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Figure 4.11: Acoustic results plotted as time response curves. . A) PEG-PLA 
formulations, B) LipidPEG formulations. Error bars = SEAM, n=5, ***p<0.0001. 
 
 
These findings demonstrate that while echogenic response is diminished by 
incorporating PEGylated species in the shell in a dose-dependent manner, at low 
incorporation levels (<10 wt% PEG-PLA and <2 wt% LipidPEG) these PEGylated UCA 
are capable of interacting with US under conditions similar to those in a clinical imaging 
setting. The size of the doses is small compared to doses of  contrast agent approved for 
use in the clinic  (0.03 and 0.3mL/kg, SonoVue) [161]. Maximal enhancement at lower 
doses is the more desirable outcome. The majority of studies on influences of shell 
properties on acoustic behavior of UCA involve phospholipid shells [162-165], but there 
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are some that deal with polymer-shelled UCA. Sanna et al. reported obtaining in vitro US 
images with the use of 100% PLGA-PEG conjugated to a targeting ligand [166]; 
however, in our hands, the use of 100% PLA-PEG produced only background [160]. In 
the case of insertion of LipidPEG, the acoustic properties ranged from close to the control 
at 0.2 wt% to complete elimination of echogenicity at 2 wt% LipidPEG. Our study 
demonstrates that the anchoring of small percentages of lipid chain PEG molecules into 
the polymer shell is a viable method of PEGylation that can be further explored for 
functionalization with bioactive molecules for drug delivery applications.  
Comparison of these two PEGylation methods has yielded valuable information 
that will inform our decisions toward achieving our long-term goals of developing 
“stealth” UCA for drug delivery and targeting. We have demonstrated the ability to 
generate PEGylated UCA capable of reflecting a focused US beam, establishing the 
upper limits of PEGylation for consistently reflective agents as 5 wt% PEG-PLA and 1 
wt% LipidPEG, respectively.  
4.2.4 In vitro Visualization of PEGylated UCA 
In conjunction with the in vitro acoustic testing performed in our laboratory, the 
UCA were also visualized in a tissue mimicking flow phantom with an US scanner used 
for clinical imaging at Thomas Jefferson University Hospital with the help of Dr. John 
Eisenbrey and Dr. Flemming Forsberg. Using a linear US transducer, images were 
collected in both fundamental B-mode grayscale mode (right) and nonlinear contrast 
mode with gold tint (left). A baseline, pre-injection image is shown in Figure 4.12A.  
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Figure 4.12: Images from ultrasound visualization of UCA in a tissue mimicking flow 
phantom. Each image was taken at a focal length of 4cm, in both non-linear contrast 
mode (left, orange) and fundamental B-mode (right, gray). A) Pre-injection empty vessel 
baseline image, B) 100% PLA, C) 1 wt% PEG-PLA, D) 2 wt% PEG-PLA, E) 5 wt% 
PEG-PLA, F) 10 wt% PEG-PLA, G) 15 wt% PEG-PLA, H) 0.2 wt% LipidPEG, I) 1 wt% 
LipidPEG, J) 2 wt% LipidPEG. 
 Strong enhancement is visible for the 100% PLA (Figure 4.12B), 1 wt% PEG-
PLA (Figure 4.12C), 2 wt% PEG-PLA (Figure 4.12D), 5 wt% PEG-PLA (Figure 4.12E), 
0.2 wt% LipidPEG (Figure 4.12H), and 1 wt% LipidPEG (Figure 4.12I) UCA. This is 
expected since these agents also showed high echogenicity in our custom acoustic setup, 
and confirms that these modified microbubbles are still functional as UCA. Inconsistent 
enhancement was observed for the 15 wt% PEG-PLA agents (Figure 4.12G), with low 
stability and visualization time. This is likely due to the bimodal distribution of intact 
UCA and non-spherical fragments present in this sample, contributing to the inconsistent 
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nature of the visible enhancement. Little to no enhancement was observed for the 10 wt% 
PEG-PLA (Figure 4.12F) and 2 wt% LipidPEG (Figure 4.12J), as expected due to the 
low echogenicity observed in previous experiments. Our visual evaluation of UCA with 
lower proportions of PEG-PLA indicate that 10 wt% appears to be the upper limit to 
maintain visibility and function within the US beam, with 1 wt% being the upper limit for 
LipidPEG incorporation. These results together with our dose response curves support the 
upper limits for PEGylation at 5 wt% PEG-PLA and 1 wt% LipidPEG, respectively.  
4.2.5 Effects of PEGylation on Resonant Frequency  
Acoustic backscattering from UCA is greatly improved when the agents are 
insonated in the same frequency range as their resonant frequency. By definition, the 
resonant frequency is the US frequency at which the UCA resonate and cavitate most. 
Therefore, it was important to understand whether the modifications to the UCA shell 
during PEGylation had any effect on the resonance of the resulting agents.  
The resonant frequency of each PEGylated UCA and the 100% PLA UCA was 
determined experimentally, taking the minimum point from the graph plotting attenuation 
vs. frequency curves (Table 4.4, Figure 4.13 and Figure 4.14).  
Results indicate that the resonant frequency of the 100% PLA UCA is 4.56MHz, 
which is well within the bandwidth range of the 5MHz transducer used for the acoustic 
evaluations discussed previously. The 1 wt% and 2 wt% PEG-PLA UCA also had a 
resonant frequency of approximately 4.5MHz, suggesting that these low proportions of 
PEG-PLA did not significantly affect the shell properties enough to shift the resonant 
frequency of the resulting UCA. A similar resonant frequency was observed for the 15 
wt% PEG-PLA UCA (4.24MHz). This was surprising in light of the low echogenicity 
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from this sample, but is likely the signal received from the smaller intact microspheres 
that are present among the non-spherical debris produced in this sample. Both the 0.2 
wt% and 1 wt% LipidPEG UCA had a resonant frequency of approximately 5MHz as 
well, suggesting that the anchoring of lipid-PEG chains into the PLA shell at low 
proportions does not cause significant changes to the shell resonance and cavitation. No 
clear resonant frequency was observed for the 2 wt% LipidPEG formulation, which can 
be expected based on the lack of echogenicity for this sample.  
 
 
 
 
Table 4.4: Resonant frequency values for 100% PLA and PEGylated UCA, taken from 
attenuation vs. frequency curves. 
 Resonant Frequency (MHz) 
100% PLA 4.56 
1 wt% PEG-PLA 4.48 
2 wt% PEG-PLA 4.52 
5 wt% PEG-PLA 7.84 
10 wt% PEG-PLA 7.76 
15 wt% PEG-PLA 4.24 
0.2 wt% LipidPEG 5.24 
1 wt% LipidPEG 4.96 
2 wt% LipidPEG N/A 
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Figure 4.13: Attenuation (dB/cm) vs. frequency (MHz) curves for 100% PLA and PEG-
PLA UCA. Solid line represents measurements taken with 5MHz unfocused transducer 
(bandwidth = 91%), and dotted line represents measurements taken with 10MHz 
unfocused transducer (bandwidth = 65%). PRF = 100Hz, Energy = 1, Damping Level = 
3, Gain = 0. 
 
 
 
Figure 4.14: Attenuation (dB/cm) vs. frequency (MHz) curves for 100% PLA and 
LipidPEG UCA. Solid line represents measurements taken with 5MHz unfocused 
transducer (bandwidth = 91%), and dotted line represents measurements taken with 
10MHz unfocused transducer (bandwidth = 65%). PRF = 100Hz, Energy = 1, Damping 
Level = 3, Gain = 0. 
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Both the 5 wt% and 10 wt% PEG-PLA UCA exhibited a shift in resonant 
frequency to approximately 7.8MHz. Based on the resonant frequency models developed  
by de Jong and Hoff, we believe the the higher proportions of PEG-PLA increased shell 
thickness and decreased shell elasticity, thus leading to an increase in the resonant 
frequency magnitude [153, 167]. These higher proportioned PEG-PLA UCA also had 
reduced average diameters, contributing to the observed increase in resonant frequency 
due to the inverse relationship these characteristics [153, 167]. Therefore, insonation 
frequency must be increased when insonating these agents to achieve maximum 
cavitation and drug delivery potential. Here we demonstrated that modifications to the 
UCA shell through PEGylation leads to structural changes affecting the oscillation of the 
encapsulated air core. These effects can potentially be mitigated by insonating the agents 
with a transducer with a center frequency similar to the resonant frequency of the 
modified UCA to allow for maximum oscillation.  
4.2.6 Effects of PEGylation on UCA Size, Zeta Potential, and Surface Morphology 
Acoustic behavior is also influenced by the physical properties of the UCA, 
particularly the size and morphology in relation to backscattering and resonance [168]. 
The strength of acoustic signal reflected from a UCA is largely influenced by the 
scattering cross-section and shell elasticity, both functions of the diameter of the agent 
[153, 169, 170]. As such, evaluation of the physical characteristics of our agents was 
crucial to fully understanding the observed trends in acoustic activity. 
All UCA formulations had an average diameter between 1-3µm (Figure 4.15), 
well within the acceptable range for clear passage through the vasculature and resonance 
in the clinical frequency range. Most PEG-PLA modifications decreased the UCA 
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diameter. Average diameters ranged from 1.67±0.13 to 2.17±0.11µm compared to 
unmodified 100% PLA UCA (2.41±0.10µm), except for 15 wt% PEG-PLA at 
2.46±0.15µm. However, only 1 wt% PEG-PLA (p<0.0001), 5 wt% PEG-PLA 
(p=0.0003), and 10 wt% PEG-PLA (p=0.0498) were significantly smaller than the 
unmodified 100% PLA UCA. Addition of PEG-PLA also caused less uniformity in size 
distribution, increasing the polydispersity index (PDI) from 0.184 for unmodified 100% 
PLA UCA to 0.308 for 1 wt% PEG-PLA. Similar degrees of uniformity were observed 
for the 2 wt% (PDI = 0.232) and 5 wt% (PDI = 0.293) groups, but both 10 wt% (PDI = 
0.357) and 15 wt% (PDI = 0.501) groups were even less uniform in size distribution. 
Addition of LipidPEG produced UCA with average diameters ranging from 1.06±0.31 to 
1.79±0.84µm, and all were significantly smaller than unmodified 100% PLA UCA 
(p<0.0001). LipidPEG incorporation also increased population size distribution compared 
to unmodified 100% PLA UCA, with 0.2 wt% measuring a PDI of 0.279, 1 wt% 
measuring a PDI of 0.275, and 2 wt% was highly non-uniform with a PDI of 0.594. Both 
15 wt% PEG-PLA and 2 wt% LipidPEG exhibited an unacceptable degree of non-
uniformity and would not be considered viable for use.  
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Figure 4.15: Average particle size of UCA. Error bars represent SEAM, n=5, *p=0.0498, 
**p=0.0003 ***p<0.0001. A) Measurements of the PEG-PLA copolymer group, B) 
Measurements of the LipidPEG lipid group. 
 
The somewhat linear trend (R2=0.7529) between wt% LipidPEG and reduction in 
UCA diameter could be due in part to the orientation of the lipid molecules within the 
UCA shell [137, 171]. As more LipidPEG molecules are added to the polymer shell, the 
shell likely becomes thicker and smaller to support the anchoring of these molecules.  
Size is not only important for acoustics, but also an important consideration for 
US-driven deposition of particles, as forces pushing them toward the vascular wall are 
more effective on the micron scale than on the nano scale [108, 168, 172]. With an 
average diameter between 1-3µm, the PEGylated agents are highly susceptible to 
radiation forces pushing them toward the vascular wall for easier extravasation once 
shattered into n-Sh. 
All UCA groups maintained a negative zeta potential (ζ) mV (Figure 4.16), 
reflective of the carboxylate end group of PLA, which helps inhibit aggregation and 
clumping in suspension, a key property for injectables to prevent forming a vascular 
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blockage during administration. FDA regulations mandate that zeta potential must have a 
magnitude of 20mV or greater to provide sufficient stabilization and aggregation 
inhibition in suspension [173]. All UCA groups met this requirement, with the exception 
of the 0.2 wt% LipidPEG group with an average zeta potential of -18.39±10.45mV.  
 
 
 
 
Figure 4.16: Average zeta potential of UCA. A) Measurements of the PEG-PLA 
copolymer group, B) Measurements of the LipidPEG group. Error bars represent SEAM, 
n=5, **p=0.0002, ***p<0.0001. 
 
 
 
Unmodified 100% PLA UCA exhibited a ζ of  -23.75±5.69mV. Addition of low 
percentages of PEG-PLA to the agent formulation increased the intensity of the negative 
charge to -29.14±0.58mV, -29.48±0.72mV, and -28.79±0.97mV for 1, 2, and 5 wt% 
respectively (p<0.0001 for all three groups compared to 100% PLA). At 10 and 15 wt%, 
proportions that had resulted in lower maximum enhancement, zeta potential values of -
22.56±0.71mV and -25.65±0.28mV were recorded, closer to 100% PLA values. This is 
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likely due to the morphological changes to these agents altering the surface group 
expression and PEG conformation on the UCA surface. The majority of ζs reported for 
PEGylated PLA nanoparticles show similar results. For example, Yao et al. reported ζ of 
-27.50±1.15mV for PEG-PLA nanoparticles [174]. For 0.2 wt% LipidPEG incorporation 
we measured a less negative ζ of -18.39±10.45mV (p=0.0002), while 1 and 2 wt% 
LipidPEG produced agents with increased negative magnitudes at -33.10±1.77mV and -
33.01±2.51mV, respectively (p<0.0001), again showing the dramatic difference in 
properties going from 0.2 to 1 wt% LipidPEG. This, again, is likely due to the 
arrangement of lipids and polymeric functional groups on the UCA surface, and given the 
reduction in echogenicity for these bubbles, suggests increased expression of –COO- 
groups on the UCA surface. Recalling that zeta potential is pH-dependent, it is important 
to note that these measurements were taken in a suspension with DI water (pH 7.0), 
which closely mimics physiological pH conditions (pH 7.4) but does not appropriately 
simulate the blood environment. PBS, however, cannot be used for these measurements 
because it shields the surface charge.  
Scanning electron microscopy (SEM) images showed that increasing the 
proportion of PEG-PLA resulted in less uniform morphology, eventually leading to non-
spherical, broken particles (Figure 4.17).  
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Figure 4.17: SEM images of UCA. Magnification 3500x, size bar 5µm. A) 100% PLA 
UCA, B) 1 wt% PEG-PLA UCA, C) 2 wt% PEG-PLA UCA, D) 5 wt% PEG-PLA UCA, 
E) 10 wt% PEG-PLA UCA, F) 15 wt% PEG-PLA UCA, G) 0.2 wt% LipidPEG UCA, H) 
1 wt% LipidPEG UCA, I) 2 wt% LipidPEG UCA. 
 
 
Passing from unmodified 100% PLA UCA through 15 wt% PEG-PLA (Figure 
4.17A-F), there is a clear morphological shift from smooth and spherical to larger 
collapsed spheres. Similar morphological changes have been observed in studies 
investigating agent PEGylation and the effect of molecular weight and surface group 
expression [159, 166]. However, this trend was not observed in the LipidPEG UCA 
groups in which all maintained a generally smooth, spherical morphology (Figure 4.17G-
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I). While Chen and Borden observed this smooth morphology with their lipid 
microbubbles [140, 147], it is interesting to observe similar behavior from these 
polymeric UCA. Considering the reduced echogenicity and visualization observed from 
the 2 wt% LipidPEG, we believe that the PEG chains oriented inward toward the 
microbubble core during the w/o emulsion, forming an inverted micelle inside of the 
polymer shell and limiting the cavitation ability of the resulting UCA by creating steric 
hindrance from PEG chain incompressibility [175].   
These results indicate that PEGylation can have a significant effect on the physical 
characteristics of polymeric UCA. We have demonstrated that spherical morphology is 
lost in a dose-dependent manner with increasing proportions of PEG-PLA co-polymer 
added to the emulsion, suggesting undesirable interactions between the co-polymer end 
groups that cannot support the double emulsion process. These morphological changes 
likely contribute to the observed changes in UCA diameter and zeta potential, as the 
average particle size can be skewed by larger non-spherical particles and differences in 
surface area exposure with non-spherical particles can lead to fluctuations in zeta 
potential measurements. Again, our findings suggest that 5 wt% PEG-PLA represents an 
upper limit for PEGylation based on observed morphology, while 1 wt% LipidPEG 
represents the upper limit for PEGylation in this method based on average diameter.  
4.2.7 Ultrasound-triggered n-Sh Production from PEGylated UCA 
 Native and PEGylated UCA were screened in our custom acoustic setup to 
determine the potential to undergo inertial cavitation and burst into n-Sh in the presence 
of a focused US. Agents were insonated with a 5MHz transducer set for high mechanical 
index (approximately 0.193, peak positive pressure 0.94MPa measured with a needle 
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hydrophone) for 15 minutes, with backscatter measurements taken every minute. As 
shown in Figure 4.18 for the PEG-PLA UCA and Figure 4.19 for the LipidPEG UCA, all 
agents lost echogenicity rapidly (reaching their acoustic half-life in 4 minutes or less, 
p<0.0001 compared to time to reach acoustic half-life under US at a lower MI) in the 
presence of this clinically-relevant US beam. The loss of signal signifies that the agents 
are shattering into fragments, and therefore can no longer reflect the signal from the 
encapsulated air core [176, 177]. 
 
 
Figure 4.18: Acoustic time response curves for 100% PLA and PEG-PLA UCA 
insonated at low energy (MI 0.152, peak positive pressure 0.7 MPa) and high energy (MI 
0.193, peak positive pressure 0.94 MPa). Dotted line represents acoustic half-life. Error 
bars = SEAM, n=5, ***p<0.0001. 
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Figure 4.19: Acoustic time response curves for 100% PLA and LipidPEG UCA 
insonated at low energy (MI 0.152, peak positive pressure 0.7 MPa) and high energy (MI 
0.193, peak positive pressure 0.94 MPa). Dotted line represents acoustic half-life. Error 
bars = SEAM, n=5, ***p<0.0001. 
  
Based on these reductions in acoustic half-life, PEGylated agents were evaluated 
for average particle size after insonation, to determine whether US-triggered cavitation 
caused significant particle diameter decrease to within the desired range for extravasation 
(between 400-700nm), as denoted by the dotted lines and red region (Figure 4.20). The 
100% PLA and all PEG-PLA agents, with the exception of 15 wt% PEG-PLA, exhibited 
n-Sh production with the resulting fragments having an average size within the desired 
range (Figure 4.20A). The LipidPEG (Figure 4.20B) mirrored the effect observed on 
echogenicity; the 0.2 wt% resembled the unmodified 100% PLA UCA and the 1 wt% and 
2 wt% showed very little size reduction. PDI for the 100% PLA n-Sh was 0.662, ranged 
from 0.444 to 0.787 for the PEG-PLA n-Sh, and from 0.579 to 0.914 for the LipidPEG n-
Sh. These findings indicate that US-triggered size reduction results in particles with 
highly non-uniform size distributions, suggesting that cavitation may burst the UCA into 
fragments of various sizes and shapes.  
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Figure 4.20: Average particle size of UCA pre-insonation and post-insonation (MI 0.193 
at 0.94MPa PPP). A) Measurements of the PEG-PLA copolymer group, B) 
Measurements of the LipidPEG group. Dotted lines represent 400-700nm range for 
extravasation of n-Sh. Error bars represent SEAM, n=5, *p=0.0498, **p=0.0003 for 
100% PLA to 5 wt% PEG-PLA, **p=0.0002 for 15 wt% PEG-PLA to 15 wt% PEG-PLA 
(post-US), ***p<0.0001. 
 
 
 
 
The US-generated size reduction was significant in the unmodified 100% PLA 
UCA (p<0.0001) and all PEG-PLA groups (1 wt% through 10 wt% PEG-PLA p<0.0001, 
15 wt% PEG-PLA p=0.0002), suggesting that PEGylation with PEG-PLA does not 
prevent shattering into n-Sh under the influence of US. The trend observed in the 
LipidPEG groups (p<0.0001) would be expected given the reduction in acoustic 
enhancement observed with the 1 and 2 wt% LipidPEG UCA, which cannot effectively 
interact with US to undergo cavitation. These results suggest that lipid-PEG chain 
arrangement and polymer shell conformations influence these acoustic interactions [175]. 
Generation of n-Sh of 400nm or less is an important aspect of our novel US-triggered 
drug delivery system, as the loaded n-Sh would be of an appropriate size to pass through 
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the pores in the leaky tumor vasculature (400-780nm) and reach the targeted tissue for 
effective therapy. We have demonstrated the ability of our PEGylated agents to shatter 
into nano-sized fragments upon exposure to a focused US beam, within the size range 
necessary for vascular escape through the leaky pores in the tumor vessel walls.  
4.2.8 Immunogenic Characterization of PEGylated UCA 
To determine the effect of PEGylation on the immune response triggered by the 
UCA, C3a activation in human serum incubated ex vivo with suspended UCA was 
measured with a specific ELISA assay (Figure 4.21).  
 
 
Figure 4.21: C3 complement activation assay results. Error bars represent SEAM, n=2. 
A) Results from the PEG-PLA copolymer group ***p<0.0001, **p=0.0077, *p=0.0371, 
B) Results from the LipidPEG lipid group ***p<0.0001. 
 
 
 
In all cases except 0.2 wt% LipidPEG (5.36±0.18ng activated C3/mL serum), the 
addition of PEG into the UCA shell effectively led to a reduction in C3 activation over 
unmodified 100% PLA UCA (5.48±0.16ng activated C3/mL serum). The amount of 
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activated C3 in the serum decreased with increased proportions of PEG-PLA, with the 
exception of 15 wt% PEG-PLA which rose back to the same level as 1 wt% PEG-PLA 
(Figure 4.21A). All of the PEG-PLA groups exhibited lower C3 activation than the 
unPEGylated 100% PLA UCA (p<0.0001), suggesting diminished immune activation. 
Both the 1 wt% (2.28±0.13ng activated C3/mL serum) and 2 wt% (3.41±0.19ng activated 
C3/mL serum) LipidPEG UCA had reduced C3 activation compared to the unmodified 
100% PLA UCA (p<0.0001).  
Unfortunately, only small amounts of activated C3 protein are needed to initiate a 
cascade of immune pathway activations [178-181]. Significant interleukin-1 production is 
observed in human monocytes with the addition of just 0.1µg C3a/well in culture, 
demonstrating the potency of this protein to accelerate immune response [178]. Our assay 
indicated that 1mg unPEGylated 100% PLA UCA/1mL human complement-preserved 
serum activated approximately 5.5ng of C3a protein, while the 5 and 10 wt% PEGylated 
UCA reduced that activation to ~1.5ng activated C3a protein/1mL serum (reduction of 
73%), which was within 1ng/mL of baseline assay controls. 
The unPEGylated 100% PLA UCA exhibited a high C3a activation rate, 
consistent with our in vivo observations with Dox-loaded UCA [2]. An explanation for 
this immunogenic activity is the interaction between the PLA carboxylic acid end groups 
on the UCA surface and the unstable thioester bond in the C3 protein, which facilitates 
binding of the C3 protein to the UCA surface therefore activating the immune response 
[133, 182, 183]. C3 activation increased in the 2 wt% LipidPEG group compared to the 1 
wt% LipidPEG group, as was also seen with the higher (15 wt%) PEG-PLA UCA 
(3.16±0.15ng activated C3/mL serum) compared to the 10 wt% PEG-PLA UCA 
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(1.43±0.02ng activated C3/mL serum). Studies on PEGylated nanocapsules identify the 
importance of molecular weight and distance between PEG chains for effective shielding 
of the underlying PLA surface from complement binding [125]. Since the 15 wt% PEG-
PLA formulation resulted in mostly non-spherical particles, surface expression of PEG 
groups is likely affected, accounting for the observed increase in C3 activation. 
Additionally, Owens and Peppas showed that hydrophilic PEG chains can orient 
themselves toward the aqueous phase during fabrication [126]. In our case, it is possible 
then that the LipidPEG chains in the 2 wt% LipidPEG UCA oriented inward toward the 
initial aqueous core and are therefore not expressed on the UCA surface, accounting for 
the observed increase in C3 activation compared to the 1 wt% LipidPEG UCA. Chen and 
Borden also showed that there is a linear correlation between the number of exposed 
reactive (carbonyl and amino) groups and the degree of C3b activation [140]. This 
relationship was not seen when the reactive groups were masked within a PEG brush on a 
lipid microbubble surface, supporting the use of PEG for immune shielding in drug 
delivery. These studies showed that C3 activation decreased in the presence of the surface 
PEG brush, and vascular circulation time was greatly increased for PEGylated agents 
compared to unPEGylated agents [184].  
We specifically wanted to investigate the differences between the use of a PEG 
co-polymer where the PEG molecules are incorporated into the polymer shell and the use 
of a lipid chain PEG molecule where the lipid chain anchors into the polymer shell 
allowing the PEG molecule to extend from the UCA surface and create a physical brush 
around the agent, determining which method resulted in the best balance between 
decreasing immunogenicity and retaining acoustic properties for future drug loading, 
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drug delivery, and targeting applications. We have demonstrated the efficacy of both 
PEGylation methods in reducing C3 activation in human complement-preserved serum, 
representing an expected reduction in immunogenic response when introduced to the 
physiological environment during patient treatment. Our results suggest that 10 wt% 
PEG-PLA and 1 wt% LipidPEG are the most effective proportions for reducing immune 
recognition and activation.  
4.2.9 UCA PEGylation Conclusions 
In an effort to determine the best formulation to achieve a balance between stealth 
and acoustic activity, we compared two PEGylation techniques; addition of increasing 
amounts of PEG-PLA copolymer and employing incorporation of LipidPEG into the 
shell. We have shown that adding PEG-PLA to the shell has a dose-dependent deleterious 
effect on acoustic properties, and inserting LipidPEG lipids has an even more dramatic 
effect at much lower proportions.  
We showed that there exists a limit to the amount of PEG that can be incorporated 
into the UCA to maintain the balance between favorable acoustic properties and immune 
shielding. For the more traditional co-polymer method of PEGylation, our results indicate 
that this balance is achieved using 5 wt% PEG-PLA copolymer formulation for 
producing “stealth” UCA, (18.85dB enhancement at 15µg/mL, t1/2 >15min at the lower 
MI and 4min at the higher MI, 1.78µm diameter, ζ -28.70mV, and C3a reduction by 
73%). In comparison, our investigations into anchoring lipid chain PEG molecules into 
the polymer shell show that the 1 wt% LipidPEG formulation best maintains the acoustic-
immunogenic balance (16.70dB enhancement at 13.5µg/mL, t1/2 5min at the lower MI 
and 2min at the higher MI, 1.24µm diameter, ζ -22.43mV, and C3a reduction by 58%). 
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Importantly, these results indicate that UCA rupture occurs at an MI of approximately 
0.2, which is well below the clinical limit of 1.9 and indicative of shells that can easily 
shatter into fragments for drug delivery in the presence of a clinically-relevant US beam. 
This study has revealed that both PEGylation methods led to development of successful 
acoustic UCA that exhibited significantly reduced immunogenicity in our ex vivo model, 
and has served as a crucial step in developing and optimizing these PEGylated UCA for 
functionalization with targeting ligands and co-encapsulated drug for applications in 
targeted drug delivery.  
4.3 Effects of Shell Functionalization and Drug Loading on PEGylated UCA for 
Targeted Cancer Therapy 
 Following the development of effective “stealth” UCA, we found that the 5 wt% 
PEG-PLA and 1 wt% LipidPEG formulations were the most appropriate for continued 
study. These agents were then functionalized for the purpose of targeted treatment and 
drug delivery. Two different modifications were performed, singularly and in tandem. 
One method was to decorate the PEGylated UCA surface with TRAIL protein, which 
serves as both a targeting and apoptotic agent to cancer cells. The other method was to 
encapsulate Doxorubicin (Dox) with the polymeric UCA shell, which would undergo 
sustained release as the PLA hydrolyzes and provide prolonged localized treatment. 
Agents were also produced that employed both of these modifications, expressing TRAIL 
on the UCA surface that also contains co-encapsulated Dox in an attempt to sensitize 
TRAIL-resistant cancer cells. Modification methods were optimized to provide UCA 
with strong acoustic enhancement, tight size distribution preferably in the 1-2µm range, 
smooth surface morphology, effective ligand activity, and sustained drug release for 
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targeting and drug delivery applications. Efficacy of these modifications is discussed in 
terms of these properties over the remainder of the subsection. 
4.3.1 Encapsulation Efficiency of Doxorubicin 
One of the modifications employed in these experiments was the encapsulation of 
3 wt% (15mg) Dox within the polymeric shell of the UCA, both TRAIL-ligated and 
native UCA. Both final drug payload and encapsulation efficiency were measured for 
each type of drug-loaded agents, based on a standard curve to determine the relationship 
between amount of free Dox in DMSO and fluorescence intensity after encapsulation 
(Figure A.2) and the encapsulation efficiency equation (Eq. 20).  
 𝐸𝑛𝑐𝑎𝑠𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛	𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 	 F	~	| JIJK]¡	~	| JIJ 	𝑥	100%  (Eq. 20) 
 
The resulting drug payload and encapsulation efficiency results are summarized in 
Table 4.5 and shown in Figure 4.22. An encapsulation efficiency of 35.09% (5.26mg) 
was achieved for the 100% PLA UCA (non-PEGylated), which represents an increase of 
approximately 15% from our previous Dox-loaded UCA [2, 3, 5, 87, 184, 185]. This 
loading increase could be due to a change in aqueous core materials from ammonium 
carbonate to ammonium carbamate or a change in PLA provider which could have made 
slight modifications to the shell that increased drug loading and retention. There was a 
significant decrease in drug payload and encapsulation efficiency with the post-
fabrication TRAIL ligation for both the 100% PLA TRAIL UCA (23.28%, 3.49mg) and 
the 5 wt% PEG-PLA TRAIL UCA (21.26%, 3.19mg) compared to their native Dox-
loaded counterparts (p<0.0001). The Dox-loaded native agents likely experience a burst 
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release when introduced to the aqueous environment during maleimide ligation, 
accounting for this loss of Dox. We also observed a significant decrease in Dox loading 
and encapsulation efficiency between the 1 wt% LipidPEG Dox UCA (17.82%, 2.76mg) 
and the 1 wt% LipidPEG Dox TRAIL UCA (12.51%, 1.88mg) (p=0.0007). These agents 
are not re-exposed to an aqueous environment after fabrication, as the TRAIL ligation to 
the LipidPEG molecule is performed separately, and these complexes are then 
incorporated into the UCA during the initial fabrication process. Coupled with the 
observation that both 1 wt% LipidPEG Dox UCA and 1 wt% LipidPEG Dox TRAIL 
UCA exhibit significantly less Dox encapsulation and payload than the 100% PLA and 5 
wt% PEG-PLA agents (p<0.0001), these results suggest that the presence of the lipids in 
the organic phase during UCA fabrication creates a lipophilic environment that cannot 
support higher levels of Dox encapsulation within the polymeric shell, with the 
hydrophilic Dox collecting in the aqueous core and being sublimated from the agents 
during lyophilization [186]. Additional studies have shown that Dox exhibits lipophilic 
behavior with anionic lipids, suggesting that Dox could have statically bound to the 
LipidPEG tails instead of the copolymer groups and could have subsequently been lost 
during lyophilization [187].  
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Table 4.5: Total drug payload and encapsulation efficiency for Dox-loaded UCA. 
 
Total Dox 
Loading 
(total mg 
Dox/total mg 
UCA) 
Final UCA 
Weight (mg) 
Encapsulation 
Efficiency 
100% PLA Dox 5.26±0.23 385±4 35.09±1.51% 
100% PLA Dox 
TRAIL 3.49±0.11 352±20 23.28±0.72% 
5 wt% PEG-PLA 
Dox 4.13±0.03 342±16 27.52±0.22% 
5 wt% PEG-PLA 
Dox TRAIL 3.19±0.06 313±24 21.26±0.40% 
1 wt% LipidPEG 
Dox 2.67±0.19 379±13 17.82±1.27% 
1 wt% LipidPEG 
Dox TRAIL 1.88±0.04 376±19 12.51±0.30% 
 
 
 
 
Figure 4.22: Effect of shell composition on Dox encapsulation efficiency. 
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 Confocal microscopy was used to confirm that Dox was encapsulated within the 
UCA polymeric shell, as shown in Figure 4.23. For all three shell compositions with and 
without TRAIL ligation, Dox was visible as red fluorescence within the polymeric shell 
of the UCA.  
 
 
 
 
Figure 4.23: Confocal images of Dox-loaded UCA, with Dox appearing as red 
fluorescence, magnification 100x, size bar = 5µm. A) 100% PLA Dox UCA, B) 5 wt% 
PEG-PLA Dox UCA, C) 1 wt% LipidPEG Dox UCA, D) 100% PLA Dox TRAIL UCA, 
E) 5 wt% PEG-PLA Dox TRAIL UCA, F) 1 wt% LipidPEG Dox TRAIL UCA. 
 
 
 
There was a visible reduction in fluorescence intensity and fluorescent UCA with 
the TRAIL-ligated agents (Figure 4.23D-F). The same weight of UCA was used in each 
test, with the sampled being vortexed before a sample was taken and a drop was placed 
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onto the slide and covered with a coverslip. We later found that the quantity of UCA per 
mg was different for each shell composition, accounting for the comparable reduction in 
visible UCA for the agents with PEGylated shells. Nonetheless, all Dox-loaded 
functionalized UCA exhibited encapsulation of drug within the polymeric shell. The 
reduction in Dox encapsulation observed in the TRAIL-ligated 100% PLA and 5 wt% 
PEG-PLA groups compared to their non-ligated counterparts suggests a loss of 
encapsulated Dox during the post-fabrication ligation process. We investigated the short-
term and long-term release profiles of Dox from these agents to determine if Dox was 
lost upon introduction to an aqueous environment.  
4.3.2 In vitro Doxorubicin Release  
To investigate the release profile of Dox from the functionalized agents, UCA 
were suspended in 50mL PBS at 37°C, both with and without the presence of ultrasound. 
Agents were evaluated for burst release of Dox upon introduction to the aqueous 
environment for 20 minutes, and also for sustained release over a period of seven days. 
Prior to determining the extent of drug release during ultrasound-triggered cavitation and 
subsequent PLA hydrolysis, a standard curve was constructed to determine the 
relationship between amount of free Dox in PBS and fluorescence intensity (Figure A.3).  
All of the Dox-loaded agents exhibited a burst of drug release upon suspension in 
the aqueous release buffer (37°C PBS) (Figure 4.24). Since the agents were washed 
extensively prior to lyophilization, this observation is not due to any residual Dox 
adsorbed to the UCA exterior and must be caused by movement of the encapsulated drug 
toward the UCA surface during sublimation of the aqueous components during freeze 
drying. Both the 100% PLA Dox UCA (Figure 4.24A) and 100% PLA Dox TRAIL UCA 
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(Figure 4.24B) showed an immediate burst of approximately 35% of the total 
encapsulated Dox with little to no further release detected over the 20 minute testing 
duration. The 5 wt% PEG-PLA Dox UCA exhibited an immediate burst of roughly 10% 
of encapsulated Dox (significantly lower than that unPEGylated 100% PLA Dox UCA, 
p<0.0001), while 5 wt% PEG-PLA Dox TRAIL UCA showed a burst release of 
approximately 16% of the total Dox loaded. Studies have shown that hydrophilic drugs 
encapsulated within PEG-PLA polymersomes exhibit a strong interaction with the 
copolymer, increasing drug retention [188]. This is an extremely encouraging result, 
since previous attempts in our lab at reducing the initial burst effect had not been 
successful. However, the 1 wt% LipidPEG Dox UCA showed significantly higher burst 
(approximately 45%, p=0.0003), as well as 1 wt% LipidPEG Dox TRAIL UCA 
(approximately 48%, p<0.0001). Actual drug release values are reported in Table 4.6.  
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Figure 4.24: Burst release (% of total loading) of Dox from functionalized UCA (n=3, 
error bars = SEAM). A) Results from the Dox-loaded UCA group, **p=0.0002 for 100% 
PLA (insonated) to 5 wt% PEG-PLA (insonated), **p=0.0003 for 100% PLA (non-
insonated) to 5 wt% PEG-PLA (non-insonated), ***p<0.0001. B) Results from the Dox-
loaded, TRAIL-ligated group, ***p<0.0001. 
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Table 4.6: Dox burst release amounts and percentage of total encapsulated drug released. 
 
 Amount of Dox 
released (µg)/mg 
UCA 
Percent of Total 
Dox Released 
100% PLA Dox 
UCA  
(non-insonated) 
5.08±0.24 36.70±1.36% 
100% PLA Dox 
UCA (insonated) 4.75±0.15 34.31±0.85% 
100% PLA Dox 
TRAIL UCA  
(non-insonated) 
3.32±0.12 36.17±0.58% 
100% PLA Dox 
TRAIL UCA 
(insonated) 
3.21±0.20 34.95±1.01% 
5 wt% PEG-PLA 
Dox UCA  
(non-insonated) 
1.01±0.06 9.32±0.57% 
5 wt% PEG-PLA 
Dox UCA 
(insonated) 
1.01±0.02 9.26±0.22% 
5 wt% PEG-PLA 
Dox TRAIL UCA  
(non-insonated) 
1.35±0.13 16.04±0.90% 
5 wt% PEG-PLA 
Dox TRAIL UCA 
(insonated) 
1.33±0.10 15.89±0.70% 
1 wt% LipidPEG 
Dox UCA  
(non-insonated) 
3.26±0.20 46.45±1.14% 
1 wt% LipidPEG 
Dox UCA 
(insonated) 
3.11±0.18 44.31±1.06% 
1 wt% LipidPEG 
Dox TRAIL UCA  
(non-insonated) 
3.60±0.33 47.53±2.49% 
1 wt% LipidPEG 
Dox TRAIL UCA 
(insonated) 
3.69±0.21 48.67±1.58% 
 
 
 
 
For all three shell types there was significantly less Dox burst release from the 
Dox-loaded, TRAIL-ligated agents than from their Dox-loaded native counterparts 
(p<0.0001). All samples were standardized to evaluate the same number of UCA (based 
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on #UCA/mg determinations described in a later section). For the 100% PLA (Figure 
4.25A) and 5 wt% PEG-PLA (Figure 4.25B) agents, this trend is likely due to the initial 
burst release of Dox when the agents are exposed to an aqueous environment during 
TRAIL ligation. For the LipidPEG agents, Dox release increased slightly over the 20 
minute testing duration, as shown in Figure 4.25C. Again, since the agents were washed 
extensively during fabrication, this release is likely due to the movement of Dox toward 
the UCA surface during lyophilization coupled with the hydrophobic nature of the PEG 
lipids disrupting the polymeric shell and allowing more interaction with the hydrophilic 
Dox. There was no statistical significance in the amount of Dox released during n-Sh 
production compared to the non-insonated controls for all agents evaluated (p>0.05).  
 
 
 
 
Figure 4.25: Burst release profiles of Dox from functionalized UCA (n=3, error bars = 
SEAM). A) Results from the 100% PLA UCA group, ***p<0.0001. B) Results from the 
5 wt% PEG-PLA group, ***p<0.0001. C) Results from the 1 wt% LipidPEG UCA 
group, ***p<0.0001. 
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It was surprising to observe a similar trend in the 1 wt% LipidPEG UCA, since 
they do not undergo a second aqueous immersion for TRAIL ligation. As described 
before, electrostatic reactions between the LipidPEG tails and Dox molecules could 
prevent encapsulation within the UCA shell, with these interactions being interrupted 
upon introduction to an aqueous environment [187]. It is also possible that the relative 
weight of the PEG-TRAIL complex creates shear stresses and additional pores in the 
polymeric shell, causing increased and more rapid release of the encapsulated drug.  
 Once the burst release profile was determined, the long-term sustained release 
profile could be calculated in a similar way using data points collected at several intervals 
over a period of 7 days. Despite the initial higher burst release of Dox from the 1 wt% 
LipidPEG UCA, the release profile for these agents appeared to level off after 72 hours 
(Figure 4.26) and their final drug payload at the end of the 7-day release study was 
similar to that of the 5 wt% PEG-PLA UCA (Figure 4.27). As shown in Figure 4.27 and 
Figure 4.26, the insonated 100% PLA Dox UCA exhibited significantly more Dox release 
than any of the other agents (p<0.0001), releasing roughly 96% (88µg Dox/mg UCA) of 
its total encapsulated drug load by the end of 168 hours (7 days).  
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Figure 4.26: Effect of shell components on sustained Dox release (n=3, error bars = 
SEAM). A) Results from the Dox-loaded UCA group, **p=0.0011, ***p<0.0001. B) 
Results from the Dox-loaded TRAIL-ligated group, *p=0.0395, **p=0.0025. 
 
 
 107 
 
Figure 4.27: Total drug release after 7 days for Dox-loaded UCA (n=3, error bars = 
SEAM), **p=0.0001, ***p<0.0001. 
 
 
 
Other than the 100 wt% PLA Dox UCA, the functionalized UCA exhibited a 
sustained release of roughly 20-30µg Dox/mg UCA over the duration of the 7-day 
measurement period (Figure 4.26). Of note, the insonated 1 wt% LipidPEG Dox TRAIL 
UCA had significantly more release (28.82µg Dox/mg UCA, p<0.0001) than both the 
insonated 100% PLA Dox TRAIL UCA (19.76 µg Dox/mg UCA) and the insonated 5 
wt% PEG-PLA Dox TRAIL UCA (20.12µg Dox/mg UCA) (Figure 4.27). This is likely 
due to the rapid and higher burst release from the 1 wt% LipidPEG agents. Additionally, 
the percent release curves (Figure 4.26B) show that the release profile for the 1 wt% 
LipidPEG Dox TRAIL UCA to be significantly different than those for the 100% PLA 
Dox TRAIL (p=0.0395) and 5 wt% PEG-PLA Dox TRAIL UCA (p=0.0025).  
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In addition to the low initial burst release exhibited by the 5 wt% Dox TRAIL 
UCA, the sustained drug release from these agents (20.12µg Dox/mg UCA insonated, 
19.38µg Dox/mg UCA non-insonated) was not significantly different from that of the 
100% PLA Dox TRAIL UCA (19.76µg Dox/mg UCA insonated, 20.66µg Dox/mg UCA 
non-insonated) (p>0.05). Figure 4.26 shows that all of the agents exhibited increasing 
prolonged Dox release, presumably as a function of PLA hydrolysis [2-4, 87, 185].  
One of the most interesting findings in this study was the burst release of Dox 
from all agents upon introduction to an aqueous environment, especially the 100% PLA 
Dox TRAIL UCA and 5 wt% PEG-PLA Dox TRAIL UCA since these agents had already 
been reintroduced to an aqueous solution during ligation. Additionally, there was no 
difference between the agents that were exposed to US and those not exposed, further 
supporting the release of Dox in response to the aqueous environment. The observed 
burst release from the non-TRAIL-ligated UCA explains the loss of Dox observed in the 
TRAIL-ligated counterparts, having been lost during ligation. Our studies also show 
drastic differences in the amount of Dox released during this initial burst with each shell 
type, with 5 wt% PEG-PLA exhibiting significantly less release than 100% PLA and 1 
wt% LipidPEG UCA. These findings have important implications for both short-term 
effects when administered intravenously (less systemic exposure) and also long-term for 
sustained release of Dox during polymer hydrolysis. Long-term release profiling revealed 
similar trends, where Dox release amounts varied between shell types.  
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4.3.3 Effects of Shell Modification on UCA Quantity 
As discussed previously, concentration of each modified UCA type was 
determined by counting the number of microbubbles present in a known weight using a 
flow cytometer (Figure 4.28).  
 
 
 
 
Figure 4.28: Concentration of UCA by weight, error bars = SEAM, n=3. A) 100% PLA 
functionalized UCA, B) 5 wt% PEG-PLA functionalized UCA, *p=0.0106 for 5 wt% 
PEG-PLA UCA to 5 wt% PEG-PLA TRAIL UCA, *p=0.0143 for 5 wt% PEG-PLA Dox 
to 5 wt% PEG-PLA Dox TRAIL, ***p<0.0001, C) 1 wt% LipidPEG groups.   
 
 
 
 
For both the 100% PLA and 1 wt% LipidPEG groups, no significant difference 
was observed between any of the functionalized agents and the unmodified native agents 
(p>0.05). This finding demonstrates that functionalization modifications to these agents 
does not have deleterious effects to the concentration of agents produced, producing 
similar populations. For the 5 wt% PEG-PLA group, UCA concentration increased with 
TRAIL ligation for both TRAIL-ligated without Dox (1.04 x 109 UCA/mg) compared to 
unmodified 5 wt% PEG-PLA UCA (6.94 x 108 UCA/mg, p=0.0106) and also for the 5 
wt% PEG-PLA Dox TRAIL UCA (8.35 x 108 UCA/mg) compared to its Dox-loaded 
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counterpart (5.03 x 108 UCA/mg, p=0.0143). This could be due to the ligation process, as 
UCA can appear more concentrated if the TRAIL molecules are counted as events 
passing through the cytometer beam. Addition of the PEG-PLA co-polymer yielded less 
UCA per mg, likely due to thicker polymeric shells. Microbubble concentration by 
weight is a critical factor in standardizing treatment groups for number of UCA delivered 
and also standardizing drug delivery to regions of interest.  
4.3.4 Effects of Shell Modification on Acoustic Enhancement and Stability  
The effects of TRAIL ligation and drug loading on the in vitro acoustic properties 
of the resulting UCA were examined. As expected, all of these manipulations had a 
demonstrated effect on acoustic response (shown in Figure 4.29, Figure 4.30, and also 
summarized in Table 4.7). 
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Figure 4.29: Acoustic results plotted as cumulative dose response curves. A) 100% PLA 
UCA functionalization group, B) 5 wt% PEG-PLA functionalization group, C) 1 wt% 
LipidPEG functionalization group. Error bars = SEAM, n=5, ***p<0.0001. 
 
 
 
The dose needed to achieve maximum enhancement nearly doubled in response to 
all modifications of 100% PLA UCA, requiring at least 13.5µg/mL UCA compared to 
7.5µg/mL UCA for the unmodified 100% PLA UCA (Figure 4.29A). Additionally, the 
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maximum enhancement from the 100% PLA TRAIL UCA (10.53±0.85 dB) and 100% 
PLA Dox TRAIL UCA (13.04±0.73 dB) were significantly reduced (p<0.0001) 
compared to that of the unmodified 100% PLA UCA (18.30±0.25 dB), suggesting that 
shell modifications during ligation have deleterious effects on the cavitation, resonance, 
and/or size of these microbubbles. Drug loading and TRAIL ligation of the 5 wt% PEG-
PLA UCA (Figure 4.29B) did not significantly affect the dosage needed to reach 
maximum enhancement, remaining at 13.5µg/mL or increasing slightly to 15µg/mL. No 
significant difference in maximum enhancement was observed between 5 wt% PEG-PLA 
Dox UCA (19.91±0.51 dB) and 5 wt% PEG-PLA UCA (18.85±0.44 dB), suggesting that 
Dox encapsulation within these agents does not disrupt the polymer shell and allows for 
cavitation and resonance at 5MHz. Additionally, there was no significant difference 
(p>0.05) between the 5 wt% PEG-PLA TRAIL UCA (12.02±0.93 dB) and the 5 wt% 
PEG-PLA Dox TRAIL UCA (13.44±0.81 dB); however, both of these agents suffered 
significant loss in echogenicity compared to their non-ligated counterparts (p<0.0001). 
As explained previously, this finding supports that TRAIL ligation by reintroduction to 
an aqueous environment is detrimental to the shell properties in terms of resonance, 
cavitation, and backscattering. There were no significant changes to maximum 
enhancement for the 1 wt% LipidPEG UCA when functionalized (Figure 4.29C), 
suggesting that this platform is the most versatile for modifications.  
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Figure 4.30: Acoustic results plotted as cumulative dose response curves, error bars = 
SEAM, n=5. A) Unmodified native UCA group, B) Dox-loaded functionalization group, 
*p=C) TRAIL-ligated functionalization group, D) Dox-loaded and TRAIL-ligated 
functionalization group. 
 
 
 
We also investigated each shell manipulation to determine any advantages or 
significant issues between the different shell types. There were no significant differences 
in maximum enhancement between any of the unmodified native UCA (Figure 4.30A), 
establishing a good baseline for comparison. When UCA were modified to encapsulate 
Dox within the polymer shell (Figure 4.30B), 5 wt% PEG-PLA Dox UCA clearly 
exhibited the best acoustic enhancement (19.91±0.51 dB), and was significantly better 
than both 100% PLA Dox UCA (16.23±0.59 dB, p=0.0292) and 1 wt% LipidPEG Dox 
UCA (16.03±1.01 dB, p=0.0158). TRAIL ligation (Figure 4.30C) resulted in 1 wt% 
LipidPEG TRAIL UCA having the highest maximum cumulative enhancement 
(14.25±0.82 dB), which was significantly higher than 100% PLA TRAIL UCA 
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(10.53±0.85 dB, p=0.0259). This is likely due to the fabrication methods, since TRAIL is 
pre-ligated to the LipidPEG molecule before the double emulsion process while the 100% 
PLA and 5 wt% PEG-PLA agents must be reintroduced to an aqueous environment for 
TRAIL ligation. 1 wt% LipidPEG Dox TRAIL UCA also showed the highest maximum 
cumulative enhancement (16.13±0.80 dB) for the Dox and TRAIL functionalization 
group (Figure 4.30D), however there was no statistical difference between the three shell 
types (p>0.05).  
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Table 4.7: Acoustic properties of PEG-PLA co-polymer and LipidPEG UCA groups. 
 
Initial dB 
Enhancement 
(Dose in 
µg/ml) 
Maximum dB 
Enhancement 
(Dose in 
µg/ml) 
US Half-
life at 
Lower 
MI (min) 
US Half-
life at 
Higher 
MI (min) 
100% PLA 
UCA 
16.45±0.63 
(1.5 µg/ml) 
18.30±0.25 
(7.5 µg/ml) >15 3 
100% PLA Dox 
UCA 
8.85±0.58 
(1.5 µg/ml) 
16.23±0.59 
(13.5 µg/ml) 8 2 
100% PLA 
TRAIL UCA 
6.25±0.95 
(1.5 µg/ml) 
10.53±0.85 
(13.5 µg/ml) >15 2 
100% PLA Dox 
TRAIL UCA 
7.76±0.47 
(1.5 µg/ml) 
13.04±0.73 
(13.5 µg/ml) >15 2 
5 wt% PEG-
PLA UCA 
13.14±0.67 
(1.5 µg/ml) 
18.85±0.44 
(15 µg/ml) >15 4 
5 wt% PEG-
PLA Dox UCA 
13.91±0.57 
(1.5 µg/ml) 
19.91±0.51 
(13.5 µg/ml) 10 2 
5 wt% PEG-
PLA TRAIL 
UCA 
7.29±1.12 
(1.5 µg/ml) 
12.02±0.93 
(15 µg/ml) >15 2 
5 wt% PEG-
PLA Dox 
TRAIL UCA 
7.62±0.73 
(1.5 µg/ml) 
13.44±0.81 
(13.5 µg/ml) 14 2 
1 wt% 
LipidPEG UCA 
13.03±0.61 
(1.5 µg/ml) 
16.31±0.83 
(13.5 µg/ml) 8 2 
1 wt% 
LipidPEG Dox 
UCA 
12.50±0.96 
(1.5 µg/ml) 
16.03±1.01 
(13.5 µg/ml) 6 2 
1 wt% 
LipidPEG 
TRAIL UCA 
9,85±0.93 
(1.5 µg/ml) 
14.25±0.82 
(13.5 µg/ml) 8 2 
1 wt% 
LipidPEG Dox 
TRAIL UCA 
12.33±0.89 
(1.5 µg/ml) 
16.13±0.80 
(13.5 µg/ml) 8 1 
 
 
 
In terms of instability within an US beam (loss of echogenicity with time, Figure 
4.31 and Figure 4.32) at a lower MI useful for imaging (0.152 at peak positive pressure 
(PPP) of 0.7 MPa), both the 100% PLA UCA and 5 wt% PEG-PLA UCA groups retained 
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their stability (acoustic half-life, t1/2, >15 min) with the exception of 100% PLA Dox 
UCA (t1/2=8min) and 5 wt% PEG-PLA Dox UCA (t1/2=10min). In fact, 100% PLA Dox 
UCA were less stable than all other UCA in the 100% PLA group (Figure 4.31A, 
p=0.0497 compared to 100% PLA TRAIL UCA, p=0.0014 compared to 100% PLA Dox 
TRAIL UCA, and p<0.0001 compared to 100% PLA UCA), suggesting that Dox 
encapsulation disrupts the shell structure making it more flexible to still allow for 
oscillations but with less stability [189]. No significant differences in stability were 
observed within the 5 wt% PEG-PLA (t1/2  between 10-15min, Figure 4.31B) and 1 wt% 
LipidPEG (t1/2  between 6-8min, Figure 4.31C) shell type groups (p>0.05).  
While the both the 5 wt% PEG-PLA and 1 wt% LipidPEG unmodified UCA are 
significantly less stable than unmodified 100% PLA UCA (p=0.0129 compared to 5 wt% 
PEG-PLA UCA, p<0.0001 compared to 1 wt% LipidPEG UCA, Figure 4.32A), their 
stability is relatively unchanged in response to shell modification, while the 100% PLA 
agents experience a loss of stability when modified as explained above. This is likely due 
to the fact that 5 wt% PEG-PLA UCA and 1 wt% LipidPEG UCA already represent 
modifications to the native 100% PLA shell, and therefore further modifications (i.e. drug 
loading and surface ligation) do not have as significant of an impact on these agents.  
When comparing the types of modification individually for each shell type, we 
found that there was no significant change in stability (p>0.05) when UCA were loaded 
with Dox (Figure 4.32B) or ligated with TRAIL (Figure 4.32C). When both loaded with 
Dox and ligated with TRAIL (Figure 4.32D), 1 wt% LipidPEG Dox TRAIL UCA were 
less stable than 100% PLA Dox TRAIL UCA (p=0.0008), suggesting that these shells are 
 117 
more easily disrupted likely due to the shear stresses of the long molecules extending 
from the UCA surface and shell instability at the point of lipid tail incorporation.  
 
 
 
 
Figure 4.31: Acoustic results plotted as time response curves, error bars = SEAM, n=5, 
dotted line represents acoustic half-life. A) 100% PLA UCA group, *p=0.0439 for 100% 
PLA UCA to 100% PLA TRAIL UCA, *p=0.0497 for 100% PLA Dox UCA to 100% 
PLA TRAIL UCA, **p=0.0014, ***p<0.0001, B) 5 wt% PEG-PLA group, C) 1 wt% 
LipidPEG group. 
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Figure 4.32: Acoustic results plotted as time response curves, error bars = SEAM, n=5, 
dotted line represents acoustic half-life. A) Unmodified native UCA group, *p=0.0129, 
***p<0.0001, B) Dox-loaded group, C) TRAIL-ligated group, D) Dox-loaded and 
TRAIL-ligated group, **p=0.0008. 
 
 
 
These findings demonstrate that while echogenic response is diminished by 
functionalization in most cases, the resulting functionalized UCA are still capable of 
interacting with US under conditions similar to those used in a clinical setting. As 
discussed previously, the acoustic enhancement observed at these comparatively low 
doses is desirable, when compared to the clinical doses of UCA such as SonoVue (0.03-
0.3mL/kg) [161].  
Results suggest that 1 wt% LipidPEG shell type is the most versatile for 
adaptation via TRAIL-ligation (native or Dox-loaded), while 5 wt% PEG-PLA best 
retains acoustic behavior for Dox loading without addition of TRAIL.  
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4.3.5 In vitro Visualization of Functionalized UCA 
In conjunction with the in vitro acoustic testing performed in our laboratory, the 
UCA were also visualized in a tissue mimicking flow phantom with a clinical US scanner 
at Thomas Jefferson University Hospital. Using a linear US transducer, images were 
collected in both fundamental B-mode grayscale mode (right) and nonlinear contrast 
mode with gold tint (left). Images of the 100% PLA group are shown in Figure 4.33, the 
5 wt% PEG-PLA group in Figure 4.34, and the 1 wt% LipidPEG group in Figure 4.35. A 
baseline, pre-injection image with these labels is shown in all these figures.  
 
 
 
 
Figure 4.33: Images from ultrasound visualization of the 100% PLA UCA group in a 
tissue mimicking flow phantom. Each image was taken at a focal length of 4cm, in both 
non-linear contrast mode (left, orange) and fundamental B-mode (right, gray). A) Pre-
injection empty vessel baseline image, B) 100% PLA, C) 100% PLA Dox, D) 100% PLA 
TRAIL, E) 100% PLA Dox TRAIL. 
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 The strongest enhancement is visible for the unmodified 100% PLA UCA (Figure 
4.33B), with visible acoustic shadowing caused by the strength of signal from the UCA 
blocking US transmission through the entire sample. Diminished enhancement is visible 
for the 100% PLA Dox (Figure 4.33C) and 100% PLA TRAIL (Figure 4.33D), which 
corresponds to the reduction in echogenicity observed in our custom acoustic setup. 
Nonetheless, the flow phantom images confirm that these modified microbubbles are still 
functional as UCA. The least enhancement was observed for the 100% PLA Dox TRAIL 
UCA (Figure 4.33E), which were barely visible with low stability and viability. However, 
these agents were still visible under conditions similar to those used in a clinical setting, 
and may require a higher dosage concentration for increased visualization.  
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Figure 4.34: Images from ultrasound visualization of the 5 wt% PEG-PLA UCA group 
in a tissue mimicking flow phantom, focal length 4cm. Each image was taken in both 
non-linear contrast mode (left, orange) and fundamental B-mode (right, gray). A) Pre-
injection empty vessel baseline image, B) 5 wt% PEG-PLA, C) 5 wt% PEG-PLA Dox, 
D) 5 wt% PEG-PLA TRAIL, E) 5 wt% PEG-PLA Dox TRAIL. 
 
 
The 5 wt% PEG-PLA group behaved similarly to the 100% PLA group under 
these visualization conditions, but with diminished overall enhancement. Since samples 
were standardized to UCA concentration per milligram so that the same number of 
bubbles were passing through the phantom in each test, these images suggest that the 
strength of the enhancement is lost as a function of the shell material. Enhancement is 
visible for the unmodified 5 wt% PEG-PLA UCA (Figure 4.34B) and the 5 wt% PEG-
PLA Dox UCA (Figure 4.34C), while the enhancement is further diminished with the 5 
 122 
wt% PEG-PLA TRAIL UCA (Figure 4.34D). Again, this corresponds with their acoustic 
performance in our custom acoustic setup. Enhancement was even further diminished for 
the 5 wt% PEG-PLA Dox TRAIL UCA (Figure 4.34E), with low stability and 
visualization time while passing through the focused US beam. Despite the diminished 
enhancement, these agents were still visible under clinical conditions, and can still be 
considered viable as functionalized UCA for targeted drug delivery.  
 
 
 
Figure 4.35: Images from ultrasound visualization of the 1 wt% LipidPEG UCA group in 
a tissue mimicking flow phantom. Each image was taken at a focal length of 4cm, in both 
non-linear contrast mode (left, orange) and fundamental B-mode (right, gray). A) Pre-
injection empty vessel baseline image, B) 1 wt% LipidPEG, C) 1 wt% LipidPEG Dox, D) 
1 wt% LipidPEG TRAIL, E) 1 wt% LipidPEG Dox TRAIL. 
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Unlike the trends observed in the 100% PLA and 5 wt% PEG-PLA groups, there 
was no discernible loss of enhancement from the unmodified 1 wt% LipidPEG UCA with 
any of the modifications (i.e. Dox loading and TRAIL ligation). Strong enhancement is 
visible for the unmodified 1 wt% LipidPEG UCA (Figure 4.35B), 1 wt% LipidPEG Dox 
UCA (Figure 4.35C), 1 wt% LipidPEG TRAIL UCA (Figure 4.35D), and 1 wt% 
LipidPEG Dox TRAIL UCA (Figure 4.35E). Again, this is in agreement with our custom 
backscatter measurements, and these images confirm that these modified agents retain 
their functionality as UCA when adapted for targeted therapy. Taken together with the 
backscatter measurements, these images further support the use of the 1 wt% LipidPEG 
shell material for TRAIL ligation, and the use of the 5 wt% PEG-PLA shell material for 
Dox encapsulation (without TRAIL).  
4.3.6 Effects of Functionalization on Resonant Frequency 
The resonant frequency of each functionalized UCA and their corresponding 
unmodified UCA was determined experimentally, taking the minimum point from the 
graph plotting attenuation vs. frequency curves (Figure 4.36). 
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Figure 4.36: Attenuation (dB/cm) vs. frequency (MHz) resonance curves. Solid line 
represents measurements taken with 5MHz unfocused transducer (bandwidth = 91%), 
and dotted line represents measurements taken with 10MHz unfocused transducer 
(bandwidth = 65%). PRF = 100Hz, Energy = 1, Damping Level = 3, Gain = 0. A) 
Measurements of the 100% PLA group, B) Measurements of the 5 wt% PEG-PLA group, 
C) Measurements of the 1 wt% LipidPEG group. 
 
 
As shown previously, the resonant frequency of the 100% PLA UCA is 4.56MHz. 
Dox-loading of the 100% PLA UCA caused a slight shift in resonance to 4.04MHz, 
which is well within the bandwidth range of the 5MHz transducer used for the acoustic 
evaluations discussed in previous subsections. Both 100% PLA TRAIL UCA and 100% 
PLA Dox TRAIL UCA showed a shift in resonant frequency to approximately 7.2MHz, 
suggesting that TRAIL ligation induces changes to the shell elasticity and stiffness that 
affect its ability to cavitate and resonate within the US beam [169, 170, 190, 191]. These 
TRAIL-ligated UCA also had reduced average diameters, which is another factor that 
inversely influences resonant frequency. Such a shift in resonance frequency could 
explain the reduced echogenicity observed in our acoustic evaluations, as the bandwidth 
of the transducer may not effectively insonate the UCA at their new resonant frequency 
resulting in reduced oscillations and cavitation. There were no major shifts in resonant 
frequency in response to modifications in the 5 wt% PEG-PLA group (range: 6.02-
7.84MHz) and the 1 wt% LipidPEG group (range: 4.68-4.96MHz). However, the 5 wt% 
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PEG-PLA group showed large fluctuations in attenuation following ligation with TRAIL, 
suggesting a non-uniform population consisting of microspheres and other particles. The 
1 wt% LipidPEG group showed the most stability in resonant frequency in response to 
modification, suggesting that this platform is most versatile for modification to desired 
applications. These findings suggest that post-fabrication TRAIL ligation in the 100% 
PLA and 5 wt% PEG-PLA UCA leads to structural changes in the shell that inhibit the 
oscillation of the encapsulated gas core in the presence of a focused US beam. Since 
these changes are not observed in the 1 wt% LipidPEG group, this shell material appears 
to be the best for generating UCA decorated with TRAIL.  
4.3.7 Effects of Drug Loading and TRAIL Ligation on UCA Size, Zeta Potential, 
and Surface Morphology 
As described previously, size and morphology play a crucial role in determining 
microbubble acoustic behavior [153, 168-170]. All UCA formulations had an average 
diameter between 1-3µm (Figure 4.37), well within the acceptable range (<6µm) for clear 
passage through the vasculature, resonance in the clinical frequency range, and 
susceptibility to radiation forces [108, 109].  
Dox and TRAIL loading in the 100% PLA group (Figure 4.37A) resulted in 
decreased UCA diameter for all three types of modification (p<0.0001). Average 
diameters ranged from 1.43±0.04 to 1.71±0.06µm compared to unmodified 100% PLA 
UCA (2.41±0.10µm). Particle size distribution, measured by polydispersity index (PDI) 
was not significantly different for any of the 100% PLA groups, ranging from 0.184 to 
0.214, indicating a tight size distribution for all 100% PLA UCA groups.  
 
 126 
 
Figure 4.37: Average particle size of UCA. Error bars = SEAM, n=5, ***p<0.0001. A) 
Measurements of the 100% PLA UCA group, B) Measurements of the 5 wt% PEG-PLA 
UCA group, C) Measurements of the 1 wt% LipidPEG UCA group, **p=0.0009 for 
1wt% LipidPEG to 1 wt% LipidPEG Dox, **p=0.0029 for 1 wt% LipidPEG to 1 wt% 
LipidPEG Dox TRAIL. 
 
 
 
For the 5 wt% PEG-PLA group (Figure 4.37B), average UCA diameter increased 
from unmodified 5 wt% PEG-PLA (1.78±0.06µm) to 5 wt% PEG-PLA Dox UCA 
(2.24±0.07µm) (p<0.0001). Taken together with the changes in echogenicity and 
#UCA/mg, this change is likely due to interaction between the polymer groups while 
accommodating Dox loading, ultimately leading to thicker, larger polymeric shells. UCA 
diameter further increased with TRAIL ligation (2.35±0.06µm, p<0.0001), likely due to 
swelling during the maleimide ligation in an aqueous solution. Our lab previously 
showed an increase in UCA size immediately upon introduction to an aqueous 
environment, supporting this theory [4]. All 5 wt% PEG-PLA UCA had a wider size 
distribution than 100% PLA UCA, with PDI ranging from 0.258 to 0.346, indicating that 
these agents are less uniform in distribution.  
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Similarly, 1 wt% LipidPEG Dox UCA (1.45±0.06µm) were larger than 
unmodified 1 wt% LipidPEG UCA (1.24±0.04µm, p=0.0009) (Figure 4.37C). This is 
likely due to rearrangement of polymer chains and lipid tail groups to accommodate Dox 
encapsulation. Average particle size decreased with TRAIL ligation, both for 1 wt% 
LipidPEG TRAIL UCA (0.89±0.02µm, p<0.0001) and 1 wt% LipidPEG Dox TRAIL 
UCA (1.04±0.03µm, p=0.0029) compared to their unmodified counterpart. This is likely 
due to steric hindrance introduced by the TRAIL molecules preventing PEG folding into 
the mushroom formation. Similar to the 5 wt% PEG-PLA group, all 1 wt% LipidPEG 
UCA exhibited an increased PDI (0.262-0.352), suggesting that these agents have a 
wider, less uniform size distribution.  
All UCA groups maintained a negative zeta potential (ζ) mV (Figure 4.38); 
however, the magnitude of this potential decreased dramatically (p<0.0001) in response 
to functionalization in the 100% PLA (Figure 4.38A) and 5 wt% PEG-PLA (Figure 
4.38B) groups. Similar reduction in ζ magnitude was observed for the 1 wt% LipidPEG 
Dox UCA (p<0.0001). In all 5 of these cases, the magnitude of the zeta potential was 
decreased below 20mV, which would be in violation of the FDA regulation for 
injectables and also suggests that these agents are susceptible to aggregation and vascular 
blockage when administered intravenously [173].  
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Figure 4.38: Average zeta potential of functionalized UCA, error bars = SEAM, n=5, 
***p<0.0001. A) Measurements of the 100% PLA UCA group, B) Measurements of the 
5 wt% PEG-PLA UCA group, C) Measurements of the 1 wt% LipidPEG UCA group. 
 
 
 
For the 100% PLA group, all functionalized agents exhibited a significantly 
decreased magnitude in zeta potential (p<0.0001) compared to the unmodified 100% 
PLA UCA (ζ = -23.75±5.69mV). The same trend is observed in the 5 wt% PEG-PLA 
group, with all functionalized agents becoming less negatively charged (p<0.0001) than 
the unmodified 5 wt% PEG-PLA UCA (ζ = -28.79±6.49mV). While addition of Dox 
caused both the 100% PLA Dox UCA (ζ = -14.43±5.10mV) and 1 wt% LipidPEG Dox 
UCA (ζ = -11.84±5.26mV) to drop below the 20mV safety cutoff, Dox-loading of the 5 
wt% PEG-PLA Dox UCA resulted in agents that could still be considered safe by FDA 
standards with an average ζ of -20.62±3.54mV. Since Dox is a hydrophilic, positively-
charged molecule, it stands to reason that its incorporation into the UCA shell would alter 
the arrangement of charged groups within the shell, leading to these changes in zeta 
potential.  
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Zeta potential was also significantly reduced (p<0.0001) in response to ligation of 
TRAIL to the surface of the 100% PLA TRAIL UCA (ζ = -8.89±5.76mV), 100% PLA 
Dox TRAIL UCA (ζ = -7.86±3.18mV), 5 wt% PEG-PLA TRAIL UCA (ζ = -
4.74±2.69mV), and 5 wt% PEG-PLA Dox TRAIL UCA (ζ = -4.82±1.14mV) compared 
to their unmodified counterparts. Again, these agents cannot be considered viable as they 
do not meet the FDA cutoff of -20mV to prevent aggregation. TRAIL is a positively-
charged protein, and it is reasonable to assume that decorating the surface of the UCA 
with TRAIL would shield the COOH on the UCA surface from detection and contribute 
to a significant dipole, ultimately altering the overall surface charge of the agent as a 
whole. However, there is no significant reduction in zeta potential magnitude when 1 
wt% LipidPEG UCA are functionalized with TRAIL. Ligation of TRAIL to the 
LipidPEG molecule is optimized such that a larger proportion of LipidPEG remains 
unligated in order to reduce immunogenicity. Since the LipidPEG molecules are capped 
with a carboxyl group, they contribute to the overall negative zeta potential of the UCA 
and mitigate the charge effects of the ligated TRAIL molecules.  
Scanning electron microscopy (SEM) images were taken to assess surface 
morphology of the functionalized agents, showing the 100% PLA group in Figure 4.39, 
the 5 wt% PEG-PLA group in Figure 4.40, and the 1 wt% LipidPEG group in Figure 
4.41. In all cases, modification did not result in any changes to surface morphology 
compared to the unmodified native agent (A). UCA retained smooth, spherical 
morphology in both the 100% PLA and 1 wt% LipidPEG groups, while the bimodal 
distribution of spheres and collapsed particles remained in the 5 wt% PEG-PLA group. 
Despite the collapsed appearance observed in the 5 wt% PEG-PLA group, these agents 
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were still acoustically active, suggesting alterations to the shell making them overly 
sensitive to the vacuum conditions for SEM imaging.  
 
 
 
Figure 4.39: SEM images of 100% PLA UCA. Magnification 3500x, size bar 5µm. A) 
100% PLA UCA, B) 100% PLA Dox UCA, C) 100% PLA TRAIL UCA, D) 100% PLA 
Dox TRAIL UCA.   
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Figure 4.40: SEM images of 5 wt% PEG-PLA UCA. Magnification 3500x, size bar 
5µm. A) 5 wt% PEG-PLA UCA, B) 5 wt% PEG-PLA Dox UCA, C) 5 wt% PEG-PLA 
TRAIL UCA, D) 5 wt% PEG-PLA Dox TRAIL UCA.   
 
 
 
Figure 4.41: SEM images of 1 wt% LipidPEG UCA. Magnification 3500x, size bar 5µm. 
A) 1 wt% LipidPEG UCA, B) 1 wt% LipidPEG Dox UCA, C) 1 wt% LipidPEG TRAIL 
UCA, D) 1 wt% LipidPEG Dox TRAIL UCA.  
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In summary, shell modification led to changes in average UCA diameter, which 
can have an effect on acoustic backscatter and cavitation. Dox loading and TRAIL 
ligation also led to increased PDI measurements for modified UCA, indicating that these 
processes modify the agents such that they become less uniform in population. Zeta 
potential was significantly altered in response to modification. When ligated with 
TRAIL, 100% PLA and 5 wt% PEG-PLA exhibit a reduction in zeta potential magnitude, 
to such a high degree that they would be considered unsafe and susceptible to aggregation 
by FDA standards. 1 wt% LipidPEG TRAIL UCA and Dox TRAIL UCA do not 
experience this reduction, and represent viable TRAIL-ligated agents. However, 1 wt% 
LipidPEG Dox UCA reduced in zeta potential enough to fall below the FDA cutoff, 
while 5 wt% PEG-PLA Dox UCA retained enough zeta potential magnitude for viability 
and stability in solution. Modification did not cause any visible changes to UCA surface 
morphology compared to the unmodified native agents, further suggesting that any 
changes to UCA behavior are due to changes in interior shell structure (stiffness and 
thickness) when considered in conjunction with the resonant frequency results.  
4.3.8 Ultrasound-triggered n-Sh Production from UCA with Shell Modifications 
 Native and modified UCA were screened in our custom acoustic setup to 
determine the potential to undergo bursting into n-Sh in the presence of focused US. 
Agents were insonated with a 5MHz transducer set for a higher mechanical index 
(approximately 0.193, peak positive pressure 0.94MPa) for 15 minutes, with backscatter 
measurements taken every minute. As shown in Figure 4.42, all functionalized agents lost 
echogenicity rapidly (reaching their acoustic half-life in 4 minutes or less, p<0.0001 
compared to time to reach acoustic half-life under US at a lower MI) in the presence of a 
 133 
clinically-relevant US beam. The loss of signal signifies that the agents can no longer 
reflect the signal from the formerly encapsulated air core, which could be lost due to 
shattering or shell rupture and subsequent shrinkage due to the gas loss [176, 177].  
 
 
 
 
Figure 4.42: Acoustic time response curves for modified UCA insonated at low energy 
(MI 0.152, peak positive pressure 0.7 MPa) and high energy (MI 0.193, peak positive 
pressure 0.94 MPa). Dotted line represents acoustic half-life. Error bars = SEAM, n=5. 
A) Results from the 100% PLA group, *p=0.0439 for 100% PLA (low energy) to 100% 
PLA TRAIL (low energy), *p=0.0497 for 100% PLA Dox (low energy) to 100% PLA 
TRAIL (low energy), **p=0.0014, ***p<0.0001, B) Results from the 5 wt% PEG-PLA 
group, ***p<0.0001, C) Results from the 1 wt% LipidPEG group, ***p<0.0001. 
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For the 100% PLA group (Figure 4.42A), the Dox-loaded UCA (p<0.0001) and 
TRAIL-ligated UCA (p=0.0439) are significantly less stable than the unmodified 100% 
PLA UCA under US with a lower MI and pressure. The 100% PLA Dox UCA, which 
reach their acoustic half-life after approximately 9 minutes, are also significantly less 
stable that 100% PLA TRAIL UCA (p=0.0497) and 100% PLA Dox TRAIL UCA 
(p=0.0014) under low-powered US insonation. This is likely due to disruptions in the 
UCA shell caused by introduction of Dox and its probable movement through the shell 
during lyophilization. No statistical differences in stability under US with a lower MI 
were observed in the 5 wt% PEG-PLA group (Figure 4.42) or the 1 wt% LipidPEG group 
(Figure 4.42), suggesting that the PEGylation may contribute to stabilizing the UCA 
shell.  
Based on these reductions in acoustic half-life, modified agents were evaluated 
for average particle size after insonation, to determine whether US exposure caused 
significant particle diameter decrease to within the desired range for extravasation 
(between 400-700nm), as denoted by the dotted lines and red region (Figure 4.43). 
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Figure 4.43: Average particle size of UCA pre-insonation and post-insonation  (MI 0.193 
at 0.94 MPa PPP). A) Measurements of the 100% PLA group, ***p<0.0001, B) 
Measurements of the 5 wt% PEG-PLA group, ***p<0.0001, C) Measurements of the 1 
wt% LipidPEG group, **p=0.0009 for 1 wt% LipidPEG to 1 wt% LipidPEG Dox, 
**p=0.0029 for 1 wt% LipidPEG to 1 wt% LipidPEG Dox TRAIL, ***p<0.0001. Dotted 
lines represent 400-700nm range, the desired range for extravasation and n-Sh 
production. Error bars represent SEAM, n=5. 
 
 
 
US-triggered size reduction was significant (p<0.0001) for each tested agent, and 
the n-Sh produced by shattering the UCA with US all have an average size within the 
desired range for extravasation. These findings suggest that shell modification with Dox, 
TRAIL, and a combination of both does not prevent shattering into n-Sh under the 
influence of US. Generation of appropriately-sized n-Sh is an important aspect of our 
novel US-triggered drug delivery system. The n-Sh from the modified shells would be of 
small enough to pass through the pores in the leaky tumor vasculature (400-780nm) and 
reach the targeted tissue for effective therapy. Therefore, we have demonstrated that our 
modified UCA are capable of oscillating and shattering into nano-sized fragments in 
response to exposure to a focused US beam, supporting their potential as targeted drug 
delivery agents.  
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4.3.9 Immunogenic Characterization of Functionalized UCA 
Experiments were performed to determine the effect of shell modification on the 
immune response triggered by the UCA using a C3a activation ELISA assay (Figure 4.44 
and Figure 4.45), as well as whether the agents exhibited contamination by bacteria using 
a limulus amebocyte lysate (LAL) chromogenic endotoxin quantification assay (Figure 
4.46).  
 
 
 
 
Figure 4.44: C3 complement activation assay results. Error bars represent SEAM, n=2. 
A) Results from the unmodified UCA group, *p=0.0143, ***p<0.0001, B) Results from 
the Dox-loaded UCA group ***p<0.0001, C) Results from the TRAIL-ligated UCA 
group ***p<0.0001, D) Results from the Dox-loaded and TRAIL-ligated UCA group 
**p=0.0072, ***p<0.0001. 
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In all three modification groups and in the unmodified control group, both 
PEGylated forms of UCA were significantly less immunogenic than the 100% PLA UCA 
(p<0.0001). Additionally, the 5 wt% PEG-PLA UCA was less immunogenic than the 1 
wt% LipidPEG UCA for all three functional groups (Dox only p<0.0001, TRAIL only 
p<0.0001, and Dox TRAIL combined p=0.0072) and the unmodified control group 
(p=0.0143).  
For the 100% PLA group (Figure 4.45A), no significant difference in 
immunogenicity was observed between the unmodified 100% PLA UCA (5.48±0.16ng 
activated C3/mL serum) and the 100% PLA Dox UCA (5.24±0.06ng activated C3/mL 
serum) (p=0.6797). Immunogenicity was significantly reduced when TRAIL was ligated 
to the 100% PLA shell, for both unmodified 100% PLA UCA to 100% PLA TRAIL 
UCA (3.99±0.15ng activated C3/mL serum, p<0.0001) and for 100% PLA Dox UCA to 
100% PLA Dox TRAIL UCA (3.98±0.19ng activated C3/mL serum, p<0.0001). No 
significant difference was observed between the 100% PLA TRAIL UCA and 100% PLA 
Dox TRAIL UCA (p>0.9999).  
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Figure 4.45: C3 complement activation assay results. Error bars represent SEAM, n=2. 
A) Results from the 100% PLA group ***p<0.0001, B) Results from the 5 wt% PEG-
PLA group ***p<0.0001, C) Results from the 1 wt% LipidPEG group **p=0.0093 
***p<0.0001. 
 
  
 Unlike the 100% PLA group, there was no significant decrease in C3 activation 
with the addition of TRAIL to the 5 wt% PEG-PLA UCA (Figure 4.45B) for unmodified 
(1.18±0.04ng activated C3/mL serum) to TRAIL-ligated (1.27±0.04ng activated C3/mL 
serum (p=0.5938) and for Dox-loaded (2.10±0.06ng activated C3/mL serum) to Dox 
TRAIL UCA (1.91±0.07ng activated C3/mL serum) (p=0.0685). This is likely due to the 
fact that immunogenicity is already significantly reduced due the the PEG groups 
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exposed on the UCA surface, compared to the 100% PLA UCA (p<0.0001). 
Encapsulation of Dox resulted in a significant increase in immunogenicity for both 5 wt% 
PEG-PLA Dox UCA compared to unloaded 5 wt% PEG-PLA UCA (p<0.0001) and for 5 
wt% PEG-PLA TRAIL UCA compared to 5 wt% PEG-PLA Dox TRAIL UCA 
(p<0.0001).  
This trend was also observed in the 1 wt% LipidPEG group (Figure 4.45C), with 
the 1 wt% LipidPEG Dox UCA (2.53±0.04ng activated C3/mL serum) significantly more 
immunogenic than unloaded 1 wt% LipidPEG UCA (1.58±0.07ng activated C3/mL 
serum) (p<0.0001) as well as 1 wt% LipidPEG Dox TRAIL UCA (2.40±0.03ng activated 
C3/mL serum) compared to 1 wt% LipidPEG TRAIL UCA (2.17±0.04ng activated 
C3/mL serum) (p=0.0093). Interestingly for the 1 wt% LipidPEG group, all modified 
agents exhibited significantly more C3 activation than the unmodified 1 wt% LipidPEG 
UCA (p<0.0001). This suggests that the modifications made to the agents during 
modification may influence the orientation and expression of the PEG molecule brush on 
the UCA surface, allowing for more interaction with the C3 protein. In both the 5 wt% 
PEG-PLA and 1 wt% LipidPEG groups, C3 activation significantly increased when Dox 
was encapsulated within the agents (p<0.0001); however, this was not observed for the 
100% PLA group despite the higher Dox encapsulation efficiency of these agents. These 
observations suggest that the modifications to the shell material may increase the 
expression of Dox closer to the UCA surface, allowing the serum to interact with the 
toxic drug and become activated.  
Our observation of reduced C3 activation in the presence of TRAIL supports the 
emerging belief that TRAIL plays a role in immune regulation [192-194]. Briefly, TRAIL 
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is a member of the tumor necrosis factor (TNF) family, of which ligands and their 
receptors have critical influence on the immune system through apoptosis in active lymph 
cells [192, 193]. Specifically, TRAIL has been demonstrated to be a regulator of CD8+ T-
cell activation as well as a preventative mechanism to autoimmune disease [192, 195, 
196]. As explained previously, C3 could also be activated through interaction of the 
unstable thioester bonds in the C3 protein and the carboxylic end groups on the PLA shell 
surface [133, 140, 182, 183]. The ligation of TRAIL to the UCA surface may provide 
some steric hindrance that reduces these interactions by blocking access to the UCA 
surface, and therefore reducing immunogenicity similar to the action of the LipidPEG 
molecules that extend from the UCA surface in the LipidPEG group.  
Based on the fabrication process, another immunogenic concern with these agents 
was the presence of endotoxins that could contaminate the agent and skew the C3 assay 
results. Endotoxin quantification assay results, shown in Figure 4.46, indicate that all of 
the experimental UCA (unmodified and functionalized) were well below the FDA limit 
of 0.2 EU/mL (p<0.0001) while still exhibiting a small amount of activation (average 
0.06 EU/mL) that can trigger the immune-regulated apoptosis cascade [41, 197].  
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Figure 4.46: Endotoxin quantification assay results. Error bars represent SEAM, n=3, 
***p<0.0001. 
 
 
 
 Overall, UCA shell modification yielded UCA that retained the ability to reduce 
immune activation through the complement system, having a low bio-burden, and also 
retaining base levels of endotoxin to support immune-regulated apoptosis. Both 5 wt% 
PEG-PLA and 1 wt% LipidPEG groups exhibited reduced complement activation 
compared to the 100% PLA group, indicating that the addition of Dox and TRAIL to the 
UCA was not deleterious to the immunogenic protection of PEGylation. Low levels of 
endotoxin were detected across all groups, indicating that the UCA were not 
contaminated with bacteria. As such, these drug-loaded and ligated agents represent a 
great potential for use as targeted drug delivery agents.  
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4.3.10 In vitro Tumoricidal Activity of Dox-loaded and TRAIL-ligated UCA 
To determine the effectiveness of these agents against breast cancer tumors, we 
performed in vitro cell studies against two breast cancer cell lines. The first, MDA-MB-
231 breast adenocarcinoma cells, is known to be sensitive to TRAIL by having abundant 
DR4 and DR5 receptors expressed on the surface. We also have extensive experience 
with these cells. The second cell line, MCF7 breast adenocarcinoma cells, was selected as 
a TRAIL-resistant population. These cells represent breast cancers that are less 
responsive to TRAIL treatments, resulting from cell-specific combinations of reduced 
expression of DR4/DR5 receptors, increased expression of decoy receptors, and 
intracellular resistance mechanisms [198]. Studies evaluated whether co-administration 
of Dox helps overcome resistance to TRAIL treatments. Dox-loaded UCA and n-Sh were 
introduced to the cells in a standardized amount based on encapsulation efficiency. A 
third cell line, MCF-12A breast epithelial cells, were evaluated as a healthy control 
group. All cells were grown in 6-well plates, incubated with each treatment for 24 hours, 
and read via flow cytometry. Cells were stained with green-fluorescent Alexa Fluor 488 
Annexin V to detect the externalization of phosphatidylserine in apoptotic cells, red-
fluorescent propidium iodide to detect nucleic acids of necrotic/dead cells, and blue-
fluorescent Hoescht blue nuclear stain to visualize live cells.  
4.3.10.1 MDA-MB-231 Cells  
 MDA-MB-231 cells were first exposed to negative and positive control treatments 
for comparison with the experimental agents. Negative control consisted of incubation 
with pure cell media, with no additives. Positive controls were free Dox, free TRAIL and 
a combination of both free Dox and free TRAIL. Flow cytometry results are shown in 
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Figure 4.47, and cell fate percentages are summarized in Table 4.8. Negative control of 
no treatment resulted in 98.52±0.38% live cells, indicating that no environmental 
conditions caused observed cell death. All three positive controls exhibited significant 
reduction in cell survival (p<0.0001). Incubation with free Dox resulted in 60.64±5.32% 
cell death and 16.95±2.81% apoptosis, leaving only 19.59±6.36% cells alive. Free 
TRAIL exposure led to 57.65±9.74% apoptosis and 26.44±10.35% cell death, with only 
15.29±1.14% cells remaining alive. The combination of free Dox and free TRAIL 
resulted in only 8.73±1.17% living cells, with 43.43±8.61% apoptotic cells and 
46.79±7.47% necrotic/dead cells. These control results will form the basis for 
determining effectiveness of the experimental agents.  
 
 
 
 
Figure 4.47: Representative flow cytometry plots for MDA-MB-231 breast cancer cells. 
A) No treatment, B) Dox Only, C) TRAIL Only, D) Dox and TRAIL Only. 
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Table 4.8: Average cell fate percentages from flow cytometry results for MDA-MB-231 
cell control groups, n=3. 
 Live Cells  (%) 
Apoptotic Cells  
(%) 
Dead Cells  
(%) 
No Treatment 98.52 ± 0.38 0.87 ± 0.18 0.28 ± 0.13 
Free Dox Only 19.59 ± 6.36 16.95 ± 2.81 60.64 ± 5.32 
Free TRAIL Only 15.29 ± 1.14 57.65 ± 9.74 26.44 ± 10.35 
Free Dox and TRAIL 
Only 8.73 ± 1.17 43.43 ± 8.61 46.79 ± 7.47 
 
For the 100% PLA shell type group (summarized in Table 4.9, flow results shown 
in Figure 4.48), negative controls of unmodified, native 100% PLA UCA (99.03±0.66% 
live cells) and 100% PLA n-Sh (92.87±2.48% live cells) were evaluated to verify that the 
polymeric shell or its hydrolytic byproducts did not cause any cell death or disruption. 
These high levels of cell survival (statistically similar to No Treatment control, p>0.9999) 
indicate that the polymeric shell is not detrimental to cell survival, and any cell death or 
apoptosis observed in the experimental groups is due to the loaded Dox or ligated 
TRAIL.  
Cell survival was decreased when MDA-MB-231 cells were exposed to the 
experimental Dox-loaded and TRAIL-ligated agents compared to their unloaded native 
UCA and n-Sh counterparts. Dox-loaded UCA resulted in 65.36±12.23% cell survival 
(p=0.0056 to 100% PLA UCA), while Dox-loaded n-Sh resulted in 53.75±16.52% cell 
survival (p=0.0004 to 100% PLA n-Sh). There was no statistical difference in cell 
survival between the Dox-loaded UCA and Dox-loaded n-Sh (p=0.9993), likely due to 
exposure to similar amounts of Dox based the burst release of Dox upon suspension in 
the cell media in addition to the similar 24-hour release profiles observed in the in vitro 
release study. The combination Dox-loaded and TRAIL-ligated UCA (64.56±6.50% live) 
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and n-Sh (41.43±0.43% live) also resulted in significantly less cell survival than their 
native counterparts (p=0.0038 and p=0.0144, respectively).  
 
 
Table 4.9: Average cell fate percentages from flow cytometry results for MDA-MB-231 
cells treated with 100% PLA group of agents, n=3. 
 Live Cells  (%) 
Apoptotic Cells  
(%) 
Dead Cells  
(%) 
100% PLA UCA 99.03 ± 0.66 0.57 ± 0.36 0.39 ± 0.30 
100% PLA n-Sh 92.87 ± 2.48 4.61 ± 1.74 2.46 ± 1.01 
100% PLA Dox UCA 65.36 ± 12.23 0.76 ± 0.05 33.11 ± 11.96 
100% PLA Dox n-Sh 53.75 ± 16.52 6.50 ± 3.17 39.49 ± 14.45 
100% PLA TRAIL UCA 86.71 ± 2.72 10.25 ± 3.42 2.39 ± 0.29 
100% PLA TRAIL  
n-Sh 52.84 ± 11.65 36.44 ± 13.17 11.21 ± 6.32 
100% PLA TRAIL UCA 
+ Free Dox 78.67 ± 5.26 12.35 ± 4.34 9.50 ± 0.99 
100% PLA TRAIL  
n-Sh + Free Dox 20.32 ± 6.91 42.55 ± 3.47 35.59 ± 4.38 
100% PLA Dox TRAIL 
UCA 64.56 ± 6.50 20.50 ± 4.64 14.69 ± 1.92 
100% PLA Dox  TRAIL 
n-Sh 41.43 ± 0.43 24.94 ± 0.38 33.50 ± 0.30 
 
 
 
 
While the cell survival rates for the Dox-loaded UCA/n-Sh and TRAIL-ligated 
UCA/n-Sh were similar (p=0.4847 for UCA, p>0.9999 for n-Sh), the cell death 
mechanisms were very different for these two groups. Dox-loaded UCA resulted in 
33.11±11.96% dead/necrotic cells and only 0.76±0.05% apoptotic cells, while Dox-
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loaded n-Sh resulted in 39.49±14.45% dead/necrotic cells with 6.50±3.17% apoptotic 
cells. Conversely, TRAIL-ligated UCA resulted in only 2.39±0.29% dead/necrotic cells 
(p=0.0152) and 10.25±3.42% apoptotic cells (p=0.0500), while TRAIL-ligated n-Sh 
resulted in 11.21±6.32% dead/necrotic cells (p=0.0436) and 36.44±13.17% apoptotic 
cells (p=0.0022). Since the mechanism of cell death for Dox includes early activation of 
p53 in tumor cells leading to DNA fragmentation and death, and TRAIL induces 
apoptosis via transmembrane signaling, this shift in cell death mechanism between these 
two treatments type can be expected [43, 44, 199]. Additionally, the TRAIL n-Sh resulted 
in a greater degree of apoptosis (36.44±13.17%) compared to TRAIL UCA 
(10.25±3.42%, p=0.0178), as well as decreased overall cell survival (52.84±11.65% live 
n-Sh to 86.71±2.72% live UCA, p=0.0051). This same trend was observed with the 
TRAIL UCA + free Dox (78.67±5.26% live; 12.35±4.34% apoptotic) and TRAIL n-Sh + 
free Dox (20.32±6.91% live, p=0.0095; 42.55±3.47% apoptotic, p=0.0019). The 
increased apoptosis observed with the n-Sh comes from an increased availability of 
TRAIL molecules to bind to the cells, utilizing the entire UCA surface as n-Sh spread 
across the cell plate surface instead of a single contact point at the UCA-cell surface 
interface [4, 200].   
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Figure 4.48: Representative flow cytometry plots for MDA-MB-231 breast cancer cells 
treated with the 100% PLA group. A) 100% PLA UCA, B) 100% PLA n-Sh, C) 100% 
PLA Dox UCA, D) 100% PLA Dox n-Sh, E) 100% PLA TRAIL UCA, F) 100% PLA 
TRAIL n-Sh, G) 100% PLA TRAIL UCA + Free Dox, H) 100% PLA TRAIL n-Sh + 
Free Dox, I) 100% PLA Dox TRAIL UCA, J) 100% PLA Dox TRAIL n-Sh. 
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Cell survival results for the 5 wt% PEG-PLA shell type group (summarized in 
Table 4.10, flow results shown in Figure 4.49) showed that negative controls of 
unmodified, native 5 wt% PEG-PLA UCA (98.80±0.13% live cells) and 5 wt% PEG-
PLA n-Sh (96.90±0.42% live cells) exhibited high levels of cell survival (p>0.9999 
compared to No Treatment control), again indicating that the shell material is non-toxic 
to the cell environment.  
Similar to the trend observed with the 100% PLA group, cell survival was 
decreased when these cells were exposed to the experimental Dox-loaded and TRAIL-
ligated agents compared to their unloaded native UCA and n-Sh counterparts. Dox-
loaded UCA resulted in 75.50±2.94% cell survival (p=0.0004), while Dox-loaded n-Sh 
resulted in 71.00±0.30% cell survival (p=0.0005). Again, no statistical difference in cell 
survival was observed between the Dox-loaded UCA and Dox-loaded n-Sh (p=0.9993), 
with correlation to the experimental Dox release profile. Both the TRAIL-ligated UCA 
(80.93±1.31% live, p=0.0030) and TRAIL-ligated UCA co-administered with free Dox 
(59.43±3.78% live, p<0.0001) significantly reduced cell survival rates compared to the 
native UCA. Similar trends were observed with the TRAIL-ligated n-Sh (67.53±3.35% 
live, p=0.0002) and TRAIL-ligated n-Sh together with free Dox (61.33±5.26% live, 
p<0.0001). However, neither of these groups exhibited significant differences between 
the intact UCA and post-US n-Sh. This is likely due to the shift in resonant frequency 
observed with these agents, suggesting an inefficient US-driven production of n-Sh. The 
combination Dox-loaded and TRAIL-ligated UCA (63.21±3.19% live) and n-Sh 
(64.19±2.68% live) also resulted in significantly less cell survival than their native 
counterparts (p<0.0001 for both). Again, these agents exhibited a shift in resonant 
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frequency, likely accounting for the lack of significance between the intact UCA and 
post-US n-Sh treatments.  
 
 
 
Table 4.10: Average cell fate percentages from flow cytometry results for MDA-MB-231 
cells treated with 5 wt% PEG-PLA group of agents, n=3. 
 Live Cells (%) Apoptotic Cells (%) Dead Cells (%) 
5 wt% PEG-PLA UCA 98.80 ± 0.13 0.77 ± 0.17 0.27 ± 0.03 
5 wt% PEG-PLA n-Sh 96.90 ± 0.42 2.04 ± 0.31 0.81 ± 0.44 
5 wt% PEG-PLA Dox 
UCA 75.50 ± 2.94 1.75 ± 0.89 22.21 ± 3.91 
5 wt% PEG-PLA Dox 
n-Sh 71.00 ± 0.30 2.17 ± 1.01 26.82 ± 1.29 
5 wt% PEG-PLA 
TRAIL UCA 80.93 ± 1.31 3.92 ± 0.97 15.79 ± 1.98 
5 wt% PEG-PLA 
TRAIL n-Sh 67.53 ± 3.35 19.93 ± 6.53 12.35 ± 5.06 
5 wt% PEG-PLA 
TRAIL UCA + Free 
Dox 
59.43 ± 3.78 17.44 ± 2.44 24.12 ± 1.35 
5 wt% PEG-PLA 
TRAIL n-Sh + Free 
Dox 
61.33 ± 5.26 19.73 ± 6.15 19.06 ± 5.91 
5 wt% PEG-PLA Dox 
TRAIL UCA 63.21 ± 3.19 19.48 ± 0.66 18.45 ± 1.20 
5 wt% PEG-PLA Dox  
TRAIL n-Sh 64.19 ± 2.68 11.55 ± 1.92 24.60 ± 2.07 
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Figure 4.49: Representative flow cytometry plots for MDA-MB-231 breast cancer cells 
treated with the 5 wt% PEG-PLA group. A) 5 wt% PEG-PLA UCA, B) 5 wt% PEG-PLA 
n-Sh, C) 5 wt% PEG-PLA Dox UCA, D) 5 wt% PEG-PLA Dox n-Sh, E) 5 wt% PEG-
PLA TRAIL UCA, F) 5 wt% PEG-PLA TRAIL n-Sh, G) 5 wt% PEG-PLA TRAIL UCA 
+ Free Dox, H) 5 wt% PEG-PLA TRAIL n-Sh + Free Dox, I) 5 wt% PEG-PLA Dox 
TRAIL UCA, J) 5 wt% PEG-PLA Dox TRAIL n-Sh. 
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Interestingly, there were no statistical differences between the intact UCA and 
post-US n-Sh for any of the treatment types. As discussed above, the TRAIL-ligated 
agents suffered a loss of echogenicity and a shift in resonant frequency after ligation, 
possibly hindering the ability of these agents to form n-Sh in response to insonation. One 
other explanation for this finding is the reduced quantity of 5 wt% PEG-PLA UCA per 
mg, which led to a large amount of UCA and n-Sh to the added to each well for 
standardization of Dox concentration among treatment groups. This could have an effect 
on the PLA hydrolysis, as well as the Dox release along a potentially altered 
concentration gradient. Another possible explanation for the TRAIL-ligated agents is that 
TRAIL ligation was less effective with this polymeric shell type. Studies have shown that 
TRAIL encapsulation within a PEGylated polymeric microsphere exhibited reduced burst 
response, higher encapsulation efficiency, and also a longer sustained release than 
unPEGylated polymeric microspheres, suggesting that the PEG helps to retain the TRAIL 
and may prevent all of the ligated molecules from binding to the cell surface [149]. 
As observed with the 100% PLA and 5 wt% PEG-PLA groups, the polymeric 
shell material of the 1 wt% LipidPEG group (Table 4.11, Figure 4.50) was non-cytotoxic 
(p>0.9999 compared to No Treatment) with the intact UCA group exhibiting 
95.69±0.84% cell survival and the post-US n-Sh group exhibiting 95.59±1.04% cell 
survival. Since all three shell types are mainly comprised of PLA, it is not surprising that 
all of the native agents exhibited similar high rates of cell survival. Dox-loaded UCA 
resulted in 80.34±2.83% cell survival (p=0.0011), while Dox-loaded n-Sh resulted in 
81.01±5.05% cell survival (p=0.0262). Again, no statistical difference in cell survival 
was observed between the Dox-loaded UCA and Dox-loaded n-Sh (p>0.9999), likely due 
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to the low encapsulation efficiency, inefficient release, and reduction in echogenicity 
which could hinder n-Sh production. Both the TRAIL-ligated UCA (83.38±1.65% live, 
p=0.0056) and TRAIL-ligated UCA co-administered with free Dox (74.65±2.12% live, 
p<0.0001) significantly reduced cell survival rates compared to the native UCA. Similar 
trends were observed with the TRAIL-ligated n-Sh (76.34±3.25% live, p=0.0045) and 
TRAIL-ligated n-Sh together with free Dox (50.81±1.53% live, p<0.0001). However, 
neither of these groups exhibited significant differences between the intact UCA and 
post-US n-Sh. This could be due to steric hindrance from the surrounding PEG chains 
preventing the TRAIL from binding to the DR4/5 receptors efficiently. The combination 
Dox-loaded and TRAIL-ligated UCA (76.42±1.97% live, p=0.0002) and n-Sh 
(52.66±2.45% live, p<0.0001) also resulted in significantly less cell survival than their 
native counterparts. Cell death was significantly increased when free Dox was co-
administered with TRAIL-ligated n-Sh (35.54±3.53% dead/necrotic cells) compared to 
TRAIL-ligated n-Sh alone (4.51±1.78% dead/necrotic cells, p=0.0131). Such an 
observation is expected, since free Dox induces significant cell death when incubated 
with MDA-MB-231 cells.  
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Table 4.11: Average cell fate percentages from flow cytometry results for MDA-MB-231 
cells treated with 1 wt% LipidPEG group of agents, n=3. 
 Live Cells (%) Apoptotic Cells (%) Dead Cells (%) 
1 wt% LipidPEG UCA 95.69 ± 0.84 2.95 ± 0.62 1.32 ± 0.32 
1 wt% LipidPEG n-Sh 95.59 ± 1.04 3.34 ± 0.83 1.04 ± 0.31 
1 wt% LipidPEG Dox 
UCA 80.34 ± 2.83 1.85 ± 0.81 17.44 ± 3.10 
1 wt% LipidPEG Dox 
n-Sh 81.01 ± 5.05 0.94 ± 0.34 17.95 ± 4.78 
1 wt% LipidPEG TRAIL 
UCA 83.38 ± 1.65 15.64 ± 1.14 1.05 ± 0.13 
1 wt% LipidPEG TRAIL 
n-Sh 76.34 ± 3.25 18.74 ± 3.52 4.51 ± 1.78 
1 wt% LipidPEG TRAIL 
UCA + Free Dox 74.65 ± 2.12 9.14 ± 0.76 16.00 ± 2.96 
1 wt% LipidPEG TRAIL 
n-Sh + Free Dox 50.81 ± 1.53 12.99 ± 5.11 35.54 ± 3.53 
1 wt% LipidPEG Dox 
TRAIL UCA 76.42 ± 1.97 10.26 ± 1.48 12.86 ± 0.73 
1 wt% LipidPEG Dox  
TRAIL n-Sh 52.66 ± 2.45 16.97 ± 8.50 29.53 ± 8.23 
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Figure 4.50: Representative flow cytometry plots for MDA-MB-231 breast cancer cells 
treated with the 1 wt% LipidPEG group. A) 1 wt% LipidPEG UCA, B) 1 wt% LipidPEG 
n-Sh, C) 1 wt% LipidPEG Dox UCA, D) 1 wt% LipidPEG Dox n-Sh, E) 1 wt% 
LipidPEG TRAIL UCA, F) 1 wt% LipidPEG TRAIL n-Sh, G) 1 wt% LipidPEG TRAIL 
UCA + Free Dox, H) 1 wt% LipidPEG TRAIL n-Sh + Free Dox, I) 1 wt% LipidPEG 
Dox TRAIL UCA, J) 1 wt% LipidPEG Dox TRAIL n-Sh. 
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Across the shell type groups, 100% PLA TRAIL n-Sh with free Dox resulted in 
significantly reduced cell survival (20.32±6.91% live) compared to both 5 wt% PEG-
PLA TRAIL n-Sh with free Dox (61.33±5.26% live, p=0.0001) and 1 wt% LipidPEG 
TRAIL n-Sh with free Dox (50.81±1.53% live, p=0.0233). This can be accounted for by 
the significantly greater degree of apoptosis induced by the 100% PLA TRAIL n-Sh with 
free Dox (42.55±3.47% apoptotic) compared to both 5 wt% PEG-PLA TRAIL n-Sh with 
free Dox (19.73±6.15% apoptotic, p=0.0012) and 1 wt% LipidPEG TRAIL n-Sh with 
free Dox (12.99±5.11% apoptotic, p=0.0028). These differences in apoptosis could be in 
relation to the amount of TRAIL ligated to the UCA surface for each shell type, 
especially for the LipidPEG group as the PEG groups may prevent the TRAIL from 
effectively binding to the DR4/5 receptors through steric hindrance. Borden and Chen 
have demonstrated that small bioactive molecules, such as streptavidin, can be hidden 
within the PEG brush on the surface of a phospholipid microbubble [140, 147, 154]. 
Overall, we observed reductions in cell viability in response to incubation with the 
modified UCA across all three shell types, supporting the potential of these agents as 
drug delivery vehicles.  
4.3.10.2 MCF7 Cells 
Similar to the MDA-MB-231 cells, TRAIL-resistant MCF7 cells were exposed to 
the negative and positive control treatments for comparison with the experimental agents. 
Flow cytometry results are shown in Figure 4.51, and average cell fate percentages are 
summarized in Table 4.12. Negative control of no treatment resulted in 95.36±1.09% live 
cells, indicating that environmental conditions did not have an effect on cell death. Both 
free Dox (23.27±3.57% live) and the combination of both free Dox and free TRAIL 
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(31.28±4.99% live) resulted in significant reduction in cell survival (p<0.0001), while 
free TRAIL did not cause significant cell apoptosis or death (84.74±5.70% live, 
p>0.9999). However, when administered in the presence of Dox, cell survival was 
significantly decreased (p<0.0001), and the percentage of apoptotic cells significantly 
increased from 8.73±1.50% for free TRAIL to 20.20±1.86% for free Dox and TRAIL 
(p=0.0086). This finding confirms that Dox acts synergistically with TRAIL to overcome 
the inherent resistance to TRAIL-induced apoptosis expressed by these cells [45, 49, 50, 
52, 157, 201].  
 
 
 
Figure 4.51: Representative flow cytometry plots for MCF7 breast cancer cells. A) No 
treatment, B) Dox Only, C) TRAIL Only, D) Dox and TRAIL Only. 
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Table 4.12: Average cell fate percentages from flow cytometry results for MCF7 cell 
control groups, n=3. 
 Live Cells  (%) 
Apoptotic Cells  
(%) 
Dead Cells  
(%) 
No Treatment 95.36 ± 1.09 3.06 ± 1.02 0.56 ± 0.12 
Free Dox Only 23.27 ± 3.57 7.51 ± 1.67 67.70 ± 3.23 
Free TRAIL Only 84.74 ± 5.70 8.73 ± 1.50 5.87 ± 4.47 
Free Dox and TRAIL 
Only 31.28 ± 4.99 20.20 ± 1.86 47.20 ± 6.31 
 
 
 
Average cell fate percentages for the 100% PLA shell type group are summarized 
in Table 4.13, and flow cytometry plots are shown in Figure 4.52. Exposure to the Dox-
loaded experimental agents as well as the TRAIL-ligated agents with Dox co-
administration resulted in reduced MCF7 cell survival. For the intact UCA, both TRAIL-
ligated UCA + free Dox (49.96±7.80% live, p=0.0011) and Dox TRAIL UCA 
(69.77±9.02% live, p=0.0493) caused significant reduction in cell survival compared to 
the native UCA (94.92±1.26% live). Considering the treatments with post-US n-Sh, 
incubation with the Dox-loaded n-Sh (52.61±10.82% live, p=0.0011), TRAIL-ligated n-
Sh co-administered with free Dox (37.37±5.39% live, p<0.0001), and Dox-loaded 
TRAIL-ligated n-Sh (67.78±3.98% live, p=0.0206) led to reduced cell survival compared 
to the native n-Sh (96.51±0.50% live).  
Cell survival is also significantly reduced when TRAIL-ligated UCA and n-Sh are 
incubated together with free Dox, compared to incubation alone in cell media. For the 
intact UCA groups, cell survival rates decrease from an average of 94.65±1.65% live 
cells for TRAIL UCA to an average of only 49.96±7.80% live cells for TRAIL UCA with 
free Dox (p=0.0001). Co-administration of Dox led to significant increases in both 
apoptotic cells (p=0.0862) and dead/necrotic cells (p=0.0347), accounting for the 
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decreased overall cell survival. Similarly, increased apoptosis (p=0.0246) and necrosis 
(p=0.0051) account for the significant cell survival reduction (p<0.0001) observed when 
Dox is co-administered with TRAIL-ligated n-Sh (98.11±0.44% to 37.37±5.39% live).  
 
 
Table 4.13: Average cell fate percentages from flow cytometry results for MCF7 cells 
treated with 100% PLA group of agents, n=3. 
 Live Cells  (%) 
Apoptotic Cells  
(%) 
Dead Cells  
(%) 
100% PLA UCA 94.92 ± 1.26 2.33 ± 0.60 2.66 ± 0.67 
100% PLA n-Sh 96.51 ± 0.50 1.67 ± 0.17 1.77 ± 0.40 
100% PLA Dox UCA 79.31 ± 4.89 3.46 ± 1.48 17.08 ± 3.02 
100% PLA Dox n-Sh 52.61 ± 10.82 3.11 ± 1.66 44.44 ± 11.82 
100% PLA TRAIL UCA 94.65 ± 1.65 2.97 ± 0.10 2.68 ± 1.04 
100% PLA TRAIL  
n-Sh 98.11 ± 0.44 0.94 ± 0.12 0.87 ± 0.31 
100% PLA TRAIL UCA 
+ Free Dox 49.96 ± 7.80 15.86 ± 4.08 32.79 ± 6.76 
100% PLA TRAIL  
n-Sh + Free Dox 37.37 ± 5.39 19.26 ± 2.97 42.38 ± 6.77 
100% PLA Dox TRAIL 
UCA 69.77 ± 9.02 14.63 ± 4.65 15.48 ± 4.39 
100% PLA Dox  TRAIL 
n-Sh 67.78 ± 3.98 12.62 ± 1.77 18.88 ± 2.33 
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Figure 4.52: Representative flow cytometry plots for MCF7 breast cancer cells treated 
with the 100% PLA group. A) 100% PLA UCA, B) 100% PLA n-Sh, C) 100% PLA Dox 
UCA, D) 100% PLA Dox n-Sh, E) 100% PLA TRAIL UCA, F) 100% PLA TRAIL n-Sh, 
G) 100% PLA TRAIL UCA + Free Dox, H) 100% PLA TRAIL n-Sh + Free Dox, I) 
100% PLA Dox TRAIL UCA, J) 100% PLA Dox TRAIL n-Sh. 
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Similar to the trend observed with the 100% PLA group, cell survival was 
decreased when these cells were exposed to the experimental 5 wt% PEG-PLA agents 
compared to their unloaded native UCA and n-Sh counterparts, with the exception of the 
TRAIL-ligated UCA and n-Sh (p<0.0001).  
Cell survival is again significantly reduced when TRAIL-ligated UCA and n-Sh 
are incubated together with free Dox and when Dox is co-encapsulated within the 
polymeric shell, compared to incubation alone in cell media. For the intact UCA groups, 
cell survival rates decrease from an average of 98.83±0.42% live cells for TRAIL UCA 
to an average of only 26.59±5.51% live cells for TRAIL UCA with free Dox (p<0.0001) 
and an average of 58.58±5.16% live cells for Dox TRAIL UCA (p=0.0009). Co-
administration of Dox led to significant increases in both apoptotic cells (p=0.0665 for 
TRAIL UCA + free Dox) and dead/necrotic cells (p<0.0001 for both TRAIL UCA + free 
Dox and Dox TRAIL UCA), accounting for the decreased overall cell survival.  
Similarly, increased apoptosis (p=0.0086 for TRAIL n-Sh + free Dox) and 
necrosis (p<0.0001 for TRAIL n-Sh + free Dox) account for the significant cell survival 
reduction (p<0.0001) observed when either free Dox is co-administered with TRAIL-
ligated n-Sh (26.59±5.51% live) or Dox is co-encapsulated within the polymeric shell 
(48.37±5.04% live) compared to TRAIL-ligated n-Sh alone (98.18±1.04% live). These 
results suggest that the 5 wt% PEG-PLA shell allows for effective localized Dox release 
to help sensitize TRAIL-resistant cells to therapeutic treatment while limiting systemic 
exposure to the toxic chemotherapeutic.  
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Figure 4.53: Representative flow cytometry plots for MCF7 breast cancer cells treated 
with the 5 wt% PEG-PLA group. A) 5 wt% PEG-PLA UCA, B) 5 wt% PEG-PLA n-Sh, 
C) 5 wt% PEG-PLA Dox UCA, D) 5 wt% PEG-PLA Dox n-Sh, E) 5 wt% PEG-PLA 
TRAIL UCA, F) 5 wt% PEG-PLA TRAIL n-Sh, G) 5 wt% PEG-PLA TRAIL UCA + 
Free Dox, H) 5 wt% PEG-PLA TRAIL n-Sh + Free Dox, I) 5 wt% PEG-PLA Dox 
TRAIL UCA, J) 5 wt% PEG-PLA Dox TRAIL n-Sh. 
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Table 4.14: Average cell fate percentages from flow cytometry results for MCF7 cells 
treated with 5 wt% PEG-PLA group of agents, n=3. 
 Live Cells (%) Apoptotic Cells (%) Dead Cells (%) 
5 wt% PEG-PLA UCA 98.99 ± 0.22 0.62 ± 0.15 0.29 ± 0.08 
5 wt% PEG-PLA n-Sh 97.04 ± 0.86 1.14 ± 0.46 1.25 ± 0.48 
5 wt% PEG-PLA Dox 
UCA 57.70 ± 2.65 4.01 ± 1.21 38.03 ± 3.45 
5 wt% PEG-PLA Dox 
n-Sh 58.73 ± 1.24 3.37 ± 0.93 38.31 ± 0.60 
5 wt% PEG-PLA 
TRAIL UCA 98.83 ± 0.42 0.59 ± 0.15 0.48 ± 0.24 
5 wt% PEG-PLA 
TRAIL n-Sh 98.18 ± 1.04 0.69 ± 0.33 1.41 ± 1.07 
5 wt% PEG-PLA 
TRAIL UCA + Free 
Dox 
26.59 ± 5.51 54.74 ± 9.79 17.17 ± 4.36 
5 wt% PEG-PLA 
TRAIL n-Sh + Free 
Dox 
39.97 ± 1.94 24.62 ± 2.76 34.76 ± 3.31 
5 wt% PEG-PLA Dox 
TRAIL UCA 58.58 ± 5.16 21.15 ± 3.79 20.31 ± 1.72 
5 wt% PEG-PLA Dox  
TRAIL n-Sh 48.37 ± 5.04 16.60 ±1.83 34.42 ± 5.32 
 
 
Within the 1 wt% LipidPEG shell type group (Figure 4.54, Table 4.15), cell 
survival was decreased when these cells were exposed to the experimental agents 
compared to their unloaded native n-Sh counterparts, with the exception of the TRAIL-
ligated n-Sh. Dox-loaded n-Sh resulted in 54.72±15.23% live cells (p=0.0086), while 
TRAIL-ligated n-Sh + free Dox resulted in 28.05±4.40% live cells (p=0.0002) and Dox-
loaded TRAIL-ligated n-Sh resulted in 24.48±1.79% live cells (p=0.0001). Only the 1 
wt% LipidPEG TRAIL UCA + free Dox produced significant reduction in cell survival 
(51.83±12.07% live cells) compared to the native UCA (97.20±0.91% live cells, 
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p=0.0045). While the other experimental intact UCA, with the exception of TRAIL-
ligated UCA, exhibited some reduction in cell survival, these reductions were not 
statistically significant within the entire group.  
Cell survival is again significantly reduced when TRAIL-ligated UCA and n-Sh 
are incubated together with free Dox and when Dox is co-encapsulated within the 
polymeric shell, compared to incubation alone in cell media. For the intact UCA groups, 
cell survival rates decrease from an average of 97.86±0.70% live cells for TRAIL UCA 
to an average of only 51.83±12.07% live cells for TRAIL UCA with free Dox 
(p<0.0001). Similarly, increased apoptosis (p<0.0001 for TRAIL n-Sh + free Dox) and 
necrosis (p<0.0001 for Dox TRAIL n-Sh) account for the significant cell survival 
reduction (p<0.0001) observed when either free Dox is co-administered with TRAIL-
ligated n-Sh (28.05±4.40% live) or Dox is co-encapsulated within the polymeric shell 
(24.48±1.79% live) compared to TRAIL-ligated n-Sh alone (93.44±2.88% live). Similar 
to the 5 wt% PEG-PLA group, these results suggest that the 1 wt% LipidPEG shell can 
allow for effective localized Dox release to help sensitize TRAIL-resistant cells.  
Unlike the other shell type groups, significant differences were observed between 
some of the TRAIL-ligated intact UCA and their corresponding n-Sh. Apoptosis was 
significantly increased in response to TRAIL-ligated n-Sh + free Dox (36.61±19.18% 
apoptotic) compared to the TRAIL-ligated UCA + free Dox (13.05±1.65% apoptotic, 
p=0.0246). This increase in apoptosis is likely due to the combination of Dox 
sensitization of the cells, as well as increased binding of ligated TRAIL molecules since 
n-Sh allow for utilization of the entire surface area of the UCA instead of the few contact 
points between the UCA spherical surface and the cell plate. Necrosis and cell death 
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increased (p=0.0034) when cells were incubated with Dox TRAIL n-Sh (57.28±3.63% 
dead/necrotic) compared to Dox TRAIL UCA (21.01±6.73% dead/necrotic). Dox is 
released from the polymeric shell via PLA hydrolysis; therefore, n-Sh may hydrolyze 
more rapidly than intact UCA based on amount of polymer resulting in an increased Dox 
concentration released from the n-Sh than intact UCA. Based on these results, the 1 wt% 
LipidPEG shell type seems to be most effective for US-triggered therapy to MCF7 cells, 
resulting in the best sensitization and n-Sh treatment efficacy.  
 
 
Table 4.15: Average cell fate percentages from flow cytometry results for MCF7 cells 
treated with 1 wt% LipidPEG group of agents, n=3. 
 Live Cells (%) Apoptotic Cells (%) Dead Cells (%) 
1 wt% LipidPEG UCA 97.20 ± 0.91 1.36 ± 0.26 1.30 ± 0.69 
1 wt% LipidPEG n-Sh 96.87 ± 1.19 1.58 ± 0.64 1.49 ± 0.58 
1 wt% LipidPEG Dox 
UCA 71.09 ± 7.04 5.61 ± 1.95 23.14 ± 7.04 
1 wt% LipidPEG Dox 
n-Sh 54.72 ± 15.23 8.60 ± 1.66 37.23 ± 13.78 
1 wt% LipidPEG TRAIL 
UCA 97.86 ± 0.70 1.16 ± 0.22 1.44 ± 0.44 
1 wt% LipidPEG TRAIL 
n-Sh 93.44 ± 2.88 2.96 ± 1.24 3.43 ± 1.66 
1 wt% LipidPEG TRAIL 
UCA + Free Dox 51.83 ± 12.07 13.05 ± 1.65 35.64 ± 12.77 
1 wt% LipidPEG TRAIL 
n-Sh + Free Dox 28.05 ± 4.40 36.61 ± 19.18 35.25 ± 18.46 
1 wt% LipidPEG Dox 
TRAIL UCA 72.77 ± 7.48 7.25 ± 1.00 21.01 ± 6.73 
1 wt% LipidPEG Dox  
TRAIL n-Sh 24.48 ± 1.79 17.67 ± 2.15 57.28 ± 3.63 
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Figure 4.54: Representative flow cytometry plots for MCF7 breast cancer cells treated 
with the 1 wt% LipidPEG group. A) 1 wt% LipidPEG UCA, B) 1 wt% LipidPEG n-Sh, 
C) 1 wt% LipidPEG Dox UCA, D) 1 wt% LipidPEG Dox n-Sh, E) 1 wt% LipidPEG 
TRAIL UCA, F) 1 wt% LipidPEG TRAIL n-Sh, G) 1 wt% LipidPEG TRAIL UCA + 
Free Dox, H) 1 wt% LipidPEG TRAIL n-Sh + Free Dox, I) 1 wt% LipidPEG Dox 
TRAIL UCA, J) 1 wt% LipidPEG Dox TRAIL n-Sh. 
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Results confirmed that all three native shell materials were not cytotoxic to the 
MCF7 cells, since incubation with intact UCA and post-US n-Sh resulted in cell survival 
similar to that of the negative No Treatment control group (p>0.9999) for each shell type 
group. Again, this confirms that any cell death or apoptosis observed in the experimental 
groups is due to the therapeutic element. Since all three shell types are mainly comprised 
of PLA, which biodegrades into lactic acid, it is not surprising that all of the native agents 
exhibited similar high rates of cell survival. 
MCF7 cell survival was unaffected by incubation with TRAIL UCA and n-Sh 
across all three shell types, with cell survival similar to those of the native agents as well 
as the No Treatment control (p>0.9999). This outcome is expected based on the 
knowledge that MCF7 cells are intrinsically resistant to TRAIL-induced apoptosis due to 
reduced expression of DR4/5 receptors on the cell surface and upregulation of the 
cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway [45, 202]. As an alternative 
to administration of free Dox or co-encapsulation of the chemotherapeutic, administration 
of a COX-2 inhibitor to the tumor cells could help reverse the intrinsic TRAIL resistance 
and improve treatment efficacy [202].   
Across the shell type groups, 1 wt% LipidPEG Dox TRAIL n-Sh resulted in 
significantly reduced cell survival (24.48±1.79% live) compared to 100% PLA Dox 
TRAIL n-Sh (67.78±3.98% live, p=0.0002). This can be accounted for by the 
significantly greater degree of cell death induced by the 1 wt% LipidPEG Dox TRAIL n-
Sh (57.28±3.63% dead/necrotic) compared to its 100% PLA counterpart (18.88±2.33% 
dead/necrotic, p=0.0162). Since the 1 wt% LipidPEG agents exhibit a higher Dox burst 
release than 100% PLA agents, these cells could have been exposed to a greater 
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concentration of Dox resulting in the observed cell death increase. Across all groups, we 
observed a reduction in cell viability when Dox was co-administered with TRAIL, 
supporting the hypothesis that cells that are intrinsically resistant to TRAIL can be 
sensitized to the apoptotic activity with use of a secondary treatment to increase death 
receptor expression and affinity to improve cell death signaling.  
4.3.10.3 MCF-12A Cells  
MCF-12A breast epithelial cells represent the healthy cells surrounding tumor 
tissue that could be susceptible to tumor treatments. These cells express the decoy TRAIL 
receptors (DcR1/DcR2) that do not signal apoptosis upon binding, and were evaluated as 
a control to investigate the effects of the experimental agents on healthy tissue 
surrounding the area of interest.  
As with the two breast cancer cell groups, MCF-12A cells were exposed to the 
negative and positive control treatments (Table 4.16, Figure 4.55). Negative control of no 
treatment resulted in 93.07±1.77% live cells, and incubation with free TRAIL resulted in 
90.40±2.21% live cells, confirming that these cells are non-reactive to TRAIL. However, 
MCF-12A are highly susceptible to Dox, resulting in only 6.08±1.42% live cells with 
88.83±1.90% dead/necrotic cells. These findings are very important when considering 
treatment regimes, as the surrounding epithelial cells experience significant necrosis 
when exposed to Dox (p<0.0001).  
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Table 4.16: Average cell fate percentages from flow cytometry results for MCF-12A cell 
control groups, n=3. 
 Live Cells  (%) 
Apoptotic Cells 
 (%) 
Dead Cells  
(%) 
No Treatment 93.07 ± 1.77 3.84 ± 1.55 2.65 ± 1.286 
Free Dox Only 6.08 ± 1.42 4.22 ± 1.20 88.83 ± 1.90 
Free TRAIL Only 90.40 ± 2.21 5.84 ± 1.15 3.52 ± 3.13 
Free Dox and TRAIL 
Only 5.31 ± 0.64 12.11 ± 1.94 81.86 ± 2.15 
 
 
 
 
 
Figure 4.55: Representative flow cytometry plots for MCF-12 breast epithelial cells. A) 
No treatment, B) Dox Only, C) TRAIL Only, D) Dox and TRAIL Only. 
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For all three shell materials, significant reductions in cell survival with 
corresponding increases in dead/necrotic cells were observed for all of the Dox-loaded 
groups compared to the native agents (p<0.0001 for all necrotic comparisons). 
Significance values compared to the corresponding native agent (UCA or n-Sh) are listed 
below the cell fate percentage in Table 4.17 - Table 4.19 for cell survival.  
 
 
Table 4.17: Average cell fate percentages from flow cytometry results for MCF-12A 
cells treated with 100% PLA group of agents, n=3. 
 Live Cells  (%) Apoptotic Cells (%) 
Dead Cells  
(%) 
100% PLA UCA 95.99 ± 1.78 1.53 ± 0.57 2.32 ± 1.16 
100% PLA n-Sh 95.94 ± 1.58 1.04 ± 0.26 2.93 ± 1.49 
100% PLA Dox  
UCA 
72.71 ± 2.59 
(p=0.0423) 1.64 ± 0.19 25.50 ± 2.85 
100% PLA Dox  
n-Sh 
58.15 ± 1.45 
(p<0.0001) 4.10 ± 1.24 37.22 ± 1.26 
100% PLA TRAIL UCA 91.84 ± 1.68 2.61 ± 0.72 4.57 ± 0.94 
100% PLA TRAIL  
n-Sh 95.53 ± 1.01 1.07 ± 0.40 3.28 ± 0.63 
100% PLA TRAIL UCA 
+ Free Dox 
73.91 ± 1.36 
(p=0.0487) 1.39 ± 0.31 14.57 ± 1.50 
100% PLA TRAIL  
n-Sh + Free Dox 
58.15 ± 1.27 
(p<0.0001) 3.34 ± 1.06 38.39 ± 0.52 
100% PLA Dox TRAIL 
UCA 
66.39 ± 8.60 
(p=0.0022) 5.03 ± 1.80 28.49 ± 6.79 
100% PLA Dox  TRAIL 
n-Sh 
68.79 ± 6.89 
(p=0.0007) 5.92 ± 2.25 25.93 ± 4.91 
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Table 4.18: Average cell fate percentages from flow cytometry results for MCF-12A 
cells treated with 5 wt% PEG-PLA group of agents, n=3. 
 Live Cells (%) Apoptotic Cells (%) Dead Cells (%) 
5 wt% PEG-PLA UCA 95.52 ± 1.64 2.15 ± 0.73 2.22 ± 0.98 
5 wt% PEG-PLA n-Sh 93.27 ± 1.43 0.98 ± 0.21 5.41 ± 1.27 
5 wt% PEG-PLA Dox 
UCA 
60.69 ± 7.91 
(p=0.0089) 1.80 ± 0.95 38.42 ± 7.42 
5 wt% PEG-PLA Dox 
n-Sh 
60.03 ± 4.11 
(p=0.0164) 2.47 ± 0.71 38.70 ± 3.94 
5 wt% PEG-PLA 
TRAIL UCA 95.81 ± 1.20 1.59 ± 0.44 2.50 ± 0.79 
5 wt% PEG-PLA 
TRAIL n-Sh 97.46 ± 0.62 0.90 ± 0.18 1.51 ± 0.42 
5 wt% PEG-PLA 
TRAIL UCA + Free 
Dox 
71.46 ± 4.98 
(p=0.0484) 5.31 ± 1.02 23.26 ± 5.13 
5 wt% PEG-PLA 
TRAIL n-Sh + Free 
Dox 
40.13 ± 12.37 
(p=0.0006) 6.10 ± 1.72 53.27 ± 10.74 
5 wt% PEG-PLA Dox 
TRAIL UCA 
69.03 ± 9.54 
(p=0.0451) 8.57 ± 1.88 22.01 ± 7.03 
5 wt% PEG-PLA Dox  
TRAIL n-Sh 
50.58 ± 5.42 
(p=0.0031) 5.03 ± 1.89 45.27 ± 7.23 
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Table 4.19: Average cell fate percentages from flow cytometry results for MCF-12A 
cells treated with 1 wt% LipidPEG group of agents, n=3. 
 Live Cells (%) Apoptotic Cells (%) Dead Cells (%) 
1 wt% LipidPEG UCA 96.87 ± 0.09 1.47 ± 0.19 1.59 ± 0.22 
1 wt% LipidPEG n-Sh 92.59 ± 0.71 2.68 ± 0.26 4.57 ± 0.44 
1 wt% LipidPEG Dox 
UCA 
79.30 ± 3.87 
(p=0.0492) 1.62 ± 0.01 18.42 ± 3.78 
1 wt% LipidPEG Dox 
n-Sh 
54.49 ± 3.84 
(p=0.0160) 2.20 ± 0.67 43.36 ± 4.40 
1 wt% LipidPEG TRAIL 
UCA 95.90 ± 1.86 1.62 ± 0.68 2.33 ± 1.17 
1 wt% LipidPEG TRAIL 
n-Sh 90.64 ± 2.54 1.83 ± 0.13 7.42 ± 2.54 
1 wt% LipidPEG TRAIL 
UCA + Free Dox 
56.35 ± 8.45 
(p=0.0003) 4.15 ± 0.23 39.14 ± 8.63 
1 wt% LipidPEG TRAIL 
n-Sh + Free Dox 
44.73 ± 15.26 
(p=0.0035) 5.59 ± 2.53 49.18 ± 12.61 
1 wt% LipidPEG Dox 
TRAIL UCA 
74.55 ± 2.36 
(p=0.0189) 7.12 ± 3.13 18.09 ± 1.29 
1 wt% LipidPEG Dox  
TRAIL n-Sh 
59.60 ± 2.86 
(p=0.0369) 2.06 ± 0.79 38.86 ± 1.21 
 
 
4.3.11 UCA Modification for Cancer Therapy Conclusions 
The work discussed here presents an innovative, dual-functioning platform to 
create a “theranostic” modality to overcome many of the challenges surrounding in vivo 
delivery of nanoparticles. The UCA provide valuable diagnostic information during 
administration, and we have shown that shell modifications for therapeutic applications 
do not compromise the ability to obtain this diagnostic information.  
 172 
Three UCA modification strategies for targeted therapy were evaluated, loading 
the UCA shell with Dox, decorating the surface of the UCA shell with TRAIL, and 
combining these two strategies in the same UCA. Based on the results discussed here, the 
5 wt% PEG-PLA UCA shell composition seems to be the best for encapsulation of Dox, 
as it reduces immunogenicity compared to native PLA, exhibits higher drug 
encapsulation efficiency (27.5%) than the 1 wt% LipidPEG UCA, exhibits sustained 
release of Dox without a large initial burst release, and also retains its acoustic behavior 
for function as a targeted drug delivery agent. On the other hand, the 1 wt% LipidPEG 
shell composition emerges as the better option for functionalization with TRAIL, as these 
agents exhibit better acoustic behavior than the 5 wt% PEG-PLA TRAIL UCA, retain 
their immunogenic reduction, retain a zeta potential of greater magnitude than -20mV to 
prevent aggregation in suspension, and are still capable of supporting co-encapsulation of 
Dox (~12% encapsulation efficiency).  
Cell studies demonstrated that all three polymeric shell types, 100% PLA, 5 wt% 
PEG-PLA, and 1 wt% LipidPEG and their hydrolytic byproducts were not cytotoxic to 
any of the three breast cell lines, indicating that any cell death observed in the 
experimental groups was in response to the therapeutic element. MDA-MB-231 cells 
were highly responsive to the therapeutic agents, exhibited significantly reduced cell 
survival in response to incubation with Dox-loaded, TRAIL-ligated, and combination 
therapy UCA and their resulting n-Sh. Results also showed that TRAIL-resistant MCF7 
breast cancer cells can be sensitized to treatment with TRAIL by co-administration of 
Dox, which led to significant reduction in cell viability for both intact UCA and n-Sh 
across all three polymeric shell types. Finally, we demonstrated that MCF-12A breast 
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epithelial cells, which represent the healthy cells surrounding the tumor, are insensitive to 
TRAIL-induced apoptosis. However, these cells are susceptible to Dox-induced necrosis, 
which is an important consideration when determining treatment regimes.  
In terms of clinical relevance, we calculated the amount of Dox that would be 
delivered from one injected dose of loaded UCA based on the maximum dose of UCA 
(20mg/mL) determined in previous animal studies (rat model) and scaled to adult humans 
(factor of 7 for body mass) [5, 90]. Considering a dose of 140mg loaded UCA, 100% 
PLA Dox UCA would deliver 1.94mg Dox, and 100% PLA Dox TRAIL UCA would 
deliver 1.29mg Dox per injection. Similarly, 140mg of 5 wt% PEG-PLA Dox UCA 
delivers 1.52mg Dox, and its TRAIL-ligated counterpart delivers 1.18mg Dox per 
injected dose. For the 1 wt% LipidPEG group, the Dox-loaded UCA deliver 0.99mg Dox 
per dose, while the TRAIL-ligated, Dox-loaded UCA deliver 0.69mg Dox per dose. The 
maximum therapeutic dose for Dox in humans is reported to be 1.62mg/kg, or 
approximately 97mg in a single systemic dose [203]. A single injected dose of our loaded 
UCA would represent ~1-2% of this amount, and therefore would be considered safe in 
terms of therapeutic index. Even taking into consideration the sustained release and 
subsequent treatments, the cumulative dose would still be below the maximum tolerated 
dose. Studies have shown high tolerance of TRAIL in humans at doses up to 30mg/kg, 
with the maximum dose delivered with our agents falling far below this therapeutic index 
threshold and still effective against susceptible cancer cells [204]. Based on the results 
presented here, our UCA represent effective cancer treatment agents that fall well below 
the therapeutic index cutoff dosage for each treatment modality while retaining efficacy. 
Dose escalation in vivo studies would be needed to determine the maximum tolerated 
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dose of loaded UCA and the maximum deliverable therapeutic doses of the loaded 
treatments.  
This study also provides a basis for investigation of encapsulation of other drugs, 
possibly hydrophobic drugs such as paclitaxel and docetaxel, or ligation of other ligands 
or proteins, such as other members of the TNF family and malaria protein VAR2CSA 
[205], to the UCA surface.  
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5. CONCLUSIONS AND FUTURE RECOMMENDATIONS 
5.1 Conclusions and Contributions to Science 
The overall objective of this thesis was the development and characterization of 
non-immunogenic, PEGylated functionalized UCA capable of locally delivering 
encapsulated drug to cancerous cells while also inducing cancer cell death through 
specific ligand binding.  
Initially, PLA UCA were ligated with TRAIL protein to determine the efficacy of 
this platform to induce cytotoxicity in susceptible breast cancer cells while retaining its 
acoustic properties. Ligation using maleimide chemistry was an effective method for 
attaching TRAIL to UCA, and these modified UCA maintained apoptotic activity 
towards susceptible breast cancer cells. Additionally, cells treated with n-Sh generated by 
US treatment of ligated TRAIL-UCA showed the greatest extent of apoptosis/cell death 
among test groups (p<0.0001), suggesting that these agents were still able to cavitate and 
shatter when exposed to therapeutic US. 
Two PEGylation techniques were investigated in an effort to reduce the 
immunogenicity of our UCA: addition of increasing amounts of PEG-PLA copolymer 
and employing incorporation of LipidPEG into the shell. Addition of PEG-PLA showed 
dose-dependent reductions in acoustic enhancement, while insertion of LipidPEG 
molecules was deleterious to acoustic properties at low proportions. Results indicated that 
the 5 wt% PEG-PLA and 1 wt% LipidPEG formulations best achieved a balance between 
retention of acoustic interaction, appropriate physical properties, and reduction in 
immune activation.  
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PEGylated UCA were then modified for targeted cancer therapies with two 
different modalities, resulting in the fabrication of three different classes of modified 
agents. Fluctuations in acoustic behavior and physical properties were observed in the 
modified agents, suggesting the chemical process of ligation negatively affects the shell’s 
ability to cavitate. Dox release profiles were determined for drug-loaded PLA, showing 
sustained release of Dox over the 7-day testing period. In vitro testing showed that cancer 
cells were susceptible to modified agents, while healthy cells are shielded from TRAIL-
induced apoptosis but remain highly susceptible to Dox-induced cell death. Additionally, 
these studies demonstrated the ability to use co-administration of Dox to overcome 
cancer cell resistance to TRAIL-mediated apoptosis. We determined that the 5 wt% PEG-
PLA formulation was optimal for creation of non-immunogenic, Dox-loaded UCA. 
However, the 1 wt% LipidPEG shell formulation appeared to perform better as non-
immunogenic, TRAIL-ligated UCA in addition to the dual-functionalized Dox-loaded, 
TRAIL-ligated UCA.  
These results represent important advances in the field of US-triggered drug 
delivery and cancer therapy with great potential for improvement over current standard 
treatments. The platforms presented here demonstrate how PEGylated polymeric UCA 
can be utilized, and modified, for localized, US-driven cancer therapy.  
We demonstrated that PEGylation of our native agents reduces immunogenicity 
through reduction of C3a complement component activation. The results presented here 
expand on the work of Mosquiera and Chen regarding PEG coatings to mask capsules 
[125, 140]. Mosquiera previously demonstrated that polymeric nanocapsules decorated 
with PEG chains resulted in base levels of C3 activation, with nanocapsules displaying 
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longer PEG chains and/or a higher surface density of PEG chains activating C3 to a lesser 
degree than other formulations [125]. Chen performed similar evaluations of PEGylated 
phospholipid microbubbles, demonstrating that longer PEG chains (5kDa) extending 
from the bubble surface can better mask the underlying surface and therapeutic agent, 
reducing immune recognition by C3b tagging protein [140]. Our work expands upon 
these studies by evaluating two different PEGylation methods for polymeric 
microbubbles, and determining the efficacy of these methods to mask Dox-loaded, 
TRAIL-ligated UCA from C3a complement component activation.  
Considering the sustained release of encapsulated Dox during PLA hydrolysis of 
n-Sh embedded within the tumor tissue following cavitation and extravasation, these 
agents present an opportunity for increased local treatment potency, allowing for a higher 
drug payload to be delivered directly to the target tumor tissue while significantly 
limiting systemic exposure. Furthermore, sustained release from the agents produced in 
this study represents the potential for the desirable metronomic treatment mechanism. 
Several studies have shown metronomic, or consistent release over time, treatment to be 
more effective in cancer therapy than traditional bolus dose administration [206-210]. 
Specifically, Klement and colleagues demonstrated tumor regression and antiangiogenic 
activity when neuroblastoma cells were exposed to continuous low-dose treatment with 
vinblastine, a neutralizing antibody that targets VEGF receptors, and VEGF receptor-2 
antibody over a period of 6 months with no evidence of collateral damage to the host 
[210]. Fontana et al. observed similar effects in response to metronomic treatment of 
patients with advanced pancreatic cancer with an oral low-dose combination of 
cyclophosphamide, celecoxib, and dexamethasone, with patients exhibiting reduced 
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plasma VEGF levels together with reduced prostate-specific antigen levels [208]. More 
recently, Bhatt et al. showed that continuous infusion of a low-dose of paclitaxel with 
oral celecoxib resulted in disease stabilization by acting as an antiangiogenic agent in a 
phase-II clinical trial involving patients with metastatic melanoma [206]. We have 
demonstrated a continuous low-dose release of Dox from the agents created in this study, 
representing the potential to improve treatment efficacy by subjecting tumor cells to 
constant, localized drug delivery as opposed to a bolus systemic injection.  
Moreover, adaptation of the UCA to carry both Dox and TRAIL represents an 
attractive two-fold treatment mechanism with the potential to greatly improve treatment 
efficacy. The study presented here expands on the work of Wu et al. evaluating the 
synergistic relationship between Dox and TRAIL in prostate cancer [211]. The prostate 
study showed a synergistic cytotoxic effect on LNCaP, LNCaP-Bcl-2, PC-3, and PC93 
prostate cancer cells in as short as 2 hours, with Dox significantly activating caspase-8, 
caspase-6, and caspase-3 which is a major player in the apoptosis cascade [44, 56, 211]. 
Our work expands upon these studies by investigating TRAIL-sensitive and TRAIL-
resistant human breast cancer cell lines, demonstrating the synergistic effects of Dox in 
sensitizing the resistant cells to TRAIL-mediated apoptosis.  
To our knowledge, this study is the first to combine PEGylation, Dox 
encapsulation, and TRAIL ligation into a single polymeric UCA population that can be 
used for US-driven targeted drug delivery. The results presented here demonstrate the 
influence of shell materials, particularly block co-polymers and lipid tails, on acoustic 
behavior, morphology and physical characteristics, drug loading capacities, and drug 
release profiles of the resulting agents. Taken together, these results can be used to 
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develop finely-tuned treatments, with specific drug release profiles or acoustic behaviors, 
customizing the treatment to the needs of the patient and physician. Future work is 
expected to investigate alternative ligands and drugs for broader applications of this 
platform.  
5.2 Future Recommendations 
 While the work presented here represents improvements and refinements over 
previous studies, there are several areas for future improvement and expansion. The 
following are some suggestions and recommendations to help guide this research further.  
 The platform discussed here has proven to significantly reduce immunogenicity 
over traditional PLA microbubbles. However, the ratios and incorporations of PEG into 
the PLA shell can be further optimized. In specific aim 2, there was a noticeable shift in 
UCA resonant frequency between the 2 wt% and 5 wt% PEG-PLA agents, suggesting a 
change in the shell properties occurs between these ratios. Future work examining the 
shell properties resulting from 3 wt% and 4 wt% PEG-PLA incorporation may prove 
important for understanding this shift and better anticipating the changes in echogenicity 
associated with PEGylation.  
 Within specific aims 1 and 3, investigating TRAIL ligation before the initial 
lyophilization may be beneficial. It may be found that by suspending the microbubble 
pellet in MES buffer and continuing with the TRAIL ligation without the intermediate 
lyophilization following initial UCA formation helps mitigate the loss of echogenicity 
resulting from the ligation process. Future experimentation should also be done to 
develop a quantification assay to determine the amount of active TRAIL ligated to the 
UCA surface.  
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 An in vivo study of the agents produced in this study would provide valuable 
information and perspective, since the experiments in this thesis only represent in vitro 
testing in a well plate. There are several limitations associated with in vitro studies, 
especially inefficient modeling of physiological conditions such as blood circulation, lack 
of 3D tumor structure, extravasation to reach tumor tissue. Biodistribution studies in vivo 
would help determine if PEGylation effectively reduces collection of intact and shattered 
particles in the spleen and healthy liver, and if increased delivery is seen in the target 
tissue. A long-term survival study would also shed light on the treatment efficacy, 
especially that of the co-encapsulated Dox with TRAIL to determine the effectiveness of 
sensitizing resistant cells to this therapy. These agents could also be evaluated in 
Opticell® cartridges in an in vitro setup to better understand the cavitation and uptake 
effects of US in this therapeutic method.  
 Another area that could benefit from future experimentation is increasing the drug 
loading within the UCA shell. Methods that could be explored include addition of drug-
loaded nanoparticles to the UCA shell, loading within the agent core, and drug layering. 
Generation of an agent with a higher drug payload that still retains its acoustic and 
immunogenic properties would be an improvement to the current agent.  
 Finally, the UCA fabrication process may benefit from adaptation to a 
microfluidics approach. Such a process would reduce the variability from user to user, 
better standardizing the resulting UCA from batch to batch. The microfluidics process 
could also be optimized to each type of agent desired, allowing for fine-tuned changes to 
UCA diameter, shell thickness, and so forth [212]. Production of a more monodisperse 
UCA population would improve echogenicity as well, allowing all UCA to cavitate at the 
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desired frequency, resulting in more effective US-triggered drug delivery. Microfluidics 
may also help increase the overall drug loading and encapsulation efficiency, which as 
discussed previously would be a substantial improvement to the current agents.  
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APPENDIX A: STANDARD CURVES 
 
 
The following section includes the standard curves created and used to determine 
the results presented throughout this thesis.  
 
 
 
 
Figure A.1: Standard curve of CF-tagged LipidPEG in DMSO used to calculate loading 
efficiency. (n=3, error bars = SEAM, λex = 495nm, , λem = 585nm, gain = 100). 
 
 
 
 
Figure A.2: Standard curve of Dox in DMSO used to calculate drug payload and 
encapsulation efficiency (n=3, error bars = SEAM, λex = 495nm, λem = 585nm, gain = 
100dB). 
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Figure A.3: Standard curve of Dox in PBS used to calculate drug burst and sustained 
release (n=3, error bars = SEAM, λex = 495nm, λem = 585nm, gain = 100dB). 
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APPENDIX B: STANDARD OPERATING PROCEDURES 
 
 
I. Protocol for Fabrication of PLA Ultrasound Contrast Agents  
The following protocol is used to produce native PLA UCA. Preparing fresh 
microcapsules is essential for all studies and takes about three hours. 
1. Weigh out the following chemicals: polymer (0.5g, record lot number as well), 
and porogens ammonium carbamate (0.78g) or ammonium carbonate (0.4g) and 
camphor (0.05g-if used) 
a. Note: Polymer should always be brought to room temp. before opening 
so that condensation does not form on the beads and cause degradation. 
For convenience you should take ~5g out of the stock solution and place it 
in a sealed vial in the freezer. 
2. Combine the polymer and 10ml of methylene chloride in a beaker (40ml max 
volume) with a stir bar and stir on a magnetic stir plate, cover with a layer of wax 
paper topped by a layer of parafilm, until camphor and polymer are dissolved 
(~15min). 
a. Note: The ratio of polymer to solvent should is important. If the cover 
opens during stirring, some methylene chloride may evaporate. You 
should be careful, but if needed you can add more methylene chloride to 
bring the level to 10ml after stirring. Also, remember to wear gloves when 
using methylene chloride. 
3. Combine porogen with 10ml of deionized water in a beaker (40ml max 
volume) with a stir bar and stir on a magnetic stir plate. 
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4. Measure out 50ml of 5% poly vinyl alcohol (PVA) and put it in a beaker 
(600ml max volume) and place it in the refrigerator. 
5. Measure out 100ml of 2% isopropyl alcohol (IPA) and keep it in the graduated 
cylinder. 
6. When the camphor and polymer are dissolved, remove stir bar and add 1ml of 
the porogen solution and sonicate with Misonix probe sonicator at 110W for 30 
seconds. Sonicate in an ice bath 3 seconds on 1 second off. 
7. After sonication, pour the solution into the cold PVA and homogenize with 
Brinkmann PT 3100 homogenizer with attached Polytron PT-DA 3020/2 
generator for 5 minutes at 9,500 rpm. 
8. After homogenization, pour the 100ml of IPA in the solution, add a larger stir 
bar, and stir on a magnetic stir plate (~375 setting) for 90 minutes. Make sure the 
vortex spans the diameter of the beaker so the solvent can fully evaporate. 
a. After homogenization remove the blade and pour the IPA over it into 
the beaker to prevent the loss of yield. 
9. After 90 minutes, combine the solution in at least 4 centrifuge tubes (50ml max 
volume) and then centrifuge for 5 minutes at 5,000 rpm (the equivalent of 
approximately 5,000 g). 
10. Decant the liquid and combine the microcapsules into 1 tube and recentrifuge 
for 5 minutes at 5,000 rpm. 
11. Decant the liquid and wash the microcapsules three times with hexane. Lay 
the centrifuge tube under the hood and let excess solvent evaporate for about 20 
min. 
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12. When the microcapsules appear to be thick and pasty, add DI water and 
recentrifuge for 5 minutes at 5,000 rpm. 
13. Decant the water, mix (fluff) the microcapsules so they are mostly in solution, 
put a kimwipe on top of the tube with a rubber band, and flash freeze using 
nitrogen (swirling the tube in nitrogen to create a cone shaped pellet and increase 
exposed surface area for lyophilization). 
14. Put the frozen microcapsules in a freeze dryer vessel and on the freeze dryer 
for at least 48 hours. 
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II. Protocol for Conducting Dose and Time Responses 
 The purpose of the dose response is to find the optimum dose where the 
ultrasound enhancement is the maximum. The purpose of a time response is to measure 
acoustic stability of the contrast agent. The time response should be done following a 
dose response at a dose less than the maximum dose. 
 
For Dose Response 
1. Weigh out 3mg of contrast agent and suspend it in 200µl of Phosphate Buffered 
Saline (PBS pH 7.4). This is your stock solution. 
2. Fill the sample vessel with 100 ml of PBS and a small stir bar, turn on the 
oscilloscope and pulser, and focus the sample vessel. 
3. For each dose, starting with 0.003mg/ml, inject 20µl of stock solution into the 
sample vessel and begin the LabView computer program. 
4. Run the program. 
5. For the next dose, 0.006mg/ml, inject another 20µl of stock solution into the 
sample vessel. Do not remove the original contents if this is a cumulative dose 
response. 
6. Continue dose response up to 0.03mg/ml or until shadowing is evident. 
 
Computer Operation for Dose Response  
1. Create a folder with appropriate subfolders. 
2. Open up the Main Ultrasound Program from LabVIEW and then open up the 
Main Ultrasound Program.vi. 
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3. Using the open file program, choose a directory path in which the data should 
be saved by opening the folder path, selecting which folder to save the data in, 
and hitting select current directory. 
4. To begin taking the dose response, push the Run button. 
5. When completed, to view the results, first under the Analyze Data tab, push 
Export Calculated Data and choose a folder to save the data to. 
6. To view results, open up the dose data file using Excel and the enhancement in 
will be displayed for each dose in mV and dB. 
 
For Time Response 
1. Choose dose on the dose response curve that is not the maximum (it should be 
on the linear part of the curve) and prepare a solution of that concentration, using 
procedure described above in the dose response section. 
2. Fill the sample vessel with 100 ml of PBS and a small stir bar, turn on the 
oscilloscope and pulser, and focus the sample vessel. 
3. Inject dose into the sample vessel and begin the LabView computer program 
(Main Ultrasound Program.vi). 
4. Run the program for 15 minutes. 
a. For n-Sh production screening, repeat this test at Energy Level 4, 
turning the energy level back down to 1 while each measurement is being 
taken.  
 
 
 206 
Computer Operation for Time Response 
1. Create a folder with appropriate subfolders. 
2. Open up the Main Ultrasound Program from LabVIEW and then open up the 
Main Ultrasound Program.vi. 
3. Using the open file program, choose a directory path in which the data should 
be saved by opening the folder path, selecting which folder to save the data in, 
and hitting select current directory. 
4. To active Time Response, select button next to “Capture waveform on set time 
interval” and set the interval and number of time points to acquire. 
5. Hit run button to begin Time Response. 
6. To view the results when completed, go to the Analyze Data tab, select Export 
Calculated Data and choose a folder to save the data to. 
7. To view results, open up the time data file using Excel and for each minute the 
enhancement will be given in mV and dB. 
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III: Protocol for Measuring UCA Size and Zeta Potential 
The following protocol is used to measure size distributions and zeta potential of 
UCA in solution using a Malvern ZetaSizer Nano ZS. Size distribution is important in 
understanding an UCA size and safety, while zeta potential is useful in understanding the 
agent’s surface charge and tendency to flocculate in suspension 
 
1. Ensure Malvern ZetaSizer is connected to CPU via USB cable, turn machine on 
and open software program DTS (Nano) 
2. Create a new data file by selecting ‘File -> New Measurement File’ 
3. Suspend 1mL of dry agent in 1mL of solution (PBS for size measurements, DI 
water or a low ionic strength buffer for zeta potential measurements) 
 
For Size Measurements 
1. Pipette 1mL of suspended UCA solution into clear plastic rectangular Malvern 
cuvette 
2. Select measurement protocol by selecting Measure-> SOPs -> Size-> PLA 
Microspheres 
3. Click “Start” in protocol window 
4. Data will be saved in data measurement file and can be exported using File -> 
Export 
5. Size cuvettes can be reused between samples, but are disposable and should be 
thrown away after several days of use (or become cloudy) 
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For Zeta Potential Measurements 
1. Pipette 1mL of suspended UCA solution into clear plastic Malvern Zeta 
Potential Capillary cuvette 
2. Select measurement protocol by selecting Measure-> SOPs -> Zeta-> PLA 
Microspheres 
3. Click “Start” in protocol window 
4. Data will be saved in data measurement file and can be exported using File -> 
Export 
5. Zeta potential capillaries are reusable and can be rinsed with DI water for 
future use 
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IV: Protocol for Counting UCA by Flow Cytometry  
The following protocol is used to measure UCA population concentration by 
weight using an BD Biosciences Accuri C6 Flow Cytometer. Concentration is an 
important consideration when determining treatment amounts and drug loading.  
Materials Needed 
- 100uL and 1000uL pipettes and tips 
- 100mL graduated cylinder 
- 2mL Eppendorf tubes (rounded bottom) 
- 2 250mL beakers 
- plastic waste cup (for tips and tubes) 
- CountBright absolute counting beads 
Bring to room temperature before use; keep lights off while using (light 
sensitive); note bead concentration and lot number from label on the bottle; 
shake the counting beads EVERY TIME before pipetting from the bottle 
 
Procedure 
1. Turn on the Accuri Flow Cytometer by pressing the button on the front of the 
machine 
2. Open the CFlow Sample software on the computer 
3. Select 24-tube rack as plate type 
4. Eject the plate and add DI water to the tube in the A01 position 
5. Name the A01 position “Wash” and adjust the settings for a 5 minute run at fast 
fluidics. Load the plate and press run  
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6. While the starting wash is running, fill each of the 2 beakers with 100mL DI 
water for sample preparation  
7. Prepare the “Beads Only” control by adding 500µL DI water and 10µL counting 
beads to a 2mL Eppendorf tube. BE SURE TO SHAKE THE BEADS WITH 
EACH USE  
8. After the wash is complete, eject the plate, and place the beads control tube in the 
A02 position. Select A02 and name the sample “Beads Only” then adjust the 
settings for a 2 minute run at medium fluidics. Load the plate and press run  
9. When the run is complete, zoom in on the line formed by the beads on the scatter 
plot (top middle of graph). Use the rectangle tool to draw a box around the beads - 
this area will be called R1 and represents those items counted that are the 
counting beads. A CV-SSC-A of approximately 10% is good  
10. Click wash when A02 is completed running and you have set the R1 area  
11. Wash the tip by selecting A01 (“Wash”) and adjusting the settings for a 1 minute 
run at fast fluidics  
12. While the wash is running, prepare the sample by mixing 2mg bubbles with 
100mL DI water in the 250mL beaker. Ensure that any clumps are broken up by 
pipetting up and down several times. Pipette 500µL of the bubble solution into a 
2mL Eppendorf tube and add 10µL counting beads (shake the bottle first!), mix 
well by shaking. Repeat twice to test sample in triplicate 
13. When the wash is complete, eject the plate. Shake the sample to ensure even 
distribution and load into position A03 in the plate. Select A03 and name the 
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sample, then adjust the settings for a 2 minute run at medium fluidics. Load the 
plate and press run  
14. Record the data at the end of the run, noting both “All” and “R1” values. Use the 
counting formula to calculate the number of bubbles (see bottom of document)  
15. Once data has been recorded, press wash  
16. Once wash is complete, select A01 and adjust settings for a 1 minute run at fast 
fluidics. Press “Add to A01” (it will no longer say “Run”) 
17. Repeat steps 12-16 for each sample, choosing the new position on the plate for 
each new tube. MAKE SURE THE WASH TUBE (A01) DOES NOT RUN OUT 
OF DI WATER!!  
18. Once all samples have been tested and washes have been run, complete another 5-
minute wash with A01 (as explained in step 5)  
19. At the conclusion of the wash, eject the plate and remove all samples except the 
wash tube in A01 
20. Load the plate and press the power button on the front of the Flow Cytometer. 
Close the CFlow software and log out of the computer.  
 
Bubble Counting Formula 
For example, if the bottle label gives a bead concentration of 0.51x105 beads/50µL:  #	𝑏𝑒𝑎𝑑𝑠10𝜇𝐿 = 0.51×10k5 = 10,200	𝑏𝑒𝑎𝑑𝑠10𝜇𝐿  
then #	𝑈𝐶𝐴𝑚𝑔 = #	𝑏𝑒𝑎𝑑𝑠10𝜇𝐿 (𝑇𝑜𝑡𝑎𝑙	𝐶𝑜𝑢𝑛𝑡	"𝐴𝑙𝑙"	– 𝐵𝑒𝑎𝑑	𝐶𝑜𝑢𝑛𝑡	"𝑅1")𝐵𝑒𝑎𝑑	𝐶𝑜𝑢𝑛𝑡	"𝑅1" 2𝑚𝑔×0.05𝜇𝐿100𝑚𝐿  
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V: Protocol for Maleimide Conjugation of TRAIL 
 
 For Ligation to UCA Surface 
1. Weigh out 60mg of freeze dried UCA into a 50mL centrifuge tube 
2. Suspend the UCA in 4mL of MES buffer (pH 5.2) 
3. Separately, prepare the cross linkers into Eppendorf tubes: 14.86mg BMPH 
(25mM), 19.17mg EDC (50mM), and 12mg sulfo-NHS (0.6 ratio to EDC) 
4. Add 1mL DI water to each Eppendorf tube (BMPH, EDC, and NHS), mix well, 
then add 1mL of each crosslinking solution to the centrifuge tube holding the 
UCA suspension **For controls without crosslinkers, omit these agents** 
5. Shake end-over-end at room temperature for 30 minutes 
6. Centrifuge the solution for 5 minutes at 5000rpm, wash with 5mL PBS, centrifuge 
again for 5 minutes, wash again with 5mL PBS, and centrifuge again to collect 
pellet 
7. Resuspend pellet in 2mL PBS 
8. Add 1.2ug TRAIL to resuspended pellet 
9. Shake end-over-end at room temperature for 90 minutes 
10. Add 50uL thioglycolic acid (5mM)* to the solution to stop the reaction 
11. Shake end-over-end at room temperature for 10 minutes 
12. Centrifuge the solution for 5 minutes at 5000rpm, wash with 5mL PBS, centrifuge 
again, repeat 3x for 3 washes 
13. Flash freeze pellet by swirling in liquid nitrogen, then lyophilize for 48 hours 
14. Store at -20C with desiccant 
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For Ligation to Carboxy-capped LipidPEG Molecule 
1. Weigh out 5mg of carboxy-capped LipidPEG into a 50mL centrifuge tube 
2. Suspend the LipidPEG in 4mL of MES buffer (pH 5.2) 
3. Separately, prepare the cross linkers into Eppendorf tubes: 95.85mg EDC and 
60mg sulfo-NHS (0.6 ratio to EDC) 
4. Add 5mL DI water to each Eppendorf tube (EDC and NHS), mix well, then add 
1mL of each crosslinking solution to the centrifuge tube holding the UCA 
suspension **For controls without crosslinkers, omit these agents** 
5. Shake end-over-end at room temperature for 30 minutes 
6. Add 6ug TRAIL to the solution 
7. Shake end-over-end at room temperature for 90 minutes 
a. During the 90 minutes, prepare the dialysis tubing by cutting ~6 inches of 
tubing for each sample and soaking the sections in DI water for at least 20 
minutes 
8. Add 250uL thioglycolic acid (5mM)* to the solution to stop the reaction 
9. Shake end-over-end at room temperature for 10 minutes 
10. Pour resulting solution into prepared length of dialysis tubing with weighted clip 
in place at the bottom of the tubing 
11. Secure the top clip, then float in 3-4L DI water on a stir plate for at least 6 hours, 
changing the water every 2 hours  
12. Freeze dialyzed solution overnight, then lyophilize frozen solution for 48 hours 
13. Store at -20C with desiccant 
*To make 5mM thioglycolic acid: Add 34.9µL thioglycolic acid to 100mL DI water 
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V: Protocol for Measurement of UCA Resonant Frequency 
 These measurements will help determine the resonance of the UCA, providing 
important information about the acoustic backscattering behavior and necessary US 
parameters for appropriate UCA evaluation.  
 
Collection of Attenuation Data 
1. Connect the power supply cable to the back of the Agilent Technologies 
oscilloscope  
2. Connect the “Ch 1” and “Ext” cables to their respective outlets on the 
oscilloscope (“Ch 1” is yellow on the front, and “Ext” is on the back) 
3. Change the transducer to the desired unfocused transducer (1, 2.25, 5, 7.5, or 10 
MHz) and submerge it in the water tank 
4. Fill the metal-plated sample holder with 250 mL of 1x PBS and place it into the 
water tank 
5. Turn on the magnetic stirrer to ~3 setting 
6. Align the transducer to be in the center of the acoustic window of the sample 
holder 
7. Turn on the pulser-receiver and adjust the settings (pulse repetition frequency: 
100Hz, gain: 0dB, energy level: 1, damping level: 3) 
8. Turn on the oscilloscope 
9. Turn on Channel 1 (yellow) by pressing its button, adjust the waveform (similar 
to initial adjustment for dose/time response curves), then turn off Channel 1 by 
pressing its button again 
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10. Press the “Math” function button to get the options at the bottom of the screen for 
span, center, etc.  
11. Adjust the span and center frequencies for the transducer being used  
a. For 5 MHz transducer, Span: 10 MHz, Center: 5 MHz 
b. For 10 MHz transducers, Span: 20 MHz, Center 10 MHz 
12. For all transducers, FFT(Ch1), Window Hanning, Scale 20bB, Offset -82.5dBV 
13. Press the “Save” function button 
14. Go to “Save” > “Settings” > “Length” and adjust recording length to 250, then 
press back 
15. Plug in your USB drive to the USB port on the front of the oscilloscope and select 
“Save to” USB drive 
16. Change your “File Name” to your preference (turn knob to change letter, press 
knob to select letter) 
17. Press “Press to Save” to record your data as the baseline 
18. Change file name to your preference for the sample you are testing 
19. Add your sample to the sample holder (0.06mg/mL), wait 10-15 seconds for the 
sample to be mixed in the holder, and record your data (3x for triplicate readings) 
20. Remove the sample holder from the tank, rinse with DI water, and fill with 250 
mL of fresh 1x PBS.  
21. Repeat steps 15-19 for each sample to be tested.  
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Other Oscilloscope Settings (should be the same, but for reference):  
Trigger: Sweep Mode Auto, Coup DC, Noise Rej Off, HF Rej Off, Holdoff 40.0ns, Mode 
Edge, Source Ch 1, Slope Rising, Level 0.0V 
Horizontal: Mode Normal, Ref Center, Main Scale 1.000us, Main Delay 140us 
Acquisition: Mode Averaging, # Avgs 512, Realtime On, Vectors On, Persistence Off 
 
Attenuation Data Processing 
1. Enter all data into Excel to generate average values for all samples 
2. Copy averaged values into OriginPro8 software (available for PC Only) 
3. Plot attenuation, 𝛂 (dB/cm) on the y-axis vs. frequency (MHz) on the x-axis 
4. Right click on plot and choose “layer contents” 
5. Click “Analysis” > “Signal Processing” > “Smoothing”  
a. Input = y-axis data 
b. Method = Savitzky-Golay 
c. Points of Window = 20 
d. Click OK, this generates new “smoothed” column 
e. Repeat for each set of averaged data 
6. Click “Plot” > “Symbol” > “Scatter” 
7. Only plot the range for the bandwidth of each transducer  
a. 2.73 - 4.27 MHz for 3.5 MHz transducer 
b. 2.7 - 7.2 MHz for 5 MHz transducer 
c. 6.7 - 13 MHz for 10 MHz transducer 
d. Determine these values from the Excel file 
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8. Right click on the line in the graph, click “Edit Range” and input cell numbers 
determined from Excel *must change each line individually* 
9. Change x-axis to MHz 
a. Double click on axis 
b. Change tick labels 
c. Divide by factor 10^6 for MHz 
10. Offset y-axis data to create a smooth graph from the 2 transducer data sets (5 and 
10MHz) 
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